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1. Introduction
1.1 Molecular Epidemiology
Traditionally, the interest of scientists in infectious diseases has been focused on the role of the
infectious agents as the origin of the disease in the higher organism. Their interest has been
expanded to include the genetic structure, the immune response and the evolutionary
consequences of public health interventions. Molecular epidemiology can be a potent tool in the
understanding of infectious diseases, as e.g. Plasmodium falciparum malaria, and the design and
evaluation of interventions for their treatment (drug trials) and prevention (exposure reducing
measures and vaccines). The practical goals of molecular epidemiology are to identify the infective
agents responsible for the disease (e.g. distinguish between the different human pathogenic
Plasmodium species), determine their physical sources, their biological (phylogenetic)
relationships, and their routes of transmission. Genes responsible for their virulence (e.g. var
genes in Plasmodium falciparum), vaccine-relevant antigens (PfMSP1/PfMSP2/PfAMA1) and
drug resistance (Pyrimethamine/Sulfadoxine resistance) have to be characterized. The use of
molecular methods may lead to the observation that arrays of symptoms could be attributed to
particular genes, as it was possible to demonstrate in other infectious diseases, e.g. Vibrio
cholerae (Mekalanos et al. 1997) or Escherichia coli (Ott et al. 1991).  
A detailed knowledge of the overall genetic structure of a pathogen population is not essential for
epidemiological tracking. Rather, the challenge is to use typing characters that change in a range
and at a rate that are informative for the particular question. The knowledge of parts of the
genetic structure may be important to understand (and ideally predict) the responses of pathogen
populations to selective pressures imposed by host immunity both natural and vaccine-induced,
and may be important for the effective management of antiparasitic interventions. For tracking the
transmission of an infectious agent in a special region, a relatively fast-changing genetic marker
will be useful. On the other hand the same marker would not be valuable for looking at trends in
the global population of Plasmodium falciparum over many decades. Polymorphic marker genes
have been shown to be very useful tools to evaluate intervention strategies, to monitor prevalence
of infectious agents or changes in frequencies of genotypes. But those selected markers must be
distinguished from non-selected markers as microsatellites (Ferdig and Su 2000) and it depends
on the scientific approach which marker system should be chosen. 
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A microbe proliferates in host tissue in which it is normally limited by physical and chemical
barriers or by predators and competitors (phagocytic and other cells of the host immune system,
and other micro-organisms). These microbial invaders often have phenotypes that enhance their
survival in this habitat (virulence factors, including the ability to attach to and invade cells and to
resist or evade the host’s constitutive chemical and cellular defences). Evolution occurs in both
the parasite population and the immune system of the host. Selection in the parasite population
favours mutants (antigenic variants) that are able to evade predators or avoid predation (see
below) and competition by invading different micro-habitats (cells and tissues) where the
immunological predation pressure is less intense (erythrocytes do not express MHCI molecules).
The key feature of science is not measurement (this is just a tool), but understanding. To
understand the occurrence of malaria in human populations, the structure of the parasite
population, the survival strategies of the parasite and of the host reflected by the immune
response, and the implications of interventions have to be investigated. 
1.2 Polymorphism and Variation - survival strategies with different goals
Polymorphism is defined as the expression of distinct alleles of a gene at a single gene locus in
different clones of the parasite (Reeder and Brown 1996), whereas variation shows the ability of
a clonal population to switch the antigenic phenotype with unchanged genotype. As pointed out
by Brunham et al. (1993), allelic polymorphism is usually a `between-host` survival strategy,
providing an individual pathogen with maximum fitness for successful infection of its host. The
biological role and impact of antigenic variation is usually considered as a `within-host-
mechanism  `that allows parasite survival in an immunocompetent host (Brunham et al. 1993).
Antigenic variation creates diverse individuals, by switching its antigenic phenotype during the
course of long-term infection of a single infected host. Both strategies are realized as immune
evasion mechanisms in malaria. 
1.3 Immune Evasion by Multiplying Short Sequences - repeats
A further strategy for immune evasion may be based in the nature of the antigenic sequence itself.
The malaria parasite may use repetitive, immunodominant epitopes as a mechanism to evade the
immune response of the human host (Anders 1986) and many of malaria antigens contain tandem
arrays of relatively short sequences. Maintenance of degeneracy within a repeat set, and the
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existence of cross-reacting epitopes in many genes of P. falciparum as a consequence of short
repetitive sequences and the biased amino acid composition, have been suggested to interfere with
the normal maturation of high affinity antibodies. The existence of cross-reacting antibodies has
often complicated the problem of identifying specific Plasmodium gene products and protective
immune responses (Berzins and Anders 2000). In addition, repetitive epitopes may induce T cell-
independent B-cell activation (Schofield 1991), suppressing antibody production to more relevant
parts of the antigen. Another strategy for immune evasion of Plasmodium falciparum was
suggested, based on the theory of 'original antigenic sin' (Good et al. 1993) as it was shown with
the influenza virus. It was supposed, that the prior exposure to one strain of Plasmodium
falciparum was able to divert the immune response to a second challenging strain by focussing
the immune response on the shared (cross-reactive) epitopes.          
1.4 Merozoite Surface Protein 2 (MSP2) – genetic structure 
Polymorphic antigens have been described in several parasite life cycle stages but are particularly
a feature of the antigens associated with the surface of the asexual blood-stage merozoites. The
merozoite surface protein 2 (MSP2) is one of the well-characterized surface proteins of P.
falciparum. MSP2 is an integral membrane (GPI anchored) protein with highly conserved
carboxy- and amino-terminal regions flanking a central variable region that is composed of non-
repetitive semi-conserved sequences surrounding repetitive highly variable repetitive sequences
(Anders and Smythe 1989; Smythe et al. 1990). Although the protein is highly polymorphic,
sequencing of MSP2-alleles and PCR-RFLP from a large number of parasite isolates from
different geographical locations has shown a virtually dimorphic structure of the molecule
(Thomas et al. 1990; Smythe et al. 1990; Fenton et al. 1991; Marshall et al. 1991; Smythe et al.
1991; Snewin et al. 1991; Prescott et al. 1994; Marshall et al. 1994; Dobano et al. 1997; Irion et
al. 1997; Felger et al. 1999a). Thus, two allelic families exist, IC1/3D7 and the FC27 families
(Smythe et al.1990), which correspond to the A and B serogroups defined by reactivity with
monoclonal antibodies (Fenton et al. 1991). The finding of structural identity between msp2 alleles
isolated from human hosts geographically and chronologically separated (Dobano et al. 1997) is
consistent with the idea that the evolution of msp2 variants may be limited by functional
compulsion. In addition, recently the first homologous gene for a Plasmodium species (P.
reichenowi) other than P. falciparum was identified showing almost identical conserved regions
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(Dubbeld et al.1998). However, in Plasmodium falciparum a high rate of amino acid changes is
seen in polymorphic regions. This finding is thought  to be indicative of immune selection acting
to promote antigenic diversity (Hughes and Hughes  1995). As in many malarial antigens MSP2
contains extensive arrays of tandemly repeated short amino acid sequences, and much of the
antibody response induced by malaria infections is directed against epitopes encoded by these
repeats (Al-Yaman et al. 1994; Taylor et al. 1995). Detailed genetic structure of msp2 is shown
in figure 1.  
The merozoite surface protein 2 has been verified as a suitable molecular marker when individual
Plasmodium falciparum infections need to be distinguished currently present in a sample. Using
the PCR technique and primers to conserved regions, it is feasible to characterize individual
parasites obtained from a subject at one point in time and this possibility of identifying individual
parasite genotypes over a time period renders detailed studies of infection dynamics. The msp2
locus is not only a useful marker gene for molecular epidemiology purposes, but the expressed
protein is also a promising vaccine candidate (Saul et al. 1999; Genton et al. 2000; Genton et al.
2001). Due to the location on the surface of the parasite and the immunological features of MSP2,
the protein was suggested as part of a three component vaccine, called Combination B, recently
tested in Papua New Guinea (Saul et al. 1999, Genton et al. 2000; Genton et al. 2001). In
immunological studies especially concerning antigenic features of MSP2, genotyping may also
offer important insides on the diversity of antigenic challenge.   
1.5 The First Year of Life - the host encounters the parasite
In areas highly endemic for malaria, repeated plasmodial infections result in the development of
acquired immunity which although not sterilising, protects older children and adults against severe
disease (Barragan et al. 1998; Gupta et al. 1999). As a result, mortality due to malaria is mainly
restricted to early childhood. Where transmission is perennial, significant clinical protection from
severe morbidity was observed up to the third month of life. In the seasonal transmission area,
disease rates rose after the sixth month of life (Snow et al. 1998).  The period of highest
susceptibility to clinical malaria among infants in such highly endemic areas occurs between the
ages of 4 and 12 months (Kitua et al. 1996), when the bulk of maternal antibodies decreases and
the own immune response against the parasites is weak. Very young infants in areas holoendemic
for malaria show mild symptoms when infected with P. falciparum, and they are comparable to
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partially immune adults with respect to parasite densities and recovery rates from infection (Kitua
et al. 1996). This protection is thought  to be conveyed by foetal haemoglobin (Pasvol et al. 1977)
or maternal antibodies, which can be detected in cord blood and which are acquired across the
placenta (Desowitz et al. 1993, Rasheed et al. 1995). In a study of Tanzanian infants, the
incidence rate of malaria-attributed morbidity reached a peak at six months of age (Kitua et al.
1996), and significant declines in the risk of severe malaria were demonstrated from the sixth
month of age (Snow et al. 1998).
These data provide direct evidence for the very early acquisition of clinical immunity. It is
hypothesised that clinical protection during the first few months of life in high transmission
settings allows active immunisation to occur and contributes to a reduction in the overall risks of
severe complicated malaria throughout childhood (Snow et al. 1998).
1.6 Humoral Immunity to P. falciparum - a general review
Acute clinical malaria, which is often life-threatening in the case of infection with P. falciparum,
is associated with replication of the asexual blood stage parasite in circulating erythrocytes (Patino
et al. 1997). The responsible parasite clone is able to reproduce to parasite numbers over the fever
threshold due to the lack of appropriate defence mechanisms of the host. This parasite clone is
called 'virulent'. The development of a vaccine against the erythrocytic stages has been hampered
by the lack of understanding of the nature and specificity of immunity in humans, or in other
words by the lack of understanding of survival strategies of the parasite. While molecular
technology has permitted identification and analysis of many blood-stage proteins, their
immunological significance for the host and biological function for the parasite are not well
understood (Long 1993).
It is well established that humoral immunity, besides cell-mediated immunity, is important in
malaria, and passive transfer of serum has been shown to have a protective or at least modifying
effect on the disease (Cohen et al. 1961; Bouharoun-Tayoun  et al. 1990;  Druilhe and Perignon
1997; Kumaratilake et al. 1997). Experiments with antibodies purified from the sera of African
adults who were clinically immune to malaria and given by passive transfer to susceptible children
have established that immunoglobulin G (IgG) is at least a main component of the defence against
the asexual blood stage of P. falciparum. Although the parasite neutralizing IgG fraction did not
inhibit merozoite invasion by itself in vitro, an antibody-dependent cellular inhibition of parasite
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growth together with monocytes was shown (Druilhe and Perignon 1994). Antibodies are directed
either against a number of identified proteins on the parasite itself or against parasite-derived
proteins expressed on the surface of the infected erythrocyte during intraerythrocytic development
of the parasite (Giha et al. 2000). Although the potential of many antigens as targets for immune
responses has been suggested, little is known about the mechanisms of protection in vivo. Once
merozoites have been released from the schizonts, cytophilic antibodies may mediate parasite
elimination by complement-dependent lysis or by cellular effector mechanisms (Druilhe and
Perignon 1997). An almost exclusive restriction of the humoral immune response to MSP2 to the
IgG3 subclass was observed by several investigators (Taylor et al. 1995; Ferrante and Rzepczyk
1997). Hence, these IgG3 antibodies are potentially effective mediators of protection by their
cytophilic nature. 
1.7 Anti-MSP2 Immune Response - the special example
Involvement of MSP2 in protective immune responses was indicated first by the merozoite
invasion inhibitory effect of mAbs to the antigen (Clark et al. 1989; Epping et al. 1988; Ramasamy
et al. 1990). The importance of MSP2 in the immune response is also suggested by the
polymorphism of the central repeat region of the antigen (Hughes and  Hughes 1995; Escalante
et al. 1998). These repeat sequences have been shown to be antigenic and are recognized by
antibodies induced by exposure to infection with malaria parasites (Al-Yaman et al. 1994; Taylor
et al. 1995). The presence of antibodies against the conserved and semi-conserved regions was
found to develop at later ages after a life long exposure to malaria and was then associated with
fewer fever episodes and less anemia (Al-Yaman et al. 1994). 
Many features of acquired immunity to malaria in humans indicate that the protective response
may be strain-specific (Staalsoe and Hviid 1998), e.g. there is the possibility that infection induces
a form of genotype-specific immune response against the MSP2 antigen that biases against
reinfection by parasites bearing identical forms of MSP2 (Eisen et al. 1998). Certain msp2
genotypes have been associated with higher parasite densities and morbidity (Engelbrecht et al.
1995) and previous studies on older children have shown that concurrent multiple infections are
associated with protection against clinical malaria in endemic areas (Al-Yaman et al. 1997; Beck
et al. 1997; Färnert et al. 1999).
Studies from Papua New Guinea have shown a negative correlation between antibody levels to
Introduction 7
MSP2 and fever recall in the previous week (Al-Yaman et al. 1994). More important though is
the demonstration in a prospective study of an association between antibody levels to 3D7 MSP2
at baseline and resistance to clinical malaria during the one year follow up (Al-Yaman et al. 1995).
Antibody levels to 3D7 MSP2 were also found to be lower among children who died of cerebral
malaria than among those who survived indicating a protective role for these antibodies against
severe malaria (Al-Yaman et al. 1997a).
A prospective longitudinal study was conducted for one year in Gabon and Cameroon to examine
the relationship between specific in vitro immune responses to two MSP2 peptides and
susceptibility to clinical malaria (Migot-Nabias et al. 1999). These peptides correspond to the N-
terminal conserved region and to the family specific region of alleles of the 3D7 allelic family,
respectively. Clinical protection was associated with elevated antibody levels to both MSP2
peptides. In contrast to results with other antigens, there was no significant difference in the ages
of individuals with a certain antibody titre to the full length recombinant or parasite-derived MSP2
molecule, but antibodies to MSP2 did correlate with parasitemia (Stowers et al. 1997). 
In adults antibody levels after two infections can reach the peak levels of antibodies obtained in
immune individuals (Baired 1998; Stowers et al. 1997; Gupta et al. 1999). The strength of an
antibody response to antigen rMSP2 and P. falciparum MSP2 was shown to be very high even
in youngest age groups (0-5 years) and antibody levels were significantly higher in parasitemic
individuals in this age group than in nonparasitemic individuals (Stowers et al. 1997).
The location of MSP2 on the merozoite surface and the ability of human anti-MSP2 antibodies
to inhibit merozoite invasion together with MSP2 specific immune protection in vivo makes this
antigen of considerable interest as a vaccine candidate (Fenton et al. 1989; Clark et al. 1989).
Hence, MSP2 is one component of a subunit vaccine against malaria which was recently assessed
in the field among individuals living in an area of Papua New Guinea highly endemic for P.
falciparum (Saul et al. 1999; Genton et al. 2000; Genton et al. 2001 Combination B).
1.8 Bed net users versus non-bed net users - an intervention strategy
In recent years, exposure reducing measures such as insecticide treated bed nets (ITNs) have been
promoted as public health tools in malaria endemic areas. On the one hand several efficacy trials
have given strong evidence that the use of ITNs improves survival and reduce malaria-attributable
morbidity (Alonso et al. 1991; D'Allessandro et al. 1995; Binka et al. 1996; Nevill et al. 1996;
Habluetzel et al. 1997; Fraser-Hurt et al. 1999; Diallo et al. 1999). On the other hand there is
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some evidence for the very early acquisition of clinical immunity in children. It is hypothesized
that clinical protection during the first few months of life in high transmission settings allows
active immunization to occur and contributes to a reduction in the overall risks of severe
complicated malaria throughout  childhood (Snow et al. 1998). However, if children are protected
from infections with ITNs, the development of malaria-specific immune response might be
impaired. There is evidence from studies that children using a net may have significantly reduced
levels of P. falciparum-specific IgG or IgM, when compared to fully exposed children not using
a net (Genton et al. 1994; Snow et al. 1996). Blood samples of a bed net study used for
genotyping parasite infections showed a significant decrease of 16.4% in microscopically
determined P. falciparum prevalence in children in the ITN group at the end of the trial (Fraser-
Hurt et al. 1999). However, no significant difference was observed in parasite density or
multiplicity of infection determined by PCR-RFLP among infected children with or without ITN
(Fraser-Hurt  et al. 1999). It was assumed that chronic infections formed a large proportion of all
infections. Hence limited reduction in exposure would not have much impact on multiplicity and
premunition might be still established (Smith et al. 1999b).
1.9 Dynamics of infection - ups and downs 
The number of concurrent infections with Plasmodium falciparum might be an important
indicator of the degree of acquired immunity against malaria, since the multiplicity of infections
increases with age over the first few years of life in parallel with the increase in clinical immunity
(Smith et al. 1999a). In addition persisting infections have been proposed to provide protection
against clinical disease when superinfected with a new parasite (Al-Yaman et al. 1997b; Beck et
al. 1997; Färnert et al. 1999). The potential benefits of multiple malaria infections may have
important implications for interventions aimed at reducing parasite prevalence in areas with high
malaria transmission. The effect of insecticide treated bed nets on the dynamics of multiple
Plasmodium falciparum infections was investigated by Smith et al. (1999b) using PCR-RFLP
genotyping data from msp2. For msp2 genotypes of the FC27 allelic family there was no
difference in multiplicity of infections detectable in children aged initially 5 to 24 months with or
without sleeping under a bed net. Hence multiplicity of infection seems unaffected by the infection
rate. In the same study the average duration of infections of parasites with a msp2 allele of the
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FC27 family was shown to be considerably higher than in infants (Felger et al. 1999b; Smith et
al. 1999b). 
It was suggested that differences between individuals in parasitologic profiles may be the result
of qualitative differences in protective immunity (Färnert et al. 1999). There might be a difference
in the virulence of parasites expressing different MSP2 alleles to persist, reflected through the
ability of the immune system to eliminate those parasites. Investigation of features of the 3D7
allelic family concerning duration of infection and recovery rates will give additional information
of parasite survival strategies.  
1.10 In summary, 
this review of the literature has demonstrated that mechanisms of the immune response against
the pathogen Plasmodium falciparum are not well understood. Although the potential  of many
antigens as targets for parasite neutralizing immune responses has been suggested, little is known
about the mechanisms of protection in vivo against the disease and the relative importance of the
different antigens as targets of this protection. The merozoite surface protein 2 of Plasmodium
falciparum is an example for the relationship between polymorphism of an antigen and the
immune response of the human host. Any attempt to elucidate the development of the immune
response to this antigen may therefore yield valuable information on the evolution of the
polymorphism providing the evasion from the pressure of the immune system. 
Following this line of reasoning, the thesis presents MSP2 as a polymorphic marker gene which
is useful to determine malariological profiles in individuals and to evaluate intervention strategies
(Paper I). In addition ti being a tool, MSP2 has been identified in other studies to be a promising
vaccine candidate. Therefore, the apparent different immunogenicity of the distinct regions of
MSP2 (Figure 1) was investigated by vaccinating Balb/c mice and in serological assays with
human sera. (Paper V). Consecutive serum samples from Tanzanian infants initially between 5 and
15 months of age from an area where transmission of malaria is intense and perennial were tested
in ELISA to investigate the development of the antibody response in early childhood and to
analyze the effect of the use of ITN to the immune response in the same period (Paper II). A new
methodology based on a latent class model for the analysis of biomedical assays which are
expected to classify samples into two groups was expounded (Paper IV). The dynamics of the
antibody response to MSP2 are described in view of the dynamics of P. falciparum infections
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measured by using the polymerase chain reaction-restriction fragment length polymorphism (PCR-
RFLP) analysis of the merozoite surface protein 2 (Paper III). Investigation of features of the 3D7
allelic family concerning duration of infection and recovery rates will give further information on
parasite survival strategies, which may be different for parasite encoding a msp2 allele of the FC27
family.  
The methods and results of this study are finally discussed in a broad framework that includes
both anti-malaria immunity and molecular epidemiology, and lastly perspectives are presented for
research and analysis strategies in the future. 
11Introduction
Figure 1: Schematic structure of the merozoite surface protein 2 
The two allelic families and the recombinant proteins with essential parts deleted are shown.
aa: amino acid, cons: conserved, fsp: family specific part, NAP: single letter code for amino
acids, Thr: Threonine
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2. Definitions
Some definitions of significance for this study (see Walliker 1983):
Allele: one of several alternative forms of a gene.
Allelic family: alleles of a gene are grouped with regards to similar characteristics, e.g.
the allelic families of msp2, Fc27- and IC1/3D7-allelic families.
Clone: a set of genetically identical parasites derived from one parasite/bacterium
by asexual reproduction.
Genotype: a genetic characteristic of a parasite, the type of allele found at a
polymorphic locus in an individual.
Isolate: a sample of parasites collected at one time from an individual (not
cultured).
Line: parasites which have been passaged in vitro, initially starting from one
isolate. If parasites have been cloned in the laboratory, they are referred
to as cloned lines.
Mother clones: commonly used in laboratory work, but may lead to confusion. Here, it is
used to describe a collection of hybridoma cells in one well, that produce
specific antibodies. These cell populations are not clonal.
Multiplicity of infection (MOI): 
number of infecting genotypes in an isolate (Beck et al. 1997).
Strain: used only for specific bacteria applied for expression purposes.
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3. Goal and Objectives
The GOAL of this study was to evaluate the molecular diversity of a molecular marker gene of
Plasmodium falciparum, the merozoite surface protein 2 (MSP2), and its relevance to the
development and the dynamic of the humoral immune response in children, initially 5-15 months
old, measured by the antibody response to the antigen MSP2 in a longitudinal setting in an area
highly endemic for P. falciparum malaria.
Objectives
1. Examine the molecular diversity of merozoite surface protein 2 (msp2) by PCR-RFLP.
2. Assess the immunogenicity of the rMSP2s and their similarity to parasitial PfMSP2 
A. Perform the recombinant expression and purification of different MSP2 protein
constructs with defined parts deleted in a procaryotic expression system.
B. Evaluate the immunogenicity of the produced recombinant proteins in mice.
C. Estimate the grade of similarity of the recombinant proteins to natural PfMSP2. 
D. Achieve the production of monoclonal antibodies to the conserved parts of PfMSP2.
3. Investigate the development of the antibody responses to rMSP2 in early childhood.
A. Establish the ELISA method for all recombinant proteins.
B. Perform the ELISA with recombinant proteins and
1. Sera from malaria non-exposed European individuals
2. Sera from malaria exposed Tanzanian children initially aged 5-15 months
C. Quantify the antibody response and assess proportion of positivity of the exposed
individuals.
D. Explore the longitudinal antibody response in correlation to genotypes of the infecting
parasites.
E. Evaluate the dynamic of P. falciparum infections in relationship to the dynamic of the
specific antibody response. 
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4. Material and Methods
4.1 Material
4.1.1 Cell lines, Plasmodium falciparum-cloned lines and Escherichia coli-strains
All P. falciparum cloned lines were received from the laboratory of R. Brun at the Swiss Tropical
Institute, Basel (Table 1.1-1). Erythrocytes for parasite cultures were obtained from members of
the STI or Blutspendezentrum beider Basel, Basel, CH.  EDTA-stabilized donor blood of the
blood group A Rh+ was washed and used as a 50% suspension. The E. coli strains used are listed
in table 1.1-2.
Table 1.1-1 P. falciparum cloned lines
Name msp2 genotype Source
K1 K1-allele MMV Laboratory of R.
Brun STI, Basel, CH.
H3B WOS3-allele
3D7 allele of the 3D7-family 
(GGSA) repeat
NF54 allele of the 3D7-family 
(GGSA) repeat
ItG2.F6 allele of the 3D7-family
FVO allele of the 3D7-family
Table 1.1-2 E. coli strains
Name Application Supplier
M15 protein expression Qiagen, Basel, CH
JM109 Transformation/Sequencing Promega, Wallisellen, CH
pMOSblue T/A cloning/Sequencing Amersham,
Buckinghamshire, UK
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Table 1.1-3 Cells for hybridoma technique
Name Purchase Source
PAI-myeloma cells mouse myeloma cells M. Brockhaus, 
F. Hoffmann-La Roche Ltd.
Basel, CH
P388/D1 cells  mouse tumor line
(macrophage)
ATCC, Rockville, ML, USA
4.1.2 Vectors
Table 1.2-1 Vectors
Name Application Source / Supplier
pMOSblueT-vector T/A cloning of PCR
products
Amersham,
Buckinghamshire, UK
pQE30 expression of recombinant
6His tagged proteins in E.
coli
Qiagen AG, Basel
pQE16 expression of recombinant
6His tagged DHFR-fusion
proteins in E. coli
Qiagen AG, Basel
pUC18 (pZF 18u) cloning of PCR products Mead & Kemper 1988
4.1.3 Antibodies and secondary reagents
Table 1.3-1 Monoclonal antibodies
Name Specificity Host Supplier
Penta-His 5xHis tag mouse Qiagen AG, Basel
anti-6xHistidine Clone AD
1.1.10
6xHis tag mouse R&D Systems, Minneapolis,
MN, USA
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Table 1.3-2 Conjugated secondary antibodies
Host Specificity Conjugate Supplier
goat Anti-human
IgG (()
FITC Caltag Laboratories 
San Francisco, CA, USA
goat Anti-mouse
IgG (()
FITC Kirkegaard & Perry
Laboratories, Gaithersburg,
MD, USA
goat Anti-human
IgG(()
HRP Kirkegaard & Perry
Laboratories, Gaithersburg,
MD, USA
goat Anti-mouse
IgG (()
AP Sigma, Buchs, CH
4.1.4 Reagents
Table 1.4-1 List of chemicals and reagents
ABTS Peroxidase substrate system Kirkegaard & Perry Laboratories Inc.
Gaithersburg, MD, USA
30% Acrylamide/Bis solution (37.5:1) Gibco BRL Life Technologies, Basel, CH
Agar DIFCO Laboratories, Detroit, MG, USA
Agarose (electrophoresis grade) Gibco BRL Life Technologies, Basel, CH
Albumin, bovine fraction V Sigma, Buchs, CH
Ammonium persulfate Serva, Heidelberg, Germany
Ampicillin Appligene Oncor, Basel, CH
8-azaguanine Sigma, Buchs, CH
Bacto tryptone DIFCO Laboratories, Detroit, MG, USA
Bacto yeast extract DIFCO Laboratories, Detroit, MG, USA
$-mercaptoethanol Fluka, Buchs, CH
BCIP Bio-Rad Laboratories AG, Glattbrugg, CH
CAPS, 99% pure Aldrich Chemicals, Buchs, CH
DAPI Sigma, Buchs, CH
DMF Sigma, Buchs, CH
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DMSO Fluka, Buchs, CH
dNTPs (100mM each) Pharmacia, Dübendorf, CH
DTT Calbiochem, San Diego, CA, USA
EDTA Sigma, Buchs, CH
Ethidium bromide Boehringer Mannheim, Mannheim, D
FCS Gibco BRL Life Technologies, Basel, CH
GuHCL Gibco BRL Life Technologies, Basel, CH
Giemsa solution Fluka, Buchs, CH
HAT-medium Boerhringer Mannheim, Mannheim, D
HEPES BDH Laboratory Supplies, Poole, UK
IMDM Gibco BRL Life Technologies, Basel, CH
Imidazole Merck, Darmstadt, Germany
IPTG Appligene Oncor, Basel, CH
L-Glutamine 200mM Gibco BRL Life Technologies, Basel, CH
Milk powder (low fat) Migros, Basel, CH
NBT Bio-Rad Laboratories AG, Glattbrugg, CH
Ni-NTA Qiagen, Basel, CH
PEG 50% w/v in 75 mM Hepes Boehringer Mannheim, Mannheim, D
Penicilline-Streptomycin  Gibco BRL Life Technologies, Basel, CH
Phosphatase substrate pNP Sigma, Buchs, CH
PMSF Merck, Darmstadt, D
RPMI 1640 Medium Gibco BRL Life Technologies, Basel, CH
Saponin (from Glysophila) Sigma, Buchs, CH
SDS Serva, Heidelberg, D
Sorbitol Fluka, Buchs,CH
TEMED Serva, Heidelberg, D
Tris base Sigma, Buchs, CH
Triton X-100 Sigma, Buchs, CH
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Trypanblue 0.4% solution in 0.85% saline ICN Biochemicals Inc.,Costa Mesa, CA,
USA
Urea, enzyme grade Gibco BRL Life Technologies, Basel, CH
X-gal Appigene Oncor, Basel, CH
4.1.5 Media, Buffers, Solutions
All solutions for cell culture work were sterilized by filtration through 0.22 :m bottle top filter
(Millipore Corporation, Bedford, MA, USA). Uncompleted media was stored up to 3 months at
4/C. After every two weeks 2 mM L-glutamine was added when completed with FCS or with
FCSi. FCS was heat inactivated at 56/C for 30 min.
Media for E. coli cultivation were autoclaved and stored at RT. Supplementation with appropriate
antibiotics was done just before use.
Ten fold PBS-buffer for ELISAs was sterilized by filtration through 0.22 :m bottle top filter
(Millipore, Corporation, Bedford, MA, USA) and was diluted just before use. 
Table 1.5-1 List of media (per 1 litre)
Name Composition application
IMDM stock medium 1 box powder (17.66 g)
IMDM
3.024 g NaHCO3 (36 mM)
stock medium for cell
culture
Cell freezing medium stock medium 
10% DMSO
30% FCS
N2-stabilates of cells
Myeloma cell medium stock medium for cell culture
5-10% FCS
5x10-2 mM $-
mercaptoethanol
culture medium for PAI
myeloma cells
Azaguanine medium Myeloma cell medium
0.132 mM 8-azaguanine
culture medium to select for
HGPRT-deficient cells
Wash medium stock medium
5x10-2 mM $-
mercaptoethanol
100 U/ml Penicillin/100
:g/ml Streptomycin
Wash medium for cell fusion
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HAT-medium wash medium 
0.1 mM Hypoxanthine
0.4x10-3 mM Aminopterin
0.016 mM Thymidine
20% FCSi
5% P388/D1 conditioned
medium
culture medium to select
hybridoma cells after fusion
procedure
Hybridoma cell medium stock medium
5x10-2 mM $-
mercaptoethanol
100 U/ml Penicillin/100
:g/ml Streptomycin
10% FCSi
culture medium for
hybridoma cells
LB medium 10 g Bacto tryptone
5 g Bacto yeast extract
10 g NaCl
culture medium for E. coli
cultures
LB agar 1 l LB medium
15 g Agar
agar plates for E. coli
cultures
LB / 25% Glycerol 50% LB medium (with
appropriate antibiotics)
50% Glycerol
freezing medium for E. coli
cultures
Super broth medium 25 g Bacto tryptone
15 g Bacto yeast extract
5 g NaCl
culture medium for E. coli
cultures used for protein
expression
P. falciparum culture
medium
11.5% RPMI 1640
0.5% Albumax
0.21% NaHCO3
50 mg hypoxanthine
5 mg neomycin sulfate
(+ 2 mM L-glutamine)
culture medium for P.
falciparum cultures
Wash medium 11.5% RPMI 1640
5 mg neomycin sulfate
washing of cultured
parasites
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Table 1.5-2 List of buffers
Name Composition Application
10x PBS 80 g NaCl
2 g KCl
11.5 g Na2HPO4
2 g KH2PO4
pH 7.2
Dialysis of recombinant
proteins
ELISA method
Saponin lysis buffer 0.03 g saponin
50 ml 1x SSC
saponin lysis of iRBCs
PDP lysis buffer 10 mM HEPES pH 7.9
10 mM KCL
0.1 mM EDTA 
0.1 mM EGTA 
1 mM DTT 
0.5 mM PMSF 
0.65% NP-40
preparation of parasite
derived proteins
20x SSC 3 M NaCl
0.3 M Na3-Citrat
pH 7.0
various
5x TBE running buffer 5 M Tris base
4 M boric acid
10 mM EDTA, pH 8.0
gel electrophoresis
blue juice 30% glycerine
10 mM Tris-HCl, pH 8.5
10 mM EDTA, pH 8.0
pinch bromphenol blue
pinch xylene cyanol
gel electrophoresis
TE 10 mM Tris-HCl, pH 8.5
1 mM EDTA
elution and storage of DNA 
10x PCR buffer 0.5 M KCl
0.1 M Tris-HCl, pH 8.8
15 mM MgCl2
PCR
Lysis buffer (native) 50 mM NaH2PO4
300 mM NaCl
10 mM imidazole
pH 8.0
native protein purification
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Wash buffer (native) 50 mM NaH2PO4
300 mM NaCl
20 mM imidazole
pH 8.0
native protein purification
Elution buffer (native) 50 mM NaH2PO4
300 mM NaCl
250 mM imidazole
pH 8.0
elution of recombinant
proteins
Buffer A 6 M Gu-HCl
0.1 M NaH2PO4
0.01 M Tris-HCl 
pH 8.0
protein purification under
denaturing conditions
Buffer B 8 M urea
0.1 M NaH2PO4
0.01 M Tris-HCl 
pH 8.0
protein purification under
denaturing conditions
Buffer C Buffer B
pH 6.3
wash buffer for protein
purification
Buffer D and E Buffer B 
pH 5.9 / pH 4.5
elution of recombinant
proteins
Diluting buffer 50 mM glycine-OH, pH 9.0
5 mM EDTA
renaturation of recombinant
proteins
Renaturation buffer 50 mM glycine-OH, pH 10.5
5 mM EDTA
renaturation of recombinant
proteins
5x SDS-PAGE sample
buffer
15% $-mercaptoethanol
15% SDS
1.5% bromphenol blue
50% glycerol
protein SDS-PAGE
5x SDS-electrophoresis
buffer
15 g Tris base
72 g glycine
5 g SDS
protein SDS-PAGE
4x Lower buffer 181.7 g Tris-HCl, pH 8.8
4 g  SDS
SDS-PAGE
Upper buffer 60.5 g Tris-HCl, pH 6.8 SDS-PAGE
Transfer buffer 10 mM CAPS
10% MeOH
pH 10.5
immunoblotting
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Wash buffer IB 50 mM Tris base
5 mM EDTA
140 mM NaCl
pH 7.4
0.05% NP-40
0.25% gelatine
immunoblotting
AP staining buffer 100 mM Tris-HCl, pH 9.5
0.5 mM MgCl2
immunoblotting
HRP staining buffer 23.5 ml 1x PBS
1.5 ml 0.3% chloronaphthol
in MeOH
10 :l H2O2
immunoblotting
Blocking buffer (AP) Wash buffer IB
1% BSA
immunoblotting with
alkaline phosphatase
conjugated ab
Blocking buffer (HRP) Wash buffer IB
1% milk powder
immunoblotting with HRP
conjugated ab
Blocking buffer (IFA) 1x PBS
1% BSA
IFA
Blocking buffer (ELISA) 1x PBS
5% milk powder
ELISA
Wash buffer (ELISA) dH2O
0.05% Tween-20
ELISA
Carbonate buffer 1.4 g Na2CO3
3.0 g NaHCO3
0.2 g MgCl2 x 6H20
pH 9.6
1g pNP
AP Substrate buffer ELISA
Buffered glycerine 0.136 g KH2PO4
3.221 g Na2HPO4 x 2H2O
80 ml glycerine
ad 100 ml
IFA
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Table 1.5-3 List of solutions
Name Composition Application
Comassie blue 0.25 g Serva blue
200 ml acetic acid 
filter before use
SDS-PAGE protein staining
Amp stock solution 100 mg / ml water E. coli culture
Kan stock solution 25 mg / ml water E. coli culture
Tet stock solution 15 mg / ml water E. coli culture
Synchronization solution 5% D-sorbitol
in dH2O
synchronization of cultured
parasites
4.1.6 Commercially available Kits
Table 1.6-1
Name Supplier Application
pMOSblue T-vector Kit Amersham,
Buckinghamshire, UK
Cloning
DNA Sequencing Dye
Terminator Kit
Perkin Elmer, Rotkreuz, CH Sequencing
QIAexpress Kit Type IV Qiagen, Basel, CH protein expression
CONCERTTM High Purity
Plasmid Miniprep system
Gibco BRL, Life
Technologies, Basel, CH
DNA preparation
NucleoSpin Extract 2 in 1 Macherey-Nagel Ag,
Oensingen, CH
DNA elution 
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4.1.7 Enzymes
4.1.7.1 DNA polymerases
Table 1.7-1 
Name Supplier Application
AmpliTaq DNA polymerase, FS Perkin Elmer, Rotkreuz, CH Sequencing
Native Pfu-polymerase Stratagene PCR
Taq DNA polymerase Gibco BRL, Life
Technologies, Basel, CH
PCR
Klenow DNA polymerase Boehringer Mannheim, D second strand synthesis
4.1.7.2 Restriction enzymes
Restriction enzymes and corresponding buffers were obtained from Gibco BRL Life
Technologies, Basel, CH,  or from New England Biolabs. 
Table 1.7-2
Name Recognition site Application 
Hinf I 5'-G | ANTC-3' PCR-RFLP
BamHI 5'-G | GATCC-3' cloning
KpnI 5'-GGTA |CC -3' cloning
EcoRI 5'-G | AATTC-3' cloning
BglII 5'-A | GATCT-3' cloning
SmaI 5'-CCC | GGG-3' cloning
HindIII 5'-A | AGCTT-3' cloning
4.1.7.3 Other enzymes
Table 1.7-3
Name Supplier Application
Lysozyme Appligene Oncor, Basel, CH protein expression
T4 DNA Ligase Amersham, Buckinghamshire, UK ligation
RNase A Boehringer Mannheim, D RNA digestion
DNase Boehringer Mannheim, D DNA digestion
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4.1.8 Primers
All primers were manufactured by Gibco BRL Life Technologies, Basel, CH.
4.1.8.1 Sequencing Primers
Table 1.8-1
Name Sequence Application
pQE Type III/IV 5'-CGGATAACAATTTCACACAG-3' Sequencing 
pQE30 
and 
pQE16
pQE Type II 5'-GGTCCAGGAGGAAAAAGGC-3'
pQErev primer 5'-GTTCTGAGGTCATTACTGG-3'
M13 fwd universal primer 5'-CCCAGTCACGACGTT-3' Sequencing 
pZF 18u
M13 rev universal primer 5'-CAGGAAACAGCTATGAC-3'
T7 promoter primer 5'-ATTAGGTGACACTATAG-3' Sequencing 
pMOSblue T
vectorU19mer primer 5'-GTTTTCCCAGTCACGACG-3'
4.1.8.2 Primer pairs for recombinant protein expression
Table 1.8-2 Primer pairs for recombinant protein expression
antigen Fwd primer (BamHI)* Rev primer (KpnI)*
23xNAP repeats 5'cgggatcccgTAGTGTAGGTGC
A'3
5'ggggtaccccACTAGCAATAGT
A'3
3D7 fsp 5'cgggatcccgTGGTAATGGTGC
T'3
5'ggggtaccccAGATTGTAATTC
G'3
4x32aa repeats 5'cgggatcccgTGCTCCAAAAGC
T'3
5'ggggtaccccAGGGGTATCAGC
A'3
6x12aa repeats 5'cgggatcccgTACTGCTACAGA
A'3
5'ggggtaccccTTGAACTTTCTGT
'3
3D7 repeats 5'cgggatcccgTCCCCTACTGGT
GCT'3
5'ggggtaccccGGTGGTAGCGGG
AGTACT'3
FC27 fsp 5'-
region
(BamHI)5'cgggatcccgTAAGAGTGTAGGTGCAAATGCTCC
AAAAggaattcc'3 (EcoRI)   + GGAATTCC (EcoRI-Primer)
3'-
region
5'ggaattccAGAAAGTTCAA
GTT'3 (EcoRI)
5'ggggtaccccAGCAGGATTT
TCA'3 (KpnI)
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3'-const.
 (BamHI-KpnI)
5'cgggatcccgTGCACCAGAGA
ATAAAGG'3
5'ggggtaccccTATGAATATGGCA'3
5'3'const.
(BamHI-KpnI)
5'cgggatcccgAATGAAGGTAA
TT'3
5'ggggtaccccTATGAATATGGCA'3
5'3'-const
w/oSP
(BamHI-KpnI)
5'cgggatcccgCTTTAATATTAA
AAATGAAAG'3
5'ggggtaccccTATGAATATGGCA'3
5'3'-const
w/oSP (BglII)
5'gaagatcttcATTTAATATTAA
AAATGAAAG'3
5'gaagatcttcTGAATATGGCAAA'3 
DHFR-5'3'-
const.
5'-region 5'gaagatcttcAATGAAGGT
AATTA'3 (BglII)
5'ggaattccTAGTATTAGA
ACCTT'3 (EcoRI)
3'-region 5'ggaattccGCACCAGAGA
ATAAA'3 (EcoRI)
5'gaagatcttcTGAATATGG
CAAA'3 (BglII)
nested MSP2
(BamHI-KpnI)
5'cgggatcccgGAGTATAAGGA
GA'3
5'ggggtaccccCTAGAACCATGCA
* Capital lettres correspond to msp2 hybridization site, small letters build the recognition site
where the restriction enzyme cuts.
aa: amino acid, fsp: family specific part, w/oSP: without sequence coding for signal peptide 
4.1.8.3 Primer pairs for msp2 genotyping PCR
Table 1.8-3
Name Sequence Position in MAD71
sequence
S1 (fwd) 5'-GAGTATAAGGAGAAGTATG-3' 111-129
S2 (fwd) 5'-GAAGGTAATTAAAACATTGTC-3' 3-23
S3 (rev) 5'-GAGGGATGTTGCTGCTCCACAG-3' 789-811
S4 (rev) 5'-CTAGAACCATGCATATGTCC-3' 709-728
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4.1.9 Markers
Table 1.9-1
Name Supplier Application
1 kb ladder Gibco BRL Life technologies DNA gel electrophoresis
Low molecular weight
marker
Pharmacia Biotech,
Dübendorf, CH
protein SDS-PAGE
Rainbow marker 756 Amersham, Buckinghamshire,
UK
protein SDS-PAGE
immunoblotting
4.1.10 Animals
Female Balb/c mice 4-6 months old were obtained by RCC Biotechnology & Animal Breeding
BRL Laboratories Ltd., Füllinsdorf, CH. 
4.1.11 Other materials and equipment
Table 1.11-1
Name Supplier
0.22 :m syringe membrane filter Schleicher und Schuell, Dassel, D
0.22 :m bottle top filter (Steritop) Millipore, Zürich, CH
10 well glass slides BioMérieux, Lausanne, CH
24-, 48-, 96-well cell culture plates Costar at Integra Biosciences, Wallisellen,
CH
96-well plates Immunlon 2 Dynex Technologies, USA
ABI Prism 310 Genetic Analyzer Perkin Elmer, Rotkreuz, CH
Dialysis tubing Chemie Brunschwig, CH
Electroporator (EasyjecT) Equibio, Boughton, Montchetsea Kent, UK
Electroporation cuvette Equibio, Boughton, Montchetsea Kent, UK
Freezing vials Nunc Inc., Naperville, IL, USA
HyBond-C extra nitrocellulose membrane Amersham, Buckinghamshire, UK
Inverted fluorescence microscope Zeiss, Basel, CH
Mini-PROTEAN II Electrophoresis cell Bio-Rad Laboratories AG, Glattbrugg, CH
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PAGE-chamber BRL V16 Gibco BRL Life Technologies, Basel, CH
Petri dishes (parasite culture) Falcon Labware, Oxnard, CA, USA
Petri dishes (bacteria) Greiner Labortechnik, Kremsmünster,
Austria
policeman rubber Costar at Integra Biosciences, Wallisellen,
CH
Sonicator (Branson Sonifier) Skan AG, Basel, CH
Titertek Multiskan MCC/340 
(ELISA reader)
BioConcept, Allschwil, CH
Whatman 3MM filter paper Whatman, Maidstone, UK
White/UV Transilluminator UVP/Life Science, Braunschweig, D
4.2 Methods
4.2.1 PCR-RFLP-genotyping
4.2.1.1 Polymerase chain reaction
The polymerase chain reaction (PCR) was used for several purposes. A negative control without
DNA template was included in each set of PCR amplifications. 
In general, a 100 :l reaction mix contained the following components: 1.5 U Taq DNA
polymerase (Gibco BRL Life Technologies), 10 :l 10x PCR buffer, 0.2 mM of each dNTP, 0.5
mM of each primer, and 0.1-1 :g DNA template.
Both a primary and a nested PCR were performed to amplify the msp2 locus from DNA extracted
from blood samples. For the primary PCR, 5 :l of the extracted DNA were added to the PCR
reaction mix. The primer pair corresponded to the nucleotides 3-23 and 789-811 of the MAD71
sequence of msp2 (Foley et al. 1992). These nucleotides belong to the conserved 5' and 3' regions
of msp2. Two :l of the primary PCR product were amplified in the nested PCR using nested
primers corresponding to nucleotides 111-129 and 709-728 of the MAD71 sequence (Foley et
al. 1992). The PCR conditions were the same for both PCRs, namely an initial denaturation step
of 5 min at 94/C, followed by cycles of 30 sec at 94/C, 2 min at 55/C, and 2 min at 70/C. A final
elongation step of 10 min at 72/C was added. The nested PCR products were separated on 10%
polyacrylamide gels (BRL V16), stained with ethidium bromide and visualized by UV light. 
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Cycle conditions for amplification of the msp2 fragments used in protein expression approach
were different concerning the annealing temperature of the primers. A lower temperature of 42/C
was chosen since the primer pairs had long non-corresponding sequences which formed the
restriction site for the ligation step. Sequence of primers used are shown in table 1.8-2
4.2.1.2 Restriction digests
In general 20 :l reaction mix was used containing 10x buffer provided by the manufacturer, 2.5
U enzyme and the appropriate amount of PCR product.  If the digested DNA was used for salt-
sensitive applications such as ligation, the digest was precipitated prior to further use.
For msp2 genotyping nested PCR products were digested with Hinf I (NEB) for 2 h at 37/C and
the DNA fragments were separated on 10% polyacrylamide gels at 200 V and 50 mA. Fragment
size was estimated using a DNA size marker (1kb ladder, Gibco BRL Life Technologies).
Samples of one patient from longitudinal studies were run side by side on the gel in order to
identify size differences of the DNA fragments. 
4.2.2 Sequencing
Sequencing was done using the DNA Sequencing Dye Terminator Kit (Perkin Elmer) based on
the dideoxy chain termination method (Sanger et al. 1977). In the cycle sequencing PCR reaction
fluorescent dideoxy nucleotides were used as terminators. The cycle sequencing PCR reaction was
conducted with a  GeneAmp PCR System 2400 (Perkin Elmer). Sequence analysis was carried
out with ABI Prism 310 Genetic Analyzer (Perkin Elmer) and ABI Prism software.
Two different cycle sequencing approaches were applied.
4.2.2.1 Direct sequencing 
PCR amplified DNA fragments were purified by using the NucleoSpinTM Extract 2 in 1 kit
according to the manufacturer's protocol. An additional purification and concentrating step was
included by DNA precipitation with 2.5 vol ethanol and 0.1 vol sodium acetate. The solution was
incubated for 15 min at RT. Precipitated DNA was centrifuged for 30 min at 4/C and 13'000g,
washed, dried and resuspended in 25 :l dH2O. DNA concentration was estimated by agarose gel
electrophoresis. DNA sample (10-30 ng) was subjected to elongation reactions with the AmpliTaq
DNA Polymerase, terminator nucleotides, and the appropriate sequencing primer (table 1.8-1).
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4.2.2.2 Sequencing of plasmids with inserted PCR products
Plasmid DNA preparation was done as described in 2.4.4. The purification and concentration step
(2.2.1 Direct sequencing) was included. Sequencing reactions were done according to the
manufacturer's protocol. The amount of subjected DNA was 200-500 ng per reaction. 
4.2.3 Second strand synthesis 
Small DNA fragments for ligation into the expression vector were produced by second stand
synthesis. The 5'end of the family specific part of FC27 alleles used for expression consists of 46
nucleotides including restriction sites at both ends (table 1.8-2). This fragment was synthesized
by Gibco BRL Life Technologies (Basel, CH) plus a primer of eight nucleotides (GGAATTCC).
Reaction mix containing 0.07 nmol single strand DNA fragment, 0.7 nmol primer, 0.1 mM
dNTPs, 3 U Klenow DNA polymerase, 0.8 :l BSA (10 mg/ml), appropriate amount of 10x
reaction buffer, was incubated for 30 min at 37/C. The Klenow DNA polymerase was inactivated
10 min at 65/C. The sample was cooled down slowly to RT to support correct re-annealing of the
short double stranded DNA. The double stranded DNA product was separated by agarose gel
electrophoresis from primer and single stranded DNA fragment. The desired DNA was purified
by gel extraction according to manufacturer's protocol (NucleoSpin™  Extract 2 in 1, Macherey-
Nagel). The following restriction digest with BamHI and EcoRI was incubated at RT overnight
to prevent denaturation of the double stranded small DNA fragment.
4.2.4 Cloning / Transformation / DNA preparation
4.2.4.1 T/A cloning
The T/A cloning method was carried out with the pMOSblue T-vector kit (Amersham) according
to the manufacturer's protocol. Briefly, the method profits from the template-independent activity
of Taq DNA polymerase adding a single adenosine nucleotide to the 3'end of double stranded
DNA. Such a PCR product can be inserted into the thymidine-tailed vector pMOSblue T-vector
without the requirement for restriction sites. PCR products were purified by gel extraction
according to manufacturer's protocol (NucleoSpin™  Extract 2 in 1, Macherey-Nagel) and the
concentration of eluted DNA was estimated by comparing the intensity of the band with the 1.6
kb band of the 1 kb ladder (100 ng / :l). The 1.6 kb band represents 10% of the whole marker
applied (10 ng / :l). The molecular ratio vector : insert was adjusted to 1:10. Fifty ng of vector
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were used per reaction mix. The 20 :l reaction mixture, recommended by the manufacturer's
protocol, was incubated at 16/C overnight. The pMOSblue T-vector allowed for blue/white
screening of recombinants, when agarose plates containing X-gal (100 :g/ml) and IPTG (100
:M) were used.   
4.2.4.2 Sticky end ligation
This method was used to insert PCR products in frame into the expression vectors pQE30 and
pQE16 (Qiagen) by using PCR primers with appropriate internal restriction sites (table 1.8-2).
Vector and insert were digested with the restriction enzymes, purified by gel extraction
(NucleoSpin™  Extract 2 in 1, Macherey-Nagel) and concentrated by ethanol precipitation. For
the digestion of pQE30 the enzymes BamHI and KpnI were chosen. This digestion had to be
performed in two consecutive reaction mixes with an ethanol precipitation in between, since the
recommended reaction buffers were not compatible. The molecular ratio vector : insert was
adjusted to 1:3 and to 1:6. The final volume of ligation mix was 20 :l. Two U per ligation
reaction of T4 DNA Ligase and the corresponding 10x T4 DNA Ligase buffer from Amersham
were used. Incubation temperature and time was chosen according to the restriction enzyme used
to produce sticky ends. 
Restriction enzyme temperature time
BamHI 4/C 16 h
BglII 16/C 16 h
EcoRI 16/C 2 h
KpnI 16/C 2 h
Ligation mix was precipitated and resuspended in 10 :l dH2O. The DNA was stored at -20/C until
use.
4.2.4.3 Transformation of E. coli cells by electroporation
Electrocompetent cells (M15, JM109 or pMOSblue) were prepared according to standard
protocols (Seidman et al. 1997) and stored at -70/C until use. The E. coli cells were transformed
with the Equibio electroporator  using a pulse program with following specifications: voltage 2.5
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kV, capacity 25 :F, shunt 201 S and pulse time 5 msec. Electrocompetent cells were thawed on
ice. 40 :l of the cells were transferred to a pre-cooled electroporation cuvette and mixed with 4
:l resuspended ligation mix (incubation 1 min on ice). The cuvette was then placed into the
electroporator.  After the pulse the cells were transferred immediately to 1 ml LB medium and
incubated for 30 min at 37/C. 200 :l were plated on an agar plate containing appropriate
antibiotics. Bacteria transformed with pMOSblue T-vector or pZF 18u vector can be screened by
blue/white selection of recombinants (Sambrock et al. 1989). Therefore, bacteria have to be plated
on X-gal/IPTG agar plates. The plates were incubated upside down overnight at 37/C.
4.2.4.4 Analysis of transformed clones
Liquid cultures of E. coli clones pre-selected on agar plates were incubated overnight. The
CONCERT™  High Purity Plasmid Miniprep System (Gibco BRL) was used to obtain very pure
plasmid DNA for subsequent approaches (protein expression , DNA sequencing) according to the
manufacturer’s protocol. Plasmid DNA was digested with appropriate restriction enzymes to
determine the insertion of PCR fragment. All restriction digests were performed as recommended
by the manufacutrer, using the provided 10x reaction buffer. Separation of the DNA  fragments
was done by agarose gel electrophoresis.
4.2.5 Expression and purification of recombinant protein fragments
Expression and purification of the protein constructs were done following manufacturer’s
protocol (QIAexpress Kit Type IV, Qiagen). Briefly, E. coli cells, transformed with one of the
expression vectors, were inoculated into 25 ml Super broth (25 g Trypton, 15 g yeast extract, 5
g NaCl ad 1 L) using the appropriate antibiotics, 100 mg/L ampicillin (Appligene) and 25 mg/L
kanamycin (Sigma), and incubated over night. Fresh Super Broth with antibiotics was inoculated
with the overnight culture (20 ml overnight culture / 1  L fresh medium) the following day. The
cells were grown at 37/C to ODA600 nm = 0.5-0.8, when the protein production was induced
by addition of IPTG (Appligene) to a final concentration of 1 mM. Cells were harvested by
centrifugation after four hours shaking. The pelleted cells were resuspended in lysis buffer (50
mM Sodium dihydrogenphosphate  pH 8.0; 300 mM Sodium chloride; 10 mM imidazole) and
incubated with 1 mg/ml lysozym 30 min on ice. Bacterial cells were ultrasonically disrupted on
ice. If the lysate became very viscous, Rnase A (10:g/ml) and Dnase I (5 :g/ml) was added and
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incubated for 15-30 min on ice. The protein solution was centrifuged at 10.000xg for  20 min at
4/C to pellet the cellular debris. The supernatants containing solubilized fusion proteins were
mixed with appropriate amount of Ni-2+ -agarose and incubated for 1 h in a shaker. Purification
was performed with imidazole (Wash buffer: lysis buffer with 20 mM imidazole, elution buffer:
lysis buffer with 250 mM imidazole). The 5'3'const. recombinant protein was expressed at 25/C
and denatured with 6 M guadinine hydrochloride (6 M GuHCl; 0.1 M sodium
dihydrogenphosphate; 0.01 M TrisCl, pH 8.0) for 1h at 4/C with stirring . Purification was
performed with 8 M Urea (decreasing pH 8.0-4.5). The recombinant protein was eluted at pH 4.5.
20 :l of each protein fraction were analysed by sodium dodecyl sulphate-polyacrylamide gel
electrophoresis (SDS-PAGE) to approximate the purity of the preparations. Pure protein fractions
were pooled and renatured by dialysis as previously described for other MSP2 recombinant
proteins (Takacs and Girard 1991). Protein preparations under native conditions were dialysed
against PBS pH 7.2 to remove imidazole. The proteins were stored at –70 /C until required.
4.2.5.1 SDS-PAGE
Protein aliquots were mixed with 5x SDS-PAGE sample buffer and denatured for 7 min at 95/C.
Aliquots containing imidazole were incubated for 10 min at 37/C. Proteins were separated
according to their molecular mass in a Mini-Protean II Electrophoresis cell (Bio-Rad
Laboratories) by running a discontinuous polyacrylamide gel (Laemmli 1970) with a acrylamide
concentration of 4% and 12.5% in the stacking (upper) gel and  in the separating (lower) gel,
respectively. The SDS-electrophoresis buffer pH 8.3 containing 24 mM Tris base, 0.19 M glycine,
and 1% SDS was used. Protein bands were visualized by staining the gel in Comassie blue
solution and destaining in dH20. The Low Molecular Weight Marker (Pharmacia Biotech) was
used to determine the molecular mass of the separated proteins.
For immunoblotting Rainbow marker 756 (Amersham) was used and the separated proteins were
transferred to a HyBond-C nitrocellulose membrane without staining the gel .
4.2.5.2 Renaturation of recombinant proteins
Renaturation of recombinant proteins was conducted as described by Takacs and Girard (1991).
Briefly, solutions of recombinant 5'3'construct protein in 8 M urea were diluted with diluting
buffer (50 mM glycine-OH, pH 9.0, 5 mM EDTA) to a protein concentration between 0.5-1.0
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mg/ml. The pH of the solution was adjusted to 10.5 with NaOH and DTT was added to 5 mM.
The solution was dialyzed against renaturation buffer (50 mM glycine-OH, pH 10.5, 5 mM
EDTA) at room temperature for 3 h. Dialysis was continued against three changes of 1x PBS pH
7.2 at 4/C over two days. Protein concentrations before and after dialysis were determined
photometrically by the method of Bradford at 8=595 nm (Bradford 1976). One ml reaction mix
containing 800 :l Comassie brilliant blue solution (Bio-Rad) and an aliquot of the protein
solutions were incubated at least 5 min at RT and the absorbance at  8=595 nm was assessed.
Each protein concentration was estimated by using a protein standard curve with different BSA
concentrations. Protein solutions were diluted to appropriate concentrations with 1x PBS for
subsequent immunological approaches. 
4.2.5.3 Preparation of dialysis tubes
The preparation of dialysis tubes was performed as previously described (Bhown et al. 1980).
Briefly, tubes with appropriate specificity (excluding molecular mass 3.5 kDa and 12-14 kDa)
were boiled for 1-2 min in following solutions: 1% Na2CO3; 0.1 M EDTA; 0.1% SDS. In between
each solution change a washing step with dH2O was included. Finally, the dialysis tubes were
boiled twice in dH2O and then stored in 0.02% sodium azide. 
4.2.6 Immunological methods
4.2.6.1 ELISA method
Optimal dilutions of the immunogens and reagents were determined by checker titration with
positive control serum pools and negative control sera (Quakyi 1980). Microtitre plates (Immulon
2; Dynex Technologies, USA) were coated with 50 ml of the protein preparations. Immunogen
concentrations ranged from 0.1mg/ml – 10 mg/ml in PBS pH 7.2. The plates were incubated
overnight at 4/C. Non-adsorbed antigen was removed and the wells were filled with 200 :l PBS
pH 7.2 containing 5% non-fat milk powder to prevent non-specific protein binding to the plastic
surface. After incubation for 2 h at 25/C, plates were washed four times for 20 sec with water
containing 0.5% Tween 20. The excess fluid was removed. Then, 50 :l of test sera diluted 1:500
or 1:1500 with 1x PBS containing 0.5% Tween 20 and 0.5% milk powder were added to the
wells in duplicates. The plates were incubated 1 h at 25/C and then washed as above. Fifty :l of
the appropriate second antibody conjugated to horse radish peroxidase diluted (1:2000) in PBS-
Molecular Diversity and Immunological Properties of MSP238
0.5%Tween/0.5%milk powder were added to each well. Again the plates were incubated for 1
h at 25/C, then washed as above. Last, 50 :l of peroxidase substrate (ABTS peroxidase substrate,
KPL) were added to each well. The absorbance at 405 nm of the content of each well was
determined after incubation for 30 min in a spectrometer (Titertek Multiskan MCC/340). A
positive standard was a pool of 20 sera from semi-immune adults from PNG. Titration of this
standard was performed in each ELISA plate to control the quality of experiments and
interexperimental variation. Sera of 36 healthy European adults, and sera from 36 healthy
European children aged 5-15 months, who had not been exposed to malaria were used as negative
controls to determine the specificity of the assay. All sera were stored at –20/C.  Each test serum
and control serum was tested against the single immunogen and, as a background control, against
a protein solution consisting of DHFR-6His (5 mg/ml PBS), produced in the same way as the
other seven recombinant proteins.
ELISA performed to analyze the antibody response to the recombinant proteins in immunized
mice and to analyze the specificity of antibodies produced by monoclonal hybridoma cells were
done in a similar way. Mouse sera were analyzed with end point titration. AP-conjugated second
anti-mouse-IgG (() antibody diluted 1:1000 and the corresponding carbonate buffer containing
1mg/ml pNP were used. After incubation for 60 min in the dark absorbance at 405 nm of the
content of each well was determined in a spectrometer (Titertek Multiskan MCC/340).
4.2.6.2 Immunoblotting
A semi-dry blotting protocol were used. Blotting was performed in a Trans-Blot SD Semidry
Transfer Cell (Bio-Rad) for 2 h at 0.8 mA per cm2 of gel. The separating gel was cut off the
stacking gel and the separated proteins were electro-blotted in a sandwich setup onto HyBond-C
extra nitrocellulose membrane. Whatman 3MM filter paper with transfer buffer (10 mM CAPS
pH 10.5, 10% MeOH) pre-soaked were used above and below the pre-soaked nitrocellulose
membrane. After the transfer the nitrocellulose membrane was washed two times with wash buffer
IB at RT and was blocked with blocking buffer (AP) or blocking buffer (HRP) (3% BSA, or 1%
MP) for 2 h, depending on the second antibody used. The appropriate dilution of the first antibody
in blocking buffer was applied and incubated at least for 1 h. After an extensive washing
procedure (6x 5 min) with wash buffer IB, the second conjugated antibody was applied and
incubated at least 1 h. Antibody dilutions recommended for the method by the supplier were used.
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Finally, the nitrocellulose membrane was washed in PBS as above. The visualization procedure
depends on the conjugated second antibody used. For AP-conjugated second antibodies
visualization was performed using NBT (0.3 mg/ml) and BCIP (0.15 mg/ml) in appropriate
concentrations in AP staining buffer pH 9.5. Incubation in the dark was done at RT until bands
were visible or maximum 30 min. For HRP-conjugated second antibodies visualization was
performed in freshly made HRP staining buffer (0.018% chloronaphthol in PBS and H2O2) for
maximum 30 min in the dark.
4.2.6.3 Immunofluorescence assay IFA
Ten-well slides were coated with P. falciparum infected red blood cells (cloned lines shown in
table 1.1-1), dried at RT and stored at -70/C until use. Defrosted and dried slides were fixed with
acetone at room temperature for five minutes. Infected erythrocytes were blocked with blocking
buffer (IFA, 1% BSA) for 15 min at RT and in the next step 25 :l of diluted mouse sera or
hybridoma supernatant (dilution in blocking buffer IFA according to ELISA titre) were added to
each well. The slides were then incubated in a humid chamber for 1 h at 37/C. The infected
erythrocytes were washed and then incubated with fluorescein isothiocyanate-labelled secondary
antibody (goat anti-mouse IgG(g), KPL) for 1 h at 37/C in a humid chamber in the dark, washed,
and examined with a fluorescence microscope. The multi-well slides were mounted with 50%
glycerin-PBS and covered with a glass slide. As negative controls non-infected erythrocytes and
pre-immunisation serum were used.
4.2.7 Vaccination 
4.2.7.1 Preparation of the recombinant antigens for immunization
The purified and pooled protein solution was mixed with 5x sample buffer and incubated for 7 min
at 96/C. For preparation of the immunogens 1ml of pre-heated protein fractions were loaded into
a single gel-wide slot of a 8% SDS-polyacrylamide gel. A 120/120/1.5 mm gel was used and was
run at low voltage (voltage 100V, current 20mA) in the cold room. A small portion of the gel was
stained with Comassie blue to locate the relevant protein band. The remainder of the gel was
soaked (without prior fixation) in ice-cold 250 mM KCl for 5 min at 4/C and was washed two
times in ice-cold dH2O for 15 min. At this time the protein became visible as milky band. The
desired protein band was cut out with a razor blade and the material was collected into a sterile
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syringe. One volume of 1x PBS was added and the semi-dry gel material was homogenized by
forcing it through the  syringe until the slurry was fine enough to inject into mice through a 21-
gauche needle. A sample of the slurry was run side by side with the Low Molecular Marker on
a gel to estimate protein concentration and purity. The slurry was stored at -20/C till the end of
the experiment. 
4.2.7.2 Vaccination of Balb/c mice
The immunogenicity of the recombinant proteins was investigated in female BALB/c mice (4-6
months old) by four injections (4x i.p.) of each immunogen (2.5-10 mg) without any further
adjuvants. Each immunogen was tested in two mice. The immunization scale was: 0, 14, 28, 42
days. Pre-immune sera were collected from each mouse. Immune-sera were collected 14 days
after the last injection. The murine sera were used in ELISA and immunoblotting for recognising
the immunogen and the parasites in IFA. Sera were stored as aliquots of 20 :l at -20/C.
The immunization time scale for mice used for monoclonal antibody production were different.
The mice were immunized by three injections (i.p.) of the immunogen (10 :g each) at day 0, 14,
28. Sera were collected from the tail vein. The specificity of produced antibodies was tested by
ELISA, IFA and immunoblotting. Three months later, the mice received the forth injection i.v.
in the tail vein of the immunogen (12 mg) suspended in PBS without any polyacrylamide. After
three days the mice were dissected. 
4.2.8 Monoclonal antibodies
To generate monoclonal antibodies directed against the 5'3'construct spleen cells of the
immunized Balb/c mouse were fused with PAI myeloma cells (mouse myeloma). The fusion was
performed according to standard procedures (Coligan et al. 1995). Instead of feeder layers, HAT
medium was supplemented with 5% conditioned medium from supernatant of  an LPS activated
monocytic cell line (P388/D1; Koren et al. 1975; Melchers and Corbel 1983; Perstidge et al.
1984).
4.2.8.1 Production of P388/D1 conditioned medium
Monocytic P388/D1 cells were cultured to 80% confluence in Iscove's medium prepared with
heat inactivated FCS (FCSi). The culture medium was removed completely and replaced by
Iscove's medium supplemented with 2% FCS and 2 :g/ml LPS from E. coli to induce activation
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of monocytes and subsequent production of B cell stimulating cytokines. After three days, the
culture supernatant was harvested and filtered through 0.22 :m bottle top filter (Millipore). The
P388/D1 supernatant was stored at -20/C until use. 
4.2.8.2 PAI cell culture
Cells lacking HGPRT die in a medium containing hypoxanthine, aminopterin and thymidine (HAT
medium), because both the main and the salvage pathways are blocked. Selection of HGPRT
deficient cells was performed according to standard protocols (Goding 1986).  PAI myeloma cells
used for cell fusion were cultured in myeloma medium containing the toxic base analogue 8-
azaguanine, which is incorporated into DNA via HGPRT, to select for HGPRT-deficient cells.
These deficient cells were harvested by scraping the cells from the bottle surface using a rubber
policeman, centrifuged 5 min at 180g and resuspended with freezing medium. The cells were
stored at –70/C until use. Prior to fusion, freshly thawed PAI myeloma cells were cultured in
hybridoma medium to 80% confluence within one week, not longer to prevent losing the HGPRT-
deficiency.
4.2.8.3 Fusion procedure
Three days after the last antigen booster injection (i.v.) the mouse was dissected under sterile
conditions. The spleen was transferred into sterile wash medium. The spleen tissue was pressed
through a mesh net by using a plunger of a syringe to obtain a single cell suspension. Prepared
PAI myeloma cell cultures were harvested and were suspended in wash medium. 10 :l of cells
were mixed with equal volume of Trypanblue solution and were transferred to a Neubauer
chamber. The concentration of viable cells was calculated by counting non-stained cells in 16
fields. The number of cells per ml is calculated by cell count x2 x10'000. Both spleen and
myeloma cells were washed twice by repeated centrifugation for 5 min at 180g. Before a third
centrifugation step followed, the cells were pooled in equal proportions (cells per spleen 1x 108).
After complete removal of wash medium, 1 ml PEG 1500 solution (Boehringer Mannheim) was
added in steps of 100 :l within one minute. During this procedure the cell pellet was slightly
agitated. The tube was attached to the center of a touring wheel (45/ angle) and the two phases
were mixed 10 min by slow rotation. After the addition of 35 ml wash medium the cells were
centrifuged for 5 min at 180g and resuspended in 160 ml HAT medium. This cell suspension was
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distributed in 200 :l portions in a 96-well culture plate and incubated at 37/C in an atmosphere
containing 5% CO2 (Carbagas, Basel, CH). Culture medium was exchanged on the third day after
the fusion procedure. Growing colonies were examined for production of anti-5'-3'-const. antigen
antibodies by ELISA. Mother clones producing the highest IgG titer were transferred into 48-well
culture plates. The specificity of the produced antibodies was tested by IFA and immunoblotting.
4.2.8.4 Subcloning of Mother clones
The IFA positive hybridoma cells were cloned by limiting dilution. Cells of one well were
resuspended by aspiration with the pipette and were diluted in HAT medium to two different final
concentrations: 0.3 and 3 cells / well. Each cell suspension was distributed in one half of a 96-well
culture plate. Outgrowing single colonies were screened by ELISA. Colonies with the highest
titres were transferred into 24-well culture plates. At this point, culture medium was changed from
HAT medium to hybridoma medium. A final transfer into 25 cm2 tissue culture flask followed.
After reaching the mid-exponential growth phase the cells were split into two 25 cm2 flasks.
4.2.8.5 Harvesting of antibody containing supernatant
The antibody containing supernatant was removed after overgrowth of cells, centrifuged for 10
min at 180g. Aliquots were stored at –20/C until use. 
4.2.8.6 Freezing of hybridoma cells
Hybridoma cells from the second flask were harvested, centrifuged for 5 min at 180g and
resuspended in cold freezing medium. Aliquots were put into –70/C within tight polystyrene
boxes to ensure slow freezing. For storage over longer time periods,  the tubes were transferred
into liquid nitrogen.
4.2.9 In vitro Parasite culture (Matile and Pink 1990)
EDTA-stabilized blood was centrifuged for 5 min at 180g. The supernatant and the white
interphase containing the white blood cells were removed. Pelleted erythrocytes were washed
twice with wash medium. The final RBC pellet was resuspended in an equal volume of culture
medium to obtain a 50% suspension. Resuspended cells were stored up to one week at 4/C. 
Parasites were cultured in 35x10 mm or 100x20 mm petri dishes (2.5 ml, 10 ml) with 5% human
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erythrocytes (blood group A Rh+) according to the protocol of Trager & Jensen (1976). The
parasite cultures were incubated at 37/C in an atmosphere consisting of 92% N2, 5% CO2, and
3% O2 (Carbagas, Basel, CH) and were split when the parasitemia reached 5-12 %. 
To determine the parasitemia of cultured parasites, blood smears were made on glass slides. These
were fixed in MeOH and stained in Giemsa solution for 15 min. The slides were analysed using
oil immersion microscopy.
4.2.9.1 Preparation of merozoites
Merozoites were harvested by using the supernatant of centrifuged iRBCs (10 min at 800g). The
supernatant was transferred to a fresh Falcon tube and centrifuged again for 10 min at 3000g.
Pelleted merozoites were resuspended and used for the preparation of parasite derived proteins
or IFA slides.
  
4.2.9.2 Synchronization of parasite cultures
Synchronization of parasites was done in two cycles. The second synchronization was performed
8-10 h after the first according to the developmental stage of the parasites. D-sorbitol provoke
osmotic lysis of all forms of the parasites except ring forms (Lambros and Vanderberg 1979).
Infected RBCs (about 10% parasitemia) were centrifuged 5 min at 800g. Pelleted cells were
resuspended in 5 volumes of pre-warmed 5% D-Sorbitol solution and were incubated for 5-10
min at 37/C. After centrifugation for 5 min at 800g cells were resuspended in 10 ml culture
medium and 200 :l fresh RBCs. 
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4.2.10 Saponin lysis of P. falciparum infected RBCs (iRBCs)
In vitro cultured parasites were isolated by saponin lysis of iRBCs according to Goman et al.
(1982). With saponin the membrane of erythrocytes is selectively lysed, whereas the
parasitophorous vacuole with the parasite inside remains undamaged. Infected RBCs were
centrifuged for 10 min at 800g. Pelleted cells were resuspended in 20 volumes of saponin lysis
buffer and incubated 10 min at RT. Centrifugation for 10 min at 3000g was performed to pellet
the parasites. The pellet was washed once in 1xSSC and stored at -70/C until use.
4.2.11 Preparation of parasite derived proteins
Preparation of parasite derived proteins was done as described previously (Lanzer et al. 1992).
About 5x109 parasites were suspended in 1ml of PDP lysis buffer (10 mM HEPES pH 7.9, 10 mM
KCL, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM DTT, 0.5 mM PMSF and 0.65% NP-40) and
centrifuged to pellet the nuclear debris. The parasite proteins were resolved in a SDS-PAGE gel
and electroblotted onto a nitrocellulose membrane. The membrane was probed  with the immune
sera of the immunised mice.
4.2.12 Presentation of antibody data
For all MSP2-specific ELISA assays, the positive control serum pool was included in each plate
as dilution series. A regression line was fitted to the control series for each antigen, and the
average of the duplicate readings of optical density at 405 nm (OD405) for each serum sample
was converted to antibody units based on the standard curve. For each single plate the OD405
of the serum pool (minus corresponding background well with DHFR-6His) diluted 1:500 was
defined as 1 unit. Results expressed in antibody units, calculated from the formula:
AU
OD test.serum OD test.serumDHFR
OD pos.serumpool OD pos.serumpoolDHFR
=
-
-
405 405
405 405
Positivity was determined from the mean reactivities plus 2 standard deviations of 36 sera of non-
exposed European children. In addition the latent class model were used to determine the
positivity of the test samples (Vounatsou et al. 1998, Irion et al. 2001a). For further calculations
the values resulted from a modelling based on a latent class model were used.
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4.2.13 Latent class model
Measurements of antibody responses in ELISA often show high levels of heterogeneity, making
it impossible to clearly distinguish responders and non-responders to particular antigens. Typically
a non-exposed control group is used to assign a cutoff value of positivity, calculated as the mean
plus 2 or 3 standard deviations. This can give rise to extremely biased estimates of response rates
when the background is variable, and especially when there is overlap between the distribution
of the control levels and that of responders. We propose that such data should be analysed by
modelling based on a latent class model. 
Assume that the observed population consists of a mixture of non-exposed control group in
proportion (1-8), not necessarily normally distributed, together with the mixing proportion 8 (the
attributable fraction) of exposed (tested) individuals. The distribution of antibody units in the
malaria-exposed children was resolved into two components (g1(.) and g2(.)). One component
corresponds to non-malaria elicited antibody levels (g1(.)) and the other to malaria elicited
antibody levels (g2(.)). Antibody levels from control samples were assumed to be a sample from
the non-malaria elicited antibodies component of the mixture. Let x 1, x2, ... xn be the set of
independent, identically distributed random variables from the two component mixture distribution
F(x) = (1 -8) g1(x) + 8 g2(x),
with g1(.) = distribution of non-malaria elicited antibody levels
g2(.) = distribution of malaria elicited antibody levels
Observations from one component distribution, g1(.) are assumed to be smaller than those from
the other and there is some overlap between the two distributions.
Figure X illustrates how F(x) compares with g1(x) in the case of 8 = 0.8 and g2(x) with the mean
of 0.7 antibody units. The density ratio D(x)=F(x)/g1(x) is the ratio of the frequency of any given
antibody unit value in the population, to the frequency in the control group. If there are no
additional antibodies measured in the tested samples then we expect this ratio to be uniformly 1
and 8=0. On the other hand, if 8 is greater than 0, we expect D to be an increasing function of x.
In the limiting case of no overlapping where g2(x)=0 provides D(x)=(1-8). (Another limiting case
where 8=1 and hence D(x)= g2(x)/g1(x).) Children whose antibody units resulting from malaria
exposure are unlikely to have very small antibody units, so that over the whole range of no
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overlapping of the two subgroups D(x) may be very close to (1-8). 
A simple way to estimate 8 is to split the data into discrete categories of antibody units (x) and
to plot the density ratio (D(x)) for these categories. This is calculated by taking the proportion
of the tested population in that category and dividing by the proportion of the control group
which falls into the same range. The average value which D(x) achieves over low antibody unit
values of x can than be used to obtain a minimally biased estimate of (1-8). Strictly, to completely
eliminate bias the value of the ratio at low antibody units should be estimated by extrapolation,
but in real data sets measurement errors are likely to account for a disproportionate proportion
of the observed density for low values of x. Hence, any bias introduced by using the recommended
procedure is minimal in contrast to errors depending on the laboratory method.
The average level of antibody units among the positive subset of the tested samples is equal to its
mean of the antibody units divided by (1-8). 
In addition to its use in estimating the prevalence of positivity, the density ratio curve can be used
to estimate the probability p that children with a given antibody unit value have antibodies
attributable to Plasmodium falciparum exposure. If there were no additional antibodies measured
then the probability of a given antibody unit would be g1(x). However, the actual probability is
F(x). The difference is attributable to the positive samples. The proportion of individuals whose
antibody level can be attributed to malaria exposure, at any given value of x is equal to: 
p x
g x
F x
F x g x
F x
D x
D x
( )
( )
( )
( ) ( ) ( )
( )
( ) ( )
( )
= = - - = - -l l l2 1 1 1
D(x) and 8 can be estimated directly from the density ratio plot (dashed line in figure 2a and 2b
in paper IV) and the calculates of p(x) thus obtained can be used as an estimate of the probability
that an individual  shows an Plasmodium specific immune response. This probability depends
upon both the individual's own antibody level and on the population distribution.
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4.2.14 Statistical analysis
To determine if any relation between different variables and antibody unit values was significant,
Spearman correlation analyses were performed on the sets of continuous data on antibody
response to an antigen versus listed variables: age of the donor, net use, parasitemia, value of
other antibody responses, multiplicity of infection, number of new acquired infections, number of
lost infections, repeat numbers of msp2 alleles of infecting parasites. Spearman correlation
analyses were used, as the data distribution was non-normal for antibody responses and the other
variables.
T-test procedure was performed to determine if there was a significant difference in antibody
response between sample pairs infected and non-infected with P. falciparum divided by family
specificity of the msp2 allele expressed by the infecting parasites.
Molecular Diversity and Immunological Properties of MSP248
49Study Populations
5. Study Populations
Malaria exposed individuals: 
1. Tanzania
The study in the malaria holoendemic area was performed in the village of Kiberege, Kilombero
District in the Morogoro  Region of southeastern Tanzania. This region is well known as an area
of high perennial malaria transmission. The village has about 6500 citizens and lies at the edge of
the Kilombero river plain. The epidemiology of malaria has been investigated in this area since
decades (Tanner et al. 1991). The annual entomological inoculation rate (EIR) is around 300
(Smith et al. 1993) and more than 60% of the children of five months of age are infected with
Plasmodium falciparum (Kitua et al. 1996). The study design has been described in detail by
Fraser-Hurt et al. (1999). The trial has been lasted from May 1996 to November 1996. In total,
122 children initially aged 5-24 months were split randomly in two groups: the ITN using group
and the control group. For our immunological study, we selected 30 children from  each group,
initially aged 5-15 months.
2. Papua New Guinea
Twenty sera from semi-immune adults inhabiting the Wosera region, a highly endemic area for
P. falciparum malaria in Papua New Guinea, were used as positive controls in various
immunological assays. These sera originate from one of seven community surveys for
immunological and parasitological baseline monitoring of a potential study population (Genton
et al. 1995).
Malaria non-exposed individuals
Sera from non-exposed adults originated from the serum bank of the Swiss Tropical Institute. The
donors have never been travelled to a tropical country.
Sera from non-exposed European children aged 5-15 months were obtained as a generous gift
from the Universitäts-Kinderspital beider Basel, Department of Virology and Serology, Basel,
Switzerland. The healthy children were part of a study concerning allergic disorders.   
Sera storage condition
All sera were stored as aliquots at -20/C until use.
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Abstract
The merozoite surface protein 2 (MSP2) of  Plasmodium falciparum is extremely polymorphic:
82 different msp2 alleles were found in four studies of molecular epidemiology conducted in
Tanzania. This diversity renders msp2 suitable as a marker gene for genotyping of parasite
infections. Amplification of msp2 by PCR, and subsequent restriction digests of the PCR product
(PCR-RFLP genotyping), have proved to be an informative tool for enumerating multiple
concurrent infections in a blood sample, and distinguishing individual alleles.
Depending on the specific questions asked in a genotyping study, analytical techniques of different
degrees of complexity are employed. The restriction fragments resulting from a single Hinf I
digest generally allow the enumeration of multiple concurrent infections and the determination of
their allelic family. When a restriction pattern is too complex to be resolved, owing to the high
number of concurrent infections, or due to the appearance of previously undescribed alleles, one
or more additional digests (Dde I, Rsa I, Scrf I) may be necessary. To unequivocally determine
individual alleles, in particular in longitudinal studies, where several consecutive samples need to
be compared with each other, a more detailed analysis involving all three additional digests is
applied. The methodological experience and results gained in four epidemiological field studies
involving msp2 genotyping are summarized. We also provide the Hinf I restriction patterns and
some nucleotide sequences of the alleles found so far in our studies in Tanzania.
Keywords: Plasmodium falciparum, merozoite surface protein 2, genotyping method, restriction
patterns, sequences, new alleles.
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Introduction
Alleles of the merozoite surface protein 2 (MSP2) are grouped into two allelic families according
to the dimorphic structure of the variable non-repetitive region (Smythe et al. 1990). The
extensive diversity is due to an allele-specific central region which comprises tandem repeats of
varying size. Different copy numbers of these repeats result in length polymorphism. These
characteristics of msp2 have been exploited by several genotyping methods. Common to all
methods of msp2 genotyping is a PCR amplification of the central part of the msp2 gene, which
comprises the allele-specific repetitive region and conserved flanking sequences. The major
methods used for msp2 genotyping are (1) analysis of size polymorphism with subsequent
hybridisation with family specific probes (Foley et al. 1992; Babiker at al. 1994; Ntoumi et al.
1995; Viriyakosol et al. 1995), or (2) restriction fragment length polymorphism of the amplified
product (Felger et al. 1993). msp2 has been used extensively as polymorphic marker gene in
different field studies in different geographic locations either within a multilocus-analysis or in a
single-locus analysis. All studies  showed extensive polymorphism at this locus, even in areas of
low endemicity.
The use of msp2 as marker has proven to be of great use when individual Plasmodium falciparum
infections need to be identified. PCR-RFLP genotyping of parasites for msp2 makes it possible
to distinguish the individual parasite infections concurrently present in a blood sample. The
possibility of tracing individual parasite clones over time allows detailed studies of infection
dynamics. In immunological studies genotyping can also provide important information on the
diversity of antigenic challenge. Most importantly, genotyping makes it possible to determine the
multiplicity of infection, which can be used as an outcome measurement of interventions, such as
drug trials, vaccine trials, or trials to determine the effect of exposure-reducing interventions. 
The msp2 gene is not only an extremely polymorphic marker gene, but its product is also a vaccine
candidate. MSP2 as part of a subunit vaccine is currently under field trial in Papua New Guinea
(PNG) (Genton et al. 1996). Two genotyping studies from PNG have already shown that the two
allelic families of msp2  are differently associated with morbidity (Engelbrecht et al. 1995; Al-
Yaman et al. 1997). Thus, using msp2 for genotyping offers both genetic diversity for high
resolution typing, and additional information on the biological role and significance of MSP2 as
an immunological target. In this paper we describe in detail the PCR-RFLP genotyping technique
and its possible applications, as well as the diversity and RFLP patterns of the msp2 alleles
detected so far in blood samples from the Kilombero District, Tanzania.  
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Methods
Extraction of deoxyribonucleic acid
Infected erythrocytes (RBC) from samples of packed cells (stored at -20o C) were used for
isolation of parasite deoxyribonucleic acid (DNA). After thawing the pellets, 5 :l of packed cells
(equivalent to about 12.5 :l of whole blood) were added to 50 :l 4 M guanidine-isothiocyanate
containing 25 mM sodium-citrate (pH 7.0) and 0.5% sodium-sarcosylsulfate; 5 :l of 0.2 M
sodium-acetate (pH 4.4) were then added. The mixture was left on ice for 10 minutes and then
extracted once with 100 :l phenol (pH8.0):chloroform (1:1), precipitated with isopropanol and
resuspended in 50 :l of distilled water. 
PCR amplification 
Both a primary and a nested PCR were performed for each sample. For primary PCR, 5 :l of the
extracted DNA (corresponding to 0.5 :l RBC pellet) were added to 95 :l of reaction mix
including 1.5 units Taq polymerase (GIBCO BRL/Life Technologies), 50 mM potassium chloride,
10mM Tris-HCl (pH 8.8), 1.5 mM magnesium-chloride, 0.2 mM of each deoxynucleotide (dNTP),
and 0.5 mM of each primer. The primer pair for primary PCR corresponded to nucleotides 3-23
and 789-811 from the 5' and 3 ' conserved region of the MAD71 sequence of msp2 (Foley et al.
1992). The PCR conditions were: 5 min at 94oC followed by 30 cycles of 30 sec at 94oC, 2 min
at 55oC, 2 min at 70oC. Two :l of the primary PCR product were reamplified in a nested reaction
(total volume 100 :l) with nested primers (Foley et al. 1992) corresonding to nucleotides 111-129
and 709-728 of the same sequence. The cycle conditions for nested PCR were the same as for the
primary reaction. In earlier msp2 genotyping studies in PNG, PCR conditions with a lower
annealing temperature, according to Foley et al. (1992), were used. However, due to the
complexity of Tanzanian P. falciparum infections, a higher annealing temperature was chosen to
increase specificity, in spite of reduced yields of PCR products. The nested PCR products were
separated on a 10% polyacrylamide (PAA) gel. Samples from which no detectable PCR product
was obtained were re-examined at least once, starting from the DNA preparation. For quality
control, DNA extraction, both rounds of PCR, and restriction digests were repeated for 10% of
all samples. 
Restriction digests 
Nested PCR products were routinely digested with Hinf I for 2 hours and then run on 10% PAA
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gels (BRL V16) using 1 mm spacers. The separation was improved if the gels were prepared at
least 1 day before use. Gels were stained with ethidium bromide and photographed or
electronically recorded. Fragment sizes were estimated by comparison with a DNA size marker
(1 kb ladder, Gibco BRL Life Technologies). If samples from longitudinal studies were to be
compared with each other, they were run side by side on the gel. When a higher discriminatory
power of the RFLP pattern was desired, usually in the case of new alleles or ambiguities,
additional Dde I, Rsa I and Scrf I restriction digests were performed. When direct comparison of
RFLP patterns with those of already defined alleles was needed, restriction digests of both the
known and the unknown PCR product were repeated, and run side by side on a PAA gel.
Similarly, when consecutive blood samples from a longitudinal study had to be compared with
each other, the digested PCR products of these samples were run on the same gel side by side, in
order to identify size differences of a few nucleotides.
Results
Diversity of Tanzanian msp2 alleles 
We performed several genotyping studies with blood samples from Ifakara or neighboring villages
in Tanzania. In all studies the same PCR-RFLP typing method was used. Taking the four studies
listed in Table 1 together, 3506 individual infections with P. falciparum were genotyped. In these
samples 82 different msp2 alleles were detected, of which 41 belonged to the FC27 family, and
41 to the 3D7 family.
Principles of PCR-RFLP genotyping 
To determine the number of concurrent infections per blood sample (multiplicity of infection), or
to discriminate whether an allele belongs to the 3D7 or FC27 allelic family, only a single restriction
digest (Hinf I) is performed on the nested PCR product of the msp2 gene. The dimorphic region
of msp2 shows family-specific Hinf I restriction sites which are located in the variable non-
repetitive region and which are shared by most alleles of the same family. Only rare point
mutations within a Hinf I site, or the appearance of a new repeat type in the FC27 family, were
found to cause deviations from the ubiquitous family-specific restriction fragments. In all other
cases, size deviations were caused by crossing over between alleles of different families. The
family-specific restriction fragments resulting from Hinf I digests of FC27-type alleles are two
fragments with lengths of 137 bp and 115 bp, and of 3D7-type alleles, two fragments of 70 bp and
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108 bp. Fragments of these sizes can easily be discriminated on a 10% PAA gel. Thus, either one
pair of fragments or the other indicates the presence of at least one allele of the respective allelic
family. If both fragment pairs appear in one sample, at least one allele of each family is present.
The total number of different alleles found in a given blood sample is determined by the remaining
Hinf I restriction fragments which form an allele-specific pattern. These restriction patterns of
individual alleles will be presented below.  
FC27 family of msp2 alleles
Table 2 lists all 41 FC27-type alleles found in these studies, their restriction fragments obtained
after Hinf I digestion of the nested PCR product, and the GenbankTM accession numbers of those
alleles already sequenced. Some alleles contained more than one 96 bp Hinf I fragment, as
indicated in Table 2. A 96 bp Hinf I fragment is generated if an allele contains at least two copies
of a 96 bp repeat unit in tandem array. Therefore, the actual number of repeats equals the number
of 96 bp fragments +1. 
Hinf I restriction digestion of a nested PCR product of FC27-type alleles normally produces two
conserved fragments of 137 bp and 115 bp, which represent the 5' and 3' ends of the amplification
product, respectively. A selection of Hinf I digested FC27-type alleles from Tanzania is shown in
Fig.1. The family-specific fragments (115 bp and 137 bp) are present in all alleles in lanes Wos6
to K1. Two repeat units (96 bp and 36 bp) are characteristic of all FC27-type alleles. At least one
copy of each repeat is normally present in an allele of the FC27 family, while different alleles vary
in the number of copies of 96 bp and 36 bp repeats present in the central region of the PCR
product. Thus, this central region gives rise to allele-specific restriction fragments. Due to
variation in the copy number of a 36 bp repeat between one and 7, the largest Hinf I fragment in
FC27-type repeats varies from 162 bp in Ifa46 to 378 bp in Ifa4. Lanes Ifa46 to K1 in Fig. 1
represent a selection of alleles, which differ only in the number of the 36 bp repeats present. The
smallest allele, Ifa46, has one copy of the repeat, the longest allele, K1, has 5 copies. A 96 bp Hinf
I fragment (as seen in Fig.1, lanes Wos6 and D10) represents two or more copies of the 96 bp
repeat unit.
In many FC27-type msp2 alleles from Tanzania, a third repeat type was discovered, which
increased the size of the family-specific 137 bp Hinf I fragment at the 3' end of the amplification
product (Irion et al. 1998a). Substituting for the 137 bp fragment, new fragment sizes were
generated by different copy numbers of this 9 bp repeat encoding the amino acids asparagine (N),
alanine (A) and proline (P).  As a result, the size of this normally conserved fragment can range
I6 Molecular Diversity and Immunological Properties of MSP2
from 146 bp in Ifa1, 182 bp in Ifa13, and 200 bp in Ifa11 to up to 335 bp in Ifa23 (see Fig.1),
which contains 23 copies of the NAP repeat.
3D7 family of msp2 alleles 
Hinf I restriction digestion of a 3D7-type allele produces two conserved restriction fragments of
70 bp and 108 bp, which both derive from the 3' end of the msp2 nested PCR product. One further
large Hinf I fragment is obtained, which varies between alleles. Individual alleles were named
according to the size of this fragment, e.g. 3D7370. Other, unusual restriction patterns can also,
though rarely, be found in this allelic family, mostly due to point mutations, creating new Hinf I
restriction sites. 3D7-type alleles with deviations from the conserved Hinf I pattern are presented
in Table 3.
Recombinant forms between the two allelic families 
Alleles which represent recombinations between the FC27 and the 3D7 family have also been
found in Tanzanian blood samples. These recombinations are revealed by Hinf I restriction
fragment analysis by their unusual fragment lengths. The Hinf I restriction digests of two
recombinant alleles (Ifa18, Ifa42) are shown in Fig. 1. Nucleotide sequencing revealed that in all
examples analysed so far, the site of recombination was located at the 5' end of the 96 bp repeat
unit (Irion et al. 1998a). In all recombinations for which sequence data are accessible, the 5' end
was derived from a 3D7-type allele, and the 3' end was of the FC27 type. PCR products of msp2,
representing recombination between the 3D7 and the FC27 allelic families, are grouped with
FC27-type alleles and listed in Table 2, because they contain mainly FC27-type sequences, in
particular the FC27-family specific 36bp and 96bp repeats.
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Multiple infections in Tanzanian blood samples 
To illustrate the use of our RFLP genotyping method for P. falciparum infection in Tanzanian
blood samples, an example of a multiple infection (multiplicity of 4) is shown in Fig. 2. The
photograph shows Hinf I restriction digests separated on a 10% PAA gel. The fifth lane represents
a naturally-occurring mixed infection in a Tanzanian blood sample. The restriction patterns of all
four individual alleles contained in this mixed infection are shown separately in lanes Wos7,
Wos12, Wos10 and 3D7400.
When analysing multiple infections, the intensity of ethidium bromide staining of individual bands
in the PAA gel has to be considered. All Hinf I fragments of an allele show the same intensity, and
can therefore be grouped together.  Fragments which are shared by several alleles, also appear as
dominant bands, as can be seen in the mixed sample of Fig. 2. Here the 115 bp and 137 bp Hinf
I fragments stood out as the strongest bands, because these two fragments were present in 3 of
the 4 co-infecting alleles. Wos 7 (Fig. 2) contained three copies of the 96bp repeat, resulting in
two 96 bp Hinf I fragments, indicated by the increased intensity of staining of this fragment
compared to the other Hinf I fragments of this allele. 
Additional restriction digests increase the resolution of the genotyping scheme  
In some studies, not only multiplicity and allelic family were to be determined, but it was also
necessary to trace individual alleles in consecutive blood samples. For this purpose, a more
complex genotyping technique was applied, involving four different restriction digests and side-by-
side runs of the samples to be compared on the gel. Because the variable, allele-specific  Hinf I
fragment of 3D7-type alleles is too large (250 to 550 bp) to identify an allele unequivocally by gel
electrophoresis, further restriction digests (Dde I, Rsa I, Scrf I) are necessary which yield smaller
and allele-specific fragment sizes. This allows further differentiation between 3D7-type alleles
showing a Hinf I fragment of similar size (differences < 10 bp). The conserved and variable
restriction fragments resulting from Rsa I, Dde I and Scrf I digests of 3D7-type alleles have been
described earlier (Felger et al. 1994). These additional restriction digests are generally done, if
infections from different blood samples need to be compared to each other. Further restriction
digests in addition to Hinf I are also useful for the determination of recombinant, new, or 3D7-type
alleles. These extra digests increase the discriminatory power of this genotyping scheme
considerably and allow the identification of individual alleles.
Potential use of msp2 genotyping by PCR-RFLP
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The potential of PCR-RFLP typing for direct comparison of blood samples is shown in Fig. 3. This
example derives from a drug test where recrudescent and new infections were  discriminated (Irion
et al. 1998b). Each lane represents a consecutive blood sample from the same donor. In this
example, baseline samples A and B (day 0 and day 3 were defined as baseline) clearly showed
RFLP patterns different from samples C and D. Sample A contains 4 different infections, two of
which belonged to the FC27 family (Ifa1, Ifa4), and two were of 3D7 type (3D7320, 3D7430). The
second baseline sample B showed the same alleles with the exception of Ifa1, which was missing.
All baseline genotypes had disappeared from subsequent samples (C and D), which both contained
two new and distinctively different infections (Ifa40 , 3D7340). By conventional microscopy, these
samples would have been identified as recrudescences and treatment failures.
Comparison of PCR-RFLP with two-loci-genotyping 
In a previous study (Beck et al. 1997) genotyping results were available for both loci, msp2
genotyped by PCR-RFLP (Beck et al. 1997), and msp1 (W. Huber, personal communication),
which was genotyped for allelic family by family-specific nested PCR amplification as described
by Huber et al. (1998). A comparison of multiplicity obtained from each locus made it possible to
assess the gain in resolution by genotyping an additional locus. The analysis of msp1 was based
on the determination of allelic families only, size variations of the msp1 PCR products not being
considered.  Only in 7 of 269 infections did the additional msp1 genotyping improve the resolution
obtained by the msp2  PCR-RFLP method (Table 4). This increased resolution was due to
infections defined as single clone infections by msp2 PCR-RFLP typing. 7 of which were defined
as mixed infections when defined by msp1 typing. In these cases, two different parasite clones
shared the same msp2 allele, or at least, produced the same RFLP pattern. However, in all cases
of multiple simultaneous infections, additional msp1 typing did not increase the multiplicity of
infection determined by msp2 PCR-RFLP genotyping. 
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Discussion
Genotyping P. falciparum field isolates is useful for a wide variety of applications. While we were
mainly interested in detecting multiplicity of mixed clone infections and in studying infection
dynamics, other research applications could include finding markers for virulence or drug
resistence. Since only limited amounts of blood are available in epidemiological studies,
amplification of a marker sequence by PCR is the method of choice. Potential genotyping markers
are sequences showing polymorphism within a parasite population. Polymorphisms in both
repetitive sequences and unique sequences have been used for genotyping (Robert et al.  1996).
When polymorphic repetitive sequences are amplified by PCR, a clone-specific pattern of multiple
bands is seen after separating the PCR products on a gel. However, for the multiple concurrent
infections, normally found in areas of high malaria transmission, these banding patterns
superimpose each other and become too complex to analyse. A selection of unique DNA
sequences, suitable as polymorphic markers, is available in P. falciparum because of its highly
diverse surface antigens. The most promising marker for genotyping is the one showing the most
extensive polymorphism. We chose msp2 as a marker gene for two reasons: (1) with 82 different
alleles detected so far in Tanzania, msp2 offers the genetic diversity necessary to allow single locus
genotyping. The polymorphism is of such an extent that superinfection with the same genotype
as the previous one is highly unlikely (Smith et al. 1999b). This fact allowed the use of msp2 as
a marker to discriminate between new P. falciparum infections and recrudescenes in a drug trial
(Irion et al. 1998). (2) Besides information on multiplicity of infection, further information about
the biological role of MSP2 can be gained from epidemiological studies which involve msp2 as a
marker gene, i.e., morbidity associations of certain msp2 alleles or an allelic family.
In analyzing genotyping data it has to be remembered that there are intrinsic limitations of the PCR
technique. It has to be noted that the number of concurrent infections detected by PCR is always
a minimum estimate of the number of  different parasite clones which are present in a carrier.
Some clones might be missed owing to the detection limit of the PCR technique, which might miss
infections of very low density, or to sequestration of parasites at sampling as shown by Farnert et
al. (1997). Furthermore,  Contamin et al. (1995) showed that in multiple infections, the most
abundant allele in a blood sample can suppress the amplification of an allele which is less abundant
in the sample. However, statistical analyses of longitudinal data can be used to estimate the extent
of such imperfect sensititvity (Smith et al. 1999b). Our knowledge of heterogeneities in densities
of individual genotypes in multiple infections remains limited, and further development of
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quantitative genotyping techniques is needed to fully understand the interdependence in multiple
clone infections. 
We are also aware that alleles resulting from recombination between the allelic families remain
undetected if no obvious alteration in the restriction patterns is caused. PCR amplification with
mixed family-specific primers provided evidence for a high frequency of recombination (Ntoumi
et al. 1997). This was not observed in our studies. A further limitation of genotyping by RFLP
consists in sequence diversity located outside the restriction sites. In order to test  this, we have
previously conducted single-strand conformation polymorphism (SSCP) experiments, using the
FC27 allele (defined by PCR-RFLP) from different isolates. We were not able to detect intraallelic
variation within 36 samples (Felger et al. 1997). In order to establish the full extent of sequence
diversity in a marker gene, direct sequencing is necessary. However, this is not feasible in
epidemiological studies, and direct sequencing is not possible if multiple infections are
simultanously present. A more detailed critical evaluation of PCR-RFLP genotyping can be found
in Snounou & Beck (1998).
In spite of the high resolution of PCR-RFLP genotyping of msp2, there is an obvious inherent
limitation in using only one locus, since two infections sharing the same msp2 allele will be
determined as one. This problem can be reduced by genotyping a second gene in addition to msp2.
Other studies have used multiple locus genotyping, with low resolution for each individual locus.
This introduces the problem of estimating the total number of concurrent infections. The
probability of recombination increases the possible maximum number of concurrent infections to
the number of multiple genotypes found at one locus times the number of multiple genotypes
found at a second locus. This rarely reflects the real situation in the individual host. However,
advanced statistical analysis allows to estimate the mean multiplicity for the host population (Hill
& Babiker, 1995). Using this method, an estimate of the mean multiplicity of 3.3 was obtained
from 53 sampes from the same area in Tanzania (Babiker et al. 1997). This estimation was based
on genotyping data generated by hybridisation with oligonucleotide probes specific for allelic
families to blotted PCR products from the two loci msp1 and msp2. This result is closely
comparable to our own findings (Fraser-Hurt  et al. 1999). However, this method does not provide
usable estimates of multiplicity for individual carriers, and the result depend on assumptions about
the population structure of the parasite.
With any genotyping method available so far, only a lower limit to the number of concurrent
infections can be determined. By adding more polymorphic markers, such as msp1, the apparent
I11msp2 Genotypes of Plasmodium falciparum
degree of diversity can be further increased, at least in single infections, and thus can contribute
to a more exact determination of multiplicity. However, for studies of infection dynamics or
comparative studies, where individual parasites need to be traced in consecutive blood samples,
the amplification of several polymorphic genetic loci does not improve the information already
gained by the most diverse marker gene. This is due to the fact, that all marker genes used to date
are unlinked, and therefore a multi-locus genotype of an individual parasite clone cannot be
identified in multiple infections.
Furthermore,  a comparison of results obtained by PCR-RFLP genotyping of msp2 with results
from genotyping for msp1 allelic families revealed that the additional locus did not contribute
much to the determination of multiplicity. msp1 typing improved the resolution of PCR based
genotyping only in 2.6 % of the samples, all of which appeared to be single infections with respect
to msp2, but were shown to be double infections with respect to msp1. We therefore concluded
that in Tanzanian blood samples, with an average of 5 detected infections per child, the single
locus PCR-RFLP typing using msp2 has adequate discriminatory power. There are some purposes
for which multilocus typing is necessary, for instance studies of linkage disequilibrium , searching
for markers of virulence of pathogenicity, or checking whether factors modifying parasite
multiplicity or diversity selectively affect particular loci (e.g., locus-specific efects of a vaccine).
Hill & Babiker (1995) also described how the mean multiplicity in a population can be estimated
from such multilocus typing data. Using this method, Babiker et al. (1997) estimated the mean
multiplicity in 53 samples from Michenga village in Tanzania to be 3.3, based on data generated
by hybridization of oligonucleotide probes specific for allelic families to blotted PCR products of
the 2 loci msp1 and msp2. While this result was very similar to direct estimates of multiplicity for
this area from PCR-RFLP genotyping of msp2 alone (Smith et al. 1999a), the multilocus approach
has several disadvantages when the objective is to relate the number of infections in a host to
individual characteristics such as age, morbidity risks, or risk factors for infection. It is much more
straightforward to analyse relationships of other variables with multiplicity when it is measured
by a single number, and the Hill & Babiker (1995)  approach does not lend itself to providing
estimates of multiplicity for individual carriers. Moreover, the estimates of multiplicity depend on
assumptions about the population structure of the parasite.
The analysis of studies involving longitudinal tracking of individual infections is also much more
straightforward if high resolution single-locus typing is used. Such applications include
comparisons of baseline and recrudescent genotypes in vaccine and drug trials in order to
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distinguish treatment failure from reinfection (Irion et al. 1998; Snounou & Beck 1998), and
studies of infection dynamics (Smith et al 1999b). High resolution typing of a single locus gives
rise directly to patterns of appearance and disappearance of individual infections. In contrast,
multi-locus genotypes of individual parasite clones cannot be identified in multiple infections, since
the marker genes used to date are unlinked. Hence longitudinal studies using multilocus
genotyping in areas of high parasite multiplicity can give rise to patterns which are difficult to
interpret.
The extreme genetic polymorphism detected in particular in msp2, but also in other surface
antigens of Plasmodium, raises further questions. For example, do individual alleles persist in time
and space, or are new forms generated constantly de novo?  A third possibility consists of a
combination of both alternatives: a panel of defined conserved alleles plus newly generated
ephemeral genotypes. Questions about the molecular evolution of msp2 alleles have been
addressed (Conway 1997; Felger et al. 1997), but not yet fully been answered. Nucleotide
sequence comparisons between alleles of distant geographical origin indicated that alleles persist
(Dobano et al. 1997).  A large body of information on msp2 genotypes is now available from the
four studies summarized here, which we have conducted in Ifakara and Kilombero valley,
Tanzania, in different years, using the same PCR-RFLP method for genotyping. The diversity of
msp2 was similar in all four studies. This suggests that though the genetic diversity is extensive,
it is nevertheless limited by structural constraints or immune selection. This hypothesis has been
previously proposed for the FC27-type alleles (Felger et al. 1997). The results of our molecular
epidemiological studies (listed in table 1) clearly showed that most of the alleles, in particular the
most frequent ones, were found in all studies at comparable prevalence (data not shown). The fact
that some rare alleles were not found in all studies might be due to sampling variation, which might
miss alleles of low frequency. Alternatively it could indicate that these rare alleles existed only for
a short period of time. Even in studies comparing genotypes found in PNG and Tanzania, no major
differences were observed, except for the group of new FC27-type alleles containing different
numbers of a new 9 bp repeat unit, which was not detected in PNG. This extensive but restricted
diversity might be due to functional constraints of MSP2 and might therefore help to elucidate the
biological role of this molecule.
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Table 1: Comparison of numbers of different msp2 alleles of Plasmodium falciparum found
in four studies of children from the Kilombero valley, Tanzania.
Reference total no. of
individual P.
falciparum
infections
no. of different
alleles
no. of FC27-
type alleles
no. of 3D7-type
alleles
Irion et al. 1997 1034 58 26 32
Beck et al. 1997 292 51 18 33
Felger et al.
1999
365 50 24 26
Fraser-Hurt et
al. 1999
1815 68 34 34
total 3506 82 41 41
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Table 2: Details of 41 msp2 genotypes of the Plasmodium falciparum FC27 allelic family from
Tanzania
 
msp2 genotypes Genbank™  accession No. Hinf I restriction fragments (bp)
D10 JO3828 1x96 115 137 162
Ifa1 AF010462         115 146 234
Ifa2         115 308 162
Ifa4         115 137 378
Ifa10         115 164 162
Ifa11 AF010454         115 200 198
Ifa13 AF010455                    115 182 162
Ifa141 AF010456 2x96  115 131 162
Ifa15         115 218 162
Ifa16         115 146 270
Ifa17 1x96  115 146 1262
Ifa181 AF010457         115 239 162
Ifa23 AF010463         115 335 162
Ifa27  1x96 115 107 1262
Ifa28         115 137 342
Ifa30 1x96 115 191 162
Ifa31 AF010458         115 191 198
Ifa32 1x96 115 137 198
Ifa33    1x96 115 137 1502
Ifa34        115 191 234
Ifa36         115 218 198
Ifa38         115 137 1262
Ifa40         115 254 162
Ifa41 AF010459         115 272 198
Ifa421 AF010460 115 31+82 162
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Ifa43         115   - 371
Ifa44         115 146 306
Ifa45 3x96  115 137 162
Ifa46 AF010461         115 137 162
Ifa471 1x96 115 -90 1262
Ifa49 115 254 162
Ifa50         115 173 198
Ifa51 1x96 115 137 234
Ifa52         115 281 162
Ifa54 2x96 115 137 1262
K1 M59766         115 137 306
Wos10 U07010         115 137 198
Wos12 U16696         115 137 270
Wos3 U07003         115 137 234
Wos6 U07006 3x96  115 137 1262
Wos7 U07007 2x96  115 137 162
1) cross over
2) deletion
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Table 3: Details of 9 msp2 genotypes of the Plasmodium falciparum 3D7 allelic family from
Tanzaniaa
msp2 genotypes Genbank accession no. Hinf I restriction fragments
(bp)
Ifa5        70, 108, -550
Ifa6   51, 70, 108, -310
Ifa7 AF033860   51, 70, 108, 386
Ifa8   51, 70, 108, -400
Ifa20        70, 23+85, -370
Ifa24 AF033859        70, 108, 266
Ifa39   51, 70, 108, -290
Ifa48   51, 70, 108, -330
Ifa53        70, 108, -250
aOnly genotypes with unusual restriction fragments are listed.
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Table 4: Numbers of concurrent infections detected by genotyping msp1 and msp2 of
Plasmodium falciparum in multiple infections in 269 blood samples from Tanzania
                                                       msp2
                  1          2            3    4          5      6        7  8
msp1 total
1 38 24 15 14 13 4 3 1 112
2 7* 15 20 17 32 13 16 23 143
3 0 0 0 1 3 4 3 3 14
269
*Samples in which genotyping for two loci resulted in a gain in the resolution of multiple infections.
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Figure 1: Hinf I restriction patterns of selected FC27-type msp2 alleles of Plasmodium falciparum
from Tanzania. Restriction fragments were separated on a 10 % PAA gel. The fragment sizes and
GenbankTM accession numbers of these alleles are listed in Table 2. Lane M: DNA size marker (1
:g of 1 kb ladder, Gibco BRL Life Technologies); lanes Wos6 and D10: alleles with 4 (Wos6) or
2 copies (D10) of the 96 bp repeat; lanes Ifa46-K1: increasing copy numbers of the 36 bp repeat
ranging from Ifa46 (1 copy) to K1(5 copies); lanes Ifa1-Ifa23: increasing numbers of the 9 bp NAP
repeat with 2, 6, 8, 23 copies, respectively; lanes Ifa18 and Ifa42: recombined alleles.
Figure 2: Hinf I digest of msp2 alleles of a Plasmodium falciparum multiple infection from a
Tanzanian blood sample, which shows a multiplicity of four concurrent infections. In order to
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demonstrate how a complex restriction pattern is analysed, digests of corresponding alleles (Wos7-
3D7400) were loaded beside the RFLP pattern of the multiple infection. Lane M1: 1 :g of 1 kb
ladder (Gibco BRL Life Technologies); lane M2: 1 :g of 100 bp DNA Marker (Gibco BRL Life
Technologies).
Figure 3: Comparison of four subsequent blood samples (days A, B, C, and D) from a patient
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infected with Plasmodium falciparum and participating in a longitudinal drug efficacy study. A and
B show genotypes of parasites at baseline, C and D represent parasites appearing after treatment.
PCR products of msp2 were digested with the restriction enzymes Dde I, Hinf I, Rsa I, and ScrF
I. The resulting fragments were separated side by side on a 10 % PAA gel. On days C and D, all
baseline genotypes had disappeared, while two new genotypes were found. Lane M: 1:g of 1 kb
ladder DNA marker (Gibco BRL Life Technologies).
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Abstract
In areas highly endemic for malaria, repeated  infections with Plasmodium falciparum  result in
the development of acquired immunity  which, although  not sterilising,  protects older children and
adults against severe disease. The immunological  basis of this immunity  is still unknown, but it
has been speculated that the accumulated immune  responses against antigenically  diverse parasite
proteins would be an important  factor. In addition, the establishment  of a persistent protection
may depend on the presence of concomitant infections. Here we report a study examining
antibody responses to different domains of different merozoite surface protein 2 (MSP2) in
consecutive serum samples from 60 Tanzanian children initially aged 5-15 months from an area
with intense and perennial  malaria  transmission.  The MSP2 alleles of the corresponding were also
analysed PCR-RFLP genotyping.
The pattern of response in these children was extremely complex with antibodies produced to
different parts of the merozoite surface protein 2 by different children. The frequency of
responders was high,  although  the magnitude  of the antibody responses was generally low. Levels
of antibody responses were quite variable to any one part of the protein. 
In addition, we demonstrated that the use of insecticide treated bed nets does influence the
development of antibody responses to MSP2. Hence, transmission  blocking interventions in
infants and children should be monitored concerning the development of immune  response to P.
falciparum.
Key words: malaria, Plasmodium falciparum, genotypes, merozoite surface protein 2,
insecticide-treated bed nets, IgG antibody response, ELISA, children, Tanzania.
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Introduction
In areas highly endemic  for malaria,  repeated infections with Plasmodium falciparum  result in
the development of acquired immunity  which, although  not sterilising,  protects older children and
adults against severe disease (Barragan et al. 1998). In infants in the  highly endemic area of the
Kilombero valley of Tanzania,  the period of highest susceptibility to clinical malaria  among infants
occurs between the ages of 4 and 12 months, and the incidence of malaria-attributable  morbidity
reaches a peak at six months of age (Kitua et al. 1996). The underlying  mechanisms of protection
in older children are poorly understood. Passive transfer experiments with purified antibodies from
hyperimmune  sera to susceptible children provided evidence for the protective or at least
modifying effect of the IgG fraction in combination with monocytes on the disease
(Bouharoun-Tayoun  et al. 1990; Kumaratilake  et al. 1997). Whilst many blood-stage proteins
have been identified, their significance  as immunological  targets is unknown (Long 1993). It is
believed that the total responses against polymorphic antigens and against parasite-derived
variable antigens on the surface of the infected erythrocyte contribute to the development of
immunity  (Giha et al. 2000). Recently, we proposed that the concomitant infections may also be
important  for the development of protective immunity (Smith et al. 1999c). This hypothesis
implies that limited cross-protection between given polymorphic antigens exist. Therefore, we
examined humoral immune responses to the merozoite surface protein 2 (MSP2), a promising
vaccine candidate (Genton et al. 2001) and one of the most diverse antigens of P. falciparum
which may be involved in protection. MSP2 is an integral  GPI-anchored membrane protein with
conserved carboxy- and amino-terminal  regions flanking  a central variable region. The variable
region comprises non-repetitive,  semi-conserved sequences and highly variable repetitive
sequences (Anders and Smythe 1989; Smythe et al. 1990). The basic structure can be classified
as dimorphic,  falling  into two allelic families: IC1/3D7  and FC27 (Thomas et al. 1990; Smythe
et al. 1990). The role of this dimorphism  is unknown, but FC27-type msp2 genotypes have been
associated with higher  parasite densities and morbidity (Engelbrecht  et al. 1995) and Felger et al.
(1997) suggested that these allelic families are subject to different selection mechanisms. In a
prospective study in Papua New Guinea, Al-Yaman et al. (1995) demonstrated a positive
association between antibody levels to 3D7-type MSP2 at baseline and reduced clinical malaria
during  one year follow-up. Antibody levels to 3D7-type MSP2 were also found to be lower
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among children who died from cerebral malaria  than among those who survived, indicating a
protective role for these antibodies against severe malaria (Al-Yaman et al. 1997a).
To investigate the role of dimorphism  and of the distinct domains of MSP2 in immunological
recognition and to assess any correlation with observed parasitemia,  we expressed different MSP2
constructs in E. coli. These constructs were tested in serological assays with multiple serum
samples from children living  in a highly endemic area in order to identify the domains recognized
and to investigate the development of antibody responses in early childhood. All infecting
parasites were genotyped for msp2 by PCR-RFLP. Because this study was performed within the
context of an insecticide treated bed net (ITN) study we were able to test the effect on antibody
dynamics of long term use of ITNs.
Study design and Methods
Serum samples: serum samples were collected in the village of Kiberege, Kilombero District,
southern Tanzania.  The area is holoendemic for malaria  with approximately 300 infectious bites
per year with perennial  transmission  and little seasonal changes of parasite prevalence and density
(Smith et al. 1993). The study was previously described in detail by Fraser-Hurt et al. (1999).
Seven consecutive finger-prick  blood samples collected at one month intervals were selected from
30 children initially  aged 5 to 15 months who used insecticide-treated nets, and from 30 children
of the same age group not using ITNs. All blood samples were genotyped by PCR-RFLP on msp2
as described and reported elsewhere (Felger et al. 1999, Smith et al. 1999b). Serum samples from
semi-immune adults from PNG were  used as positive controls. Sera from 36 healthy European
adults and from 36 European children aged 5-15 months, all never exposed to malaria,  were used
as negative controls. 
Production of recombinant msp2-clones: seven different msp2 constructs as shown in figure 1
were expressed in the procaryotic pQE expression system (Qiagen) in E. coli M15.
Corresponding primer pairs with restriction sites (5’ BamHI, 3' KpnI) were used to amplify
distinct regions in the msp2 gene (Table 1) derived from different msp2 alleles. Subsequently,
PCR products were cloned in the pQE30 expression vector as a fusion protein with six histidine
residues at the 5' end. For an improved yield, the 5'3'-constant  recombinant  protein was fused to
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the mouse DHFR sequence (pQE16) using the BglII restriction site. All expressed constructs
were confirmed by DNA sequencing on an ABI-Sequencer (Perkin Elmer).  The recombinant
constructs 23xNAP repeats, 3D7 family specific part, 4x32 aa repeats, 6x12 aa repeats, and 3D7
repeats were identical to the original  protein regions and contained amino  acids resulting  from the
restriction sites at the ends of the sequences. A single nucleotide change from guanosine to
adenosine occurred at position 68 in the 5'3'construct,  resulting  in an amino acid change from
glycine to glutamic  acid also found in naturally  occurring msp2 alleles. The sequence coding for
the family specific part of the FC27 allele showed a duplication of the last 14 amino acids. 
Expression and purification of rMSP2: all constructs were produced according to the
manufacturer’s  protocol (Qiagen). Briefly, after transformation by electroporation  Super broth
(25 g Trypton, 15 g yeast extract, 5 g NaCl ad 1 L) with 100 mg/l ampicillin  (Appligene) and 25
mg/l kanamycin (Sigma), was inoculated  with an over night  culture and incubated in a shaker at
37oC to an OD600 nm = 0.5-0.8. Protein expression was induced by addition of IPTG (Appligene)
to a final concentration of 1 mM. Cells were harvested by centrifugation after four hours. Cells
were resuspended in lysis buffer (50 mM Sodium dihydrogenphosphate  pH 8.0; 300 mM Sodium
chloride; 10 mM imidazole), incubated with 1 mg/ml lysozym for 30 min on ice, and broken up
on ice by ultrasound.  The solution was spun at 10.000xg for 20 min at 4 oC, the supernatant
containing  the fusion protein was mixed with Ni2+-agarose and incubated for 1 h in a shaker. The
protein-Ni2+-mixture  was washed with 20 mM imidazole, and the protein was eluted with 250 mM
imidazole. The 5'3'constant  recombinant  protein was expressed at 25oC, denatured with 6 M
Guadininehydrochloride (6 M GuHCl; 0.1 M sodium dihydrogenphosphate; 0.01 M TrisCl, pH
8.0), and purified with 8 M Urea with decreasing pH. The recombinant  protein was eluted at pH
4.5. Twenty :l of each protein fraction were analysed by SDS-PAGE electrophoresis to
approximate the purity of the preparations. Pure protein fractions were pooled and renatured by
dialysis as previously described for other MSP2 recombinant  proteins (Takacs and Girard 1991).
Protein preparations under native conditions were dialysed against PBS pH 7.2 to remove
imidazole. The protein content was estimated by the method of Bradford at 595 nm (Bradford
1976). Expression levels were found to vary, ranging  from approx. 10 mg/l to 0.1 mg/l.  Proteins
were stored at -70oC until used.
Immunological assays: all recombinant  protein constructs were recognized by
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anti-6His-antibodies  (Qiagen, R&D). Two point five to ten :g of each recombinant  protein was
used to immunize female balb/c mice by four injections (i.p.).  Sera were collected 14 days after
the last injection. All sera recognized the respective protein specifically in ELISAs and on
immunoblots  using protein preparations from strain K1 and NF54. High ELISA titres (1:12 800
- 1:25 600)  were obtained with the 5'3'construct, the  6x12 aa repeats, the 4x32 aa repeats, and
the FC27-family specific construct. A median titre (1:1600)  was obtained with the 3D7-repeats,
and low titres (1:100) with the 23xNAP repeats and 3D7-family specific construct. Except for the
latter two constructs, all sera recognized mature parasites in a grape-like structure in IFAs.
Specificity was high since sera recognised only parasites with the corresponding MSP2 allele,
except sera against the 3D7-repeat construct, which  showed cross-reactivity with FC27 alleles.
All experiments were controlled with non-immune sera and with protein fractions from non-
infected erythrocytes.
ELISA with sera from infants: Optimal dilutions of the immunogens  and reagents were
determined by checker titration  with positive control serum pools (20 semi-immune  adults from
PNG) and negative control sera (36 European non-exposed children aged  5-15 months and 36
European non-exposed adults) (Quakyi 1980). Microtitre plates (Immulon 2; Dynex
Technologies, USA) were coated with 50 :l of protein preparations. Protein concentrations
ranged from 0.1:g/ml to 10 :g/ml in PBS pH 7.2, but these concentrations were not associated
with the absorption levels of antibodies. Plates were incubated overnight  at 4oC, and non-adsorbed
antigen was removed. Plates were blocked with 200 :l PBS pH 7.2, 5% nonfat milk powder and
incubated for 2 h at 25oC. Fifty :l of test sera in 1:500 dilutions (1:1500 dilutions for the
5'3'construct  and 6x12 aa repeats construct) in PBS, containing 0.5% Tween 20 and  0.5% milk
powder, was added in duplicates and incubated for 1 h at 25oC. After washing, 50 :l horse radish
peroxidase-conjugated second antibody (dilution1:2000 in PBS-0.5% Tween20/0.5% milk
powder) was added and plates were incubated for 1 h at 25oC. After washing,  50 :l peroxidase
substrate (ABTS peroxidase substrate, KPL) was added to each well, and the absorbance was
measured at 405 nm after 30 min in a spectrophotometer (Titertek Multiskan MCC/340). Twenty
sera from semi-immune  adults from PNG were used as standard, and the European sera were used
as negative controls. Each sera was also tested against a DHFR-6His preparation (5 :g/ml in
PBS) produced similarly as the recombinant proteins.
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Data presentation: a positive control serum pool was included on each plate in serial dilutions in
all MSP2-specific ELISA assays. A regression line was fitted to the control series for each
antigen, and the average of the duplicate readings of optical  density at 405 nm (OD405) for each
serum sample was converted to antibody units based on the standard curve. For each single plate
the OD405 of the serum pool (minus corresponding background from the DHFR-6His-control)
diluted 1:500 was defined as 1 unit.  Results were expressed in antibody units and positivity was
initially  calculated as mean values of sera from 36 non-exposed children + 2 standard deviations.
For improved accuracy, the latent class model was used (Vounatsou et al. 1998). Adjustment of
the model to the ELISA data and the comparison to standard calculation of cutoff values
(mean+2sd) is reported elsewhere (Irion et al. 2001a). 
Statistical analysis: to determine if any relation between different variables and antibody unit
values was significant,  Spearman’s correlation analyses were performed on sets of continuous data
on antibody response to a particular antigen versus listed variables: age of the donor, net use,
parasitemia, value of other antibody  responses, multiplicity  of infection, and repeat numbers of
msp2 alleles of infecting parasites. Spearman’s correlation analyses were used, as the data
distribution was non-normal for antibody responses and the other variables.
Two sets of analysis were done: In the first analysis, the samples were considered as independent
samples with their observed antibody value. In the second analysis, subsequent sample pairs of
individuals  were formed and the changes of antibody titres from the previous to the current
sample of an individual  were assessed. The change of antibody titres in sample pairs was
correlated with several parameters, including  the number of infections and the genotype
determined in the current sample.  The correlation of infection dynamics such as acquisition and
loss of infections measured by PCR-RFLP analysis of the msp2 locus and anti-MSP2 immune
responses is described elsewhere (Irion et al 2001b).
Results
Controls: titration  of the positive standard serum pool in each assay was highly reproducible and
allowed inter-experimental  comparison. Antibody values of 36 sera from non-exposed children
were used to calculate the proportion of antibody-positive Tanzanian children. Two antigens
showed high and highly variable measurements with  the negative control sera:  the FC27 family
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specific region and the 5'3'construct (Table 2). Thus, determination cut-off values as the mean
plus 2 standard deviations using non-immune  sera was not appropriate and ELISA data were
analysed with the methodology based on a latent class model (Irion et al 2001a).
Frequency and magnitude of responses: the frequency of responders in the Tanzanian children
samples was high,  although  the magnitude  of the responses expressed in antibody units was
generally low (Table 2). For the various antigen constructs positivity determined by the latent
class model ranged from 53% (4x32 aa repeats) to 92% (6x12 aa repeats). Low antibody values
were obtained with the 3D7 family specific part, the 23xNAP repeats,  and the 4x32 aa repeats.
Medium antibody unit values were found with the 6x12 aa repeats, 3D7 repeats, and FC27 family
specific regions. High antibody unit values were observed with the conserved regions of MSP2.
Antibody correlation with malariometric indices: the antibody response against all antigen
constructs was positively correlated with age (Spearman’s correlation p<0.001 for all antigens),
except for 6x12 aa repeats (p=0.108), and for the 5'3'construct  (p=0.063). The age coefficient for
the 5'3'construct  was rs=!0.19 and suggests that antibody responses against the conserved regions
of MSP2 decrease with age. 
We also tested the correlation between the change of antibody values from the previous to the
current sample of an individual. There was a negative correlation with the 3D7 family specific
part, the 3D7 repeats, and the FC27 family specific part (p=0.048, p=0.003, and p<0.001,
respectively) indicating  no further  boosting within the sampling interval. The other antigen
constructs showed no significant correlation between two consecutive samples. 
The antibody values were higher in parasitemic individuals than in individuals without current
parasite presence. All associations were significantly  higher  (p<0.001), except for the 5'3'construct
and 6x12 aa repeats. Antibody values were also significantly  correlated  with parasite density
(Spearman’s correlation:  p<0.001 for all except the 5'3'construct  with p=0.01). Only the 6x12 aa
repeats was not significantly  correlated with parasite density  Spearman’s correlation revealed no
significant  correlation of the antibody dynamic between the previous and the current sample and
parasitemia and parasite density, respectively, suggesting that the change of antibody levels is
independent from newly acquired infections or changes are not that fast.
Antibody responses against one antigen were correlated with antibody responses against any other
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antigen in individual  samples (Spearman’s correlation p<0.05) with the exception of the antibody
response against the 5'3' construct, which was only correlated with responses against  the
constructs representing the 4x32 aa repeats, and the 23xNAP repeats.
Antibody titres increased with the number of infections detected by msp2 PCR-RFLP-genotyping,
called the multiplicity  of infections. Antibody concentrations against all antigen constructs were
positively correlated with overall multiplicity, but also multiplicity within both allelic families,
except for the 6x12 aa repeats and 5'3'construct and the number of infections expressing 3D7
alleles (Table3a).
A relatively weak but still significant correlation was observed between the  change of antibody
response of two consecutive samples and the number of msp2 alleles in the corresponding blood
sample (Table 3b). The change of antibody levels to 3D7 repeats correlated positively with the
number of msp2 alleles belonging to the  3D7 allelic family (p<0.05). A positive correlation was
also found for antibody responses against the 3D7 family specific part, 3D7 repeats, 4x32 aa
repeats and the number of msp2 alleles belonging to the FC27 allelic family.
Correlation of antibody concentrations and FC27 alleles containing the highest number of
repeats: the association between antibody responses to any antigen and the presence of an FC27
allele with the highest number of both the 32 aa repeats and the 12 aa-repeats was also analysed
by Spearman’s correlation analysis. Antibody responses to all tested  antigens were significantly
higher  in those samples containing  infections with parasites having the FC27 allele with the
highest number of the different repeat types (all p<0.03).
When the Spearman’s correlation analyses of antibody change were conducted with paired
consecutive samples, antibody response to 4x32 aa repeats showed to correlate with all FC27
alleles possessing the highest number of repeats (p<0.05). The change of antibody response to the
5'3'construct  antigen was significantly  higher  in samples with alleles containing  the highest number
of 12 aa repeats, and the change of antibody response to 3D7 repeats was significantly  higher  in
samples with the highest number of 32 aa repeats (both p=0.033). A borderline significance was
calculated for the correlation of the change of antibody levels to 3D7 family specific part between
the previous and the current sample and the presence of infections expressing alleles with the
highest number of 32 aa repeats (p=0.05).
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Antibody correlation with net use: children sleeping under an ITN showed significantly  lower
antibody levels to the 3D7 family specific part, the 3D7 repeats, the 4x32 aa repeats, and the
23xNAP repeats (all p<0.001). There was a non-significant reduction in antibody levels against
the 5'3'construct  in ITN users, and a non-significant  positive association with antibody responses
against the 6x12 aa repeats and to FC27 family specific part. There was no correlation observed
in the change of antibody levels of two consecutive samples and net use.
Discussion
The extensive antigenic  diversity of P. falciparum and the repetitive structure of many malaria
antigens imposes a major challenge to identify protein regions which might elicit protective
antibodies. The merozoite surface protein 2 of P. falciparum contains distinct regions which are
both highly conserved and highly polymorphic, as well as domains which show distinct
dimorphism.  We attempted to determine the immunological  recognition of these individual
domains in naturally  occurring infections in young children of a highly malaria  endemic area. We
produced six recombinant  proteins in E. coli which elicited antibodies in mice recognizing  mature
parasites or parasite proteins  in Western blots. Expression in E. coli seems to be acceptable for
malaria  proteins since P. falciparum probably does not modify MSP2 and other proteins by post-
translationally N- and O-glycosylation (Dieckman-Schuppert et al. 1992; Berhe et al. 2000).
We found that all domains of MSP2 were readily recognized by sera from young children living
in a highly endemic area. However, antibody titres were quite low, the response was variable
against the distinct protein domains, and the antibody dynamics was extremely complex as has
been recently shown in a small study from Irian Jaya (Weisman et al 2001). The most frequently
recognized antigen was the 5'3' construct. Antibody titres against this antigen were high,  but it
was also frequently recognized by sera from non-exposed individuals,  indicating  cross-reactivity.
In fact, this  serum also recognized parasites in IFAs. Similar high background levels in ELISAs
and IFAs with plasmodial antigens were also found by others (Biggar et al. 1985; Howard et al.
1993; Saul et al. 1999). Whether this is a natural  phenomena or it is due to the fusion of the
5'region with the 3'region and the DHFR molecule is unclear. But P. falciparum cross-reacting
antibodies have also been described with many human  pathogenic viruses, such as Rift valley
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fever, HTLV, HIV, Polio, Influenza (McLaughlin  et al. 1987) and related parasites like Babesia
microti (Chisholm et al. 1978). Such shared sequences could possibly function in mimicry,  decoy,
or immunosuppression.
The apparent contradictory results obtained with antibodies measurements directed against the
MSP2 conserved region might  be due to different recombinant  antigen products and production
protocols, or to different study populations. Stowers et al. (1997) reported a strong correlation
of antibody levels with both age and the recognition of other antigens,  whereas others found no
antibodies against the conserved regions of MSP2 (Thomas et al. 1990; Taylor et al. 1995;
Nagendran and Ramasamy 1996; Lougovskoi et al. 1999). Migot-Nabias et al. (1999) reported
a frequency of responders against a N-terminal  peptide in children aged 5-17 years similar  to ours.
In our study, antibody titres against this construct showed no age dependance, nor were they
associated with parasite presence. This suggest that the responses are either not specifically
boosted or the antibody titres are already at an equilibrium. On the other hand, a weak but
significant correlation of the antibody response and parasite density or number of FC27 like
infections suggests a boosting effect by the total parasite load. Since our recombinant  5'3'construct
elicited antibodies in mice which recognised mature parasites in IFAs, we believe that the
measured response reflects at least partial recognition of malaria relevant epitopes.
The overall frequency of responders to most parts of the protein was high but the magnitude  of
responses was low in most individuals.  Frequencies were generally higher  than reported in other
studies (Stowers et al. 1997; Migot-Nabias et al. 1999). This might  be the result of our more
precise method of calculating  positivity using the latent class model (Vounatsou et al. 1998, Irion
et al. 2001a). The increased length of the peptides used which consequently might  represent more
linear and non-contiguous epitopes might also  influence antibody binding. 
Immunity  against severe malaria  is acquired early in life in highly endemic areas (Kitua et al. 1996;
Snow et al. 1998), and the observed significant correlation of all responses except against the
5'3'construct  and the 6x12 aa repeats with age and parasite presence might  reflect the developing
immunity. Because of limited morbidity records and a generally low morbidity in these children
we were not able to determine whether any of the observed anti-MSP2 responses were associated
with protection against clinical disease. On the contrary, the correlation with parasite density
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would suggest that measured antibodies rather reflect  exposure than protection. It is difficult to
reconcile since repeated and continuous exposure to P. falciparum may be required to reach and
keep high IgG reactivities. 
In this study, parasite genotyping allowed to assess the effect of parasite genotypes on the
response to the various MSP2 domains. We were interested to see whether the infection dynamics
affects immune  responses, and to what degree these responses were specific. We previously
speculated that established infections offer cross-protection against newly invading  clones in older
children (Smith  et al. 1999c), and we and others showed that multiple  infections seem to protect
against clinical disease (Beck et al. 1997; Al-Yaman et al. 1997b; Färnert  et al. 1999). It also has
been shown that both prevalence and concentration of antibodies to the non-repetitive part of the
3D7 antigen correlated with reduced morbidity (Al-Yaman  et al. 1994, 1995, 1997a; Taylor et
al. 1998). In our study, the antibody titres  to the 3D7 family specific part were marginal
compared to the titres in adults, and might  reflect the susceptibility of these children,  due to a lack
of antibodies against the 3D7 family specific part. In this respect, it is interesting to note  that a
recent subunit vaccine trial in Papua New Guinea including the 3D7 form of MSP2 showed a
significant reduction of 3D7-like infections in the follow up period (Genton et al. 2001).
The antibody titres against the repeats except the FC27 4x32 aa repeat were all comparatively
high.  This would support the speculation that presence of these repeats might  divert the immune
response from critical epitopes within these or other parasite molecules (Anders 1986;  Kemp et
al. 1987; Bickle et al. 1993). We observed various pattern in responses against these repeats, in
particular  the lack of age dependence of antibody titres to the FC27 6x12 aa repeats. High levels
and a high rate of responders to these repeats are in accordance with findings  from other groups
(Ranford-Cartwright  et al. 1996). This group also showed that antigens with increasing  numbers
of repeats yielded higher antibody titres. We immunized mice with the 6x12  aa repeats and this
sera highly specific recognized MSP2 alleles with 5x12 aa  repeats but hardly MSP2 alleles with
only 3x12 aa repeats (data not shown). FC27-like parasites observed in our study mostly had
msp2 alleles contained more than three 12 aa repeat units. However, nearly 70 % of detected
FC27-like parasites contained only one 32 aa repeat, whereas our test antigen contained 4x32 aa
repeats. The immune  response against this antigen showed a highly significant correlation with
the presence of msp2 allele containing  four 32 aa repeats. This might  explain the overall low titre
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against this antigen and suggests a similar  importance of the repeat number. It is further  supported
by the fact that mouse sera against the 4x32 aa repeat poorly recognized parasites containing  one
32 aa repeat only, whereas parasites with 4 repeats were strongly recognized. We must  assume
that most antibodies produced in mice upon immunization react with conformational epitopes
created by more than one 32 aa repeat or with epitopes located at the junction of two repeat units.
A similarly  low response was observed with the 23xNAP repeats, and again MSP2 antigens with
more than two NAP repeats were relatively rare.
The 3D7 repeats were recognized by 90 % of sera, and the change of antibody titres against these
3D7 repeats between two consecutive samples was significantly  correlated with the number of
present FC27 alleles. This clearly implies that parasites expressing FC27-like MSP2 provoke
production of antibodies cross-reacting with the 3D7 repeats. Such cross reactivity of affinity
purified human  antibodies to the 3D7 repeat with FC27 alleles has been shown previously
(Smythe et al. 1990). The 32 aa repeat of FC27 alleles contains the sequence Ala-Ser-Gly-Ser
which is also present in the 3D7 sequence and might be responsible for the cross-reaction. This
sequence has also been identified as a hot spot of recombination (Irion et al. 1997). The FC27 12
aa repeat in turn seems to stimulate responses to the FC27 4x32 aa repeats and the constant
region. It is conceivable that such broad cross-stimulation  might  be an evasion strategy to divert
the immune  responses, but also will influence parasite dynamics and co-infections to a large
degree. Whether these antibodies have a protective value remains to be elucidated.
Within this study, we were also able to test whether transmission blocking interventions might
affect the development of potentially protective immune  responses. There is much debate over
the long-term effects of control measures such as ITNs, which reduce malaria transmission and
possibly interfere with the development of immunity  to malaria  (Snow and Marsh 1995; Trape and
Rogier 1996). During six months  use of ITNs we observed no reduction in multiplicity  despite
a significant  reduction in the parasite density and patent prevalence  of P. falciparum infections
(Fraser-Hurt  et al. 1999; Smith et al. 1999b). This led to the speculation that prevention of  only
a small proportion of infections may not hinder the establishment of premunition  or concomitant
immunity  (Smith  et al. 1999c). But by analysing immune  responses against MSP2 we demonstrate
that longer term ITN use does indeed influence the development of these responses to some
extent. Antibody titres to the 3D7 family specific part, the 3D7 repeats, the 4x32 aa repeats, and
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the 23xNAP repeats were significant  lower in children sleeping under a bed net. A similar
reduction in antibody titres was shown for other antigens in a previous study in Papua New
Guinea (Genton et al. 1994). The antibody responses to the 5'3'construct, the FC27 family
specific part, and the 6x12 aa repeats were not affected. This demonstrates that investigating  the
antibody response to one or two antigens is not sufficient  for the assessment of the effect of an
intervention  (Kitua et al. 1999), since immunogenicity  varies between different antigens and even
between different parts within one antigen.
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Figure 1: recombinant  antigens representing  distinct parts of the merozoite surface protein 2
(MSP2) of P. falciparum. 
aa: amino  acid, cons: conserved regions, DHFR: Dihydrofolate reductase, fsp: family specific part,
NAP: single letter code of amino acids, Thr: Threonine. 
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Table 1. PCR primer pairs used to amplify distinct parts of msp2 
antigen Fwd primer (BamHI)* Rev primer (KpnI)* Allele aa sequence
23xNAP
repeats
5'cgggatcccgTAGTGTAGGTG
CA'3
5'ggggtaccccACTAGCAATAG
TA'3
Ifa23 SVGA-(NAP)23
- NADTIASG
3D7 fsp 5'cgggatcccgTGGTAATGGTG
CT'3
5'ggggtaccccAGATTGTAATT
CG'3
FCR3 aa109-214
4x32aa
repeats
5'cgggatcccgTGCTCCAAAAG
CT'3
5'ggggtaccccAGGGGTATCAG
CA'3
Ifa45 APK-(32aa
repeat)4-ADTP
6x12aa
repeats
5'cgggatcccgTACTGCTACAG
AA'3
5'ggggtaccccTTGAACTTTCTG
T'3
K1+1 TAT-(ESNSRS
PPITTT)6-ESS
3D7
repeats
5'cgggatcccgTCCCCTACTGG
TGCT'3
5'ggggtaccccGGTGGTAGCGG
GAGTACT'3
PPT- 49aa
(GAS rich)-
GGSSTPATT
FC27 fsp 5'-
region
(BamHI)5'cgggatcccgTAAGAGTGTAGGTGCAAATG
CTCCAAAAggaattcc'3 (EcoRI) +           GGAATTCC
(EcoRI-Primer)
K1 KSVGANAPK-
GIP-(FC27fsp)-
APQEPQTAE
NENPA3'-
region
5'ggaattccAGAAAGTTCA
AGTT'3 (EcoRI)
5'ggggtaccccAGCAGG
ATTTTCA'3 (KpnI)
DHFR-
5'3'-
construct
5'-
region
5'gaagatcttcAATGAAGGT
AATTA'3 (BglII)
5'ggaattccTAGTATTA
GAACCTT'3 (EcoRI)
K1     
         
(5'-region K1
aa 1-50)-RNS
-(3'-region K1
207-280aa)      
aa 23 Glu
3'-
region
5'ggaattccGCACCAGAGA
ATAAA'3 (EcoRI)
5'gaagatcttcTGAATAT
GGCAAA'3 (BglII)
* Capital letters correspond to msp2 hybridization  site, small  letters build the recognition  site where the restriction
enzyme cuts.
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Table 2. Mean titres and estimates of positivity
Mean titre in
negative controls
(s.d.)
Estimated
Proportion of
test sera positive1
Mean titre in
positive test
sera1 (units) 
Mean titre in
negative test
sera1 (units)
Overall mean
titre in test sera
(units)
6x12 aa repeats 0.032 (0.022) 0.923 0.481 0.049 0.447
3D7 fsp 0.003 (0.003) 0.754 0.067 0.004 0.052
3D7 repeats 0.009 (0.005) 0.895 0.210 0.012 0.190
5'3' construct 0.281 (0.280) 0.856 1.866 0.344 1.647
4x32 aa repeats 0.004 (0.003) 0.526 0.071 0.004 0.039
FC27 fsp 0.090 (0.094) 0.786 0.356 0.106 0.302
23xNAP repeats 0.007 (0.005) 0.660 0.162 0.010 0.111
 1As estimated from latent class models; 
Table 3a: Spearman correlation analyses of achieved antibody titres with multiplicity of
infection (MOI)
antigen N_3D7 N_FC27
rs (p=) rs (p=)
6x12 aa repeats 0.04 0.469 0.14 0.007
3D7 fsp 0.49 <0.001 0.40 <0.001
3D7 repeats 0.33 <0.001 0.34 <0.001
5'3'-construct 0.05 0.392 0.17 0.001
4x32 aa  repeats 0.29 <0.001 0.39 <0.001
FC27 fsp 0.24 <0.001 0.24 <0.001
23xNAP repeats 0.31 <0.001 0.36 <0.001
N: number of infections expressing one msp2 of the allelic families, p: P value, rs: correlation coefficient
Table 3b: Spearman correlation analyses of antibody unit change (difference between
current and previous sample) with multiplicity of infection (MOI) 
antigen N_3D7 N_FC27
rs (p=) rs (p=)
6x12 aa repeats 0.01 0.9 0.03 0.5
3D7 fsp 0.10 0.08 0.12 0.030
3D7 repeats 0.11 0.04 0.12 0.029
5'3'-construct -0.02 0.7 0.11 0.07
4x32 aa  repeats 0.08 0.14 0.14 0.012
FC27 fsp 0.03 0.5 0.08 0.13
23xNAP repeats -0.03 0.5 0.00 0.9
Longitudinal study of antibody response to MSP2 of P. falciparum II17
References
Al-Yaman F, Genton B, Anders RF, Falk M, Triglia  T, Lewis D, Hii J, Beck HP, Alpers MP. 1994. Relationship
between humoral  response to merozoite surface antigen  2 and malaria  morbidity in a highly  endemic area
of Papua New Guinea. American Journal of Tropical Medicine and Hygiene  51:593-602.
Al-Yaman F, Genton B, Anders R, Taraika J, Ginny M, Mellor S, Alpers MP. 1995. Assessment of the role of the
humoral response to Plasmodium falciparum MSP2 compared to RESA and SPf66 in protecting Papua
New Guinean children from clinical malaria. Parasite Immunology 17:493-501.
Al-Yaman F, Genton B, Reeder JC, Mokela D, Andres RF, Alpers MP. 1997a. Humoral response to defined
Plasmodium falciparum antigens  in cerebral and uncomplicated malaria  and their relationship  to parasite
genotype. American Journal of Tropical Medicine and Hygiene  56:430-435.
Al-Yaman F, Genton B, Reeder JC, Anders RF, Smith T, Alpers MP. 1997b. Reduced risk of clinical  malaria  in
children  infected with multiple  clones of Plasmodium falciparum in a highly  endemic area: a prospective
community study. Transactions of the Royal Society of Tropical Medicine and Hygiene  91:602-605.
Anders RF. 1986. Multiple cross-reactivities amongst antigens  of Plasmodium falciparum impair  the development
of protective immunity against malaria. Parasite Immunology 8:529-539.
Anders RF and Smythe JA.1989. Polymorphic antigens in Plasmodium falciparum. Blood 74:186-196.
Barragan A, Kremsner PG, Weiss W, Wahlgren M, Carlson J. 1998. Age-related buildup of  humoral  immunity
against epitopes for rosette formation  and agglutination  in African areas of malaria  endemicity. Infection
and Immunity 66:4783-4787.
Beck HP, Felger I, Huber W, Steiger S, Smith  T, Weiss N, Alonso PL, Tanner  M. 1997. Analysis of multiple
Plasmodium falciparum infections in Tanzanian children during the trial  of the malaria vaccine SPf66.
The Journal of Infectious Diseases 175:921-926.
Berhe S, Gerold P, Kedees MH, Holder AA, Schwarz RT. 2000. Plasmodium falciparum: merozoite surface
proteins 1 and 2 are not posttranslationally  modified by classical N- or O-glycans. Experimental
Parasitology 94:194-197.
Bickle Q, Anders RF, Day K, Coppel RL. 1993. The S-antigen  of Plasmodium falciparum: repertoire and origin
of diversity. Molecular and Biochemical Parasitology  61:189-196. 
Biggar RJ, Gigase PL, Melbye M, Kestens L, Sarin PS, Bodner AJ, Demedts P, Stevens WJ, Paluku L, Delacollette
C, et al. 1985. ELISA HTLV retrovirus antibody reactivity associated with malaria  and immune  complexes
in healthy Africans. The Lancet 2:520-523.
Bouharoun-Tayoun H, Attanath  P, Sabchareon A, Chongsuphajaisiddhi T, Druilhe P. 1990. Antibodies that
protect humans  against Plasmodium falciparum blood stages do not on their own inhibit  parasite growth
and invasion in vitro, but act in cooperation with monocytes. Journal of Experimental Medicine 172:1633-
1641.
Bradford MM. 1976. A rapid and sensitive method for the quantification of microgram quantities of protein
utilising the principle of protein-dye binding. Anal. Biochem. 72:284-254.
Chisholm ES, Ruebush TK 2d, Sulzer AJ, Healy GR. 1978. Babesia microti infection in man:  evaluation of an
indirect  immunofluorescent  antibody test. American Journal of tropical Medicine and Hygiene 27:14-19.
Dieckmann-Schuppert A, Bender S, Odenthal-Schnittler M, Bause E, Schwarz RT.1992. Apparent lack of N-
glycosylation in the asexual intraerythocytic stage of Plasmodium falciparum. European Journal of
Biochemistry 205:815-25. 
Engelbrecht F, Felger I, Genton B, Alpers M, Beck HP. 1995. Plasmodium falciparum: Malaria morbidity is
associated with specific merozoite surface antigen 2 genotypes. Experimental Parasitology 81:90-95.
Molecular Diversity and Immunological Properties of MSP2II18
Färnert A, Rooth I, Svensson A, Snounou G, Björkman A. 1999. Complexity of Plasmodium falciparum infections
is consistent over time and protects against clinical  disease in Tanzanian children. The Journal of
Infectious Diseases 179:989-995. 
Felger I, Marshall  VM, Reeder JC, Hunt JA, Mgone CS, Beck HP. 1997. Sequence diversity and molecular
evolution of the merozoite surface antigen  2 of Plasmodium falciparum. Journal of Molecular Evolution
45:154-160.
Felger I, Irion A, Steiger S, Beck HP. 1999a. Epidemiology of multiple Plasmodium falciparum in Tanzania.  2.
Genotypes of merozoite surface protein 2 of Plasmodium falciparum in Tanzania.  Transactions of the
Royal Society of Tropical Medicine and Hygiene  93 (Suppl.1):S1/3-S1/9.
Fenton B, Clark JT, Khan CM, Robinson JV, Walliker D, Ridley R, Scaife JG, McBride JS. 1991. Structural  and
antigenic  polymorphism of the 35- to 48-kilodalton merozoite surface antigen  (MSA-2) of the malaria
parasite Plasmodium falciparum. Moleular and Cellular Biology 11:963-974.
Fraser-Hurt N, Felger I, Edoh D, Steiger S, Mashaka M, Masanja H, Smith  T, Mbena F, Beck HP. 1999.
Epidemiology of multiple  Plasmodium falciparum infections. 9. Effect of insecticide-treated bed nets on
haemoglobin  values, prevalence and multiplicity  of infection with Plasmodium falciparum in a
randomised controlled trial  in Tanzania.  Transactions of the Royal Society of Tropical Medicine and
Hygiene 93 (Suppl.1):S1/47.
Genton B, Hii J, Al-Yaman F, Paru R, Beck HP, Ginny M, Dagoro H, Lewis D, Alpers MP. 1994. The use of
untreated bed nets and malaria  infection, morbidity and immunity.  Annals of Tropical Medicine and
Parasitology 88:263-270. 
Genton B, Betuela I, Felger I, Al-Yaman F, Anders R, Saul A, Rare L, Baisor M, Lorry K, Brown GV, Pye D,
Irving DO, Smith TA, Beck HP, Alpers MP. 2001. A recombinant blood-stage malaria vaccine reduces
Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase I/IIb trial
in Papua New Guinea.  Nature Medicine (submitted).
Giha HA, Staalsoe T, Dodoo D, Roper C, Satti GM, Arnot DE, Hviid L, Theander TG. 2000. Antibodies to
variable Plasmodium falciparum-infected erythrocyte surface antigens  are associated with protection from
novel malaria infections.  Immunology Letters 71:117-26.
 Howard RF, Jensen JB, and Franklin  HL. 1993. Reactivity profile of human  anti-82-kilodalten  rhoptry protein
antibodies generated during  natural  infection with P. falciparum. Infection and Immunity 61:2960-2965.
Irion A, Beck HP, Felger I. 1997. New repeat unit  and hot spot of recombination  in FC27-type alleles of the gene
coding for Plasmodium falciparum merozoite surface protein 2. Molecular and Biochemical Parasitology
90:367-370.
Irion A, Beck HP, Smith  T. 2001a. Assessment of positivity in immuno-assays with variable and high  levels of
background: A new approach applied to antibody response to Plasmodium falciparum MSP2. Journal of
Immunological Methods (Submitted).
Irion A, Felger I, Smith  T, Beck HP. 2001b. Dynamics of Plasmodium falciparum infections and anti-MSP2
immune response in young children. (In preparation)
Kemp DJ, Coppel RL, Anders RF. 1987. Repetitive proteins and genes of malaria.  Annual Review of Microbiology
41:181-208.
Kitua AY, Smith  T, Alonso PL, Masanja H, Menendez C, Urassa H, Kimario  J, Tanner  M. 1996. Plasmodium
falciparum malaria  in the first year of life in an area of intense and perennial transmission. Tropical
Medicine and International Health  1:475-484.
Kitua AY, Urassa H, Wechsler M, Smith  T, Vounatsou P, Weiss NA, Alonso PL, Tanner  M. 1999. Antibodies
against Plasmodium falciparum vaccine candidates in infants  in an area of intense and perennial
transmission:  relationships  with clinical  malaria  and with entomological inoculation rates. Parasite
Immunology 21:307-317.
Longitudinal study of antibody response to MSP2 of P. falciparum II19
Kumaratilake LM, Ferrante A, Jaeger T, Morris-Jones SD. 1997. The role of complement, antibody and tumour
necrosis factor alpha in the killing  of P. falciparum by the cell line THP-1. Infection and Immunity
65:5342-5345.
Long CA. 1993. Immunity to blood stages of malaria. Current Opinion in Immunology 5:548-556. 
Lougovskoi AA, Okoyeh NJ, Chauhan  VS.1999. Mice immunised with synthetic peptide from N-terminal
conserved region of merozoite surface antigen-2  of human  malaria  parasite Plasmodium falciparum can
control infection induced by Plasmodium yoelii yoelii 265BY strain. Vaccine 18:920-930.
McLaughlin GL, Benedik MJ, Campbell GH. 1987. Repeated immunogenic  amino acid sequences of Plasmodium
species share sequence homologies with proteins from humans  and human  viruses. American Journal of
Tropical Medicine and Hygiene  37:258-262.
Migot-Nabias F, Luty AJF, Ringwald P, Vaillant  M, Dubois B, Renaut A, Mayombo J, Minh TN, Fievet N, Mbessi
JR, Millet P, Deloron P. 1999. Immune response against Plasmodium falciparum asexual blood-stage
antigens  and disease susceptibility in Gabonese and Cameroonian  children.  American Journal of Tropical
Medicine and Hygiene 61:488-494.
Nagendran K and Ramasamy R. 1996. Isotypes of natural  acquired antibodies to a repetitive & non-repetitive
epitope on Plasmodium falciparum surface proteins in an endemic area of Sri Lanka. Indian Journal of
Medical Research 103:142-145.
Quakyi I. 1980. The development and validation  of an enzyme linked immunosorbent assay for malaria.
Tropenmedizin und Parasitologie 31:1-8.
Ranford-Cartwright LC, Taylor RR, Asgari-Jirhandeh  N, Smith  DB, Roberts PE, Robinson VJ, Babiker HA,
Riley EM, Walliker D, McBride JS. 1996. Differential antibody recognition of FC27-like Plasmodium
falciparum merozoite surface protein MSP2 antigens  which lack 12 amino acid repeats. Parasite
Immunology 18:411-420.
Saul A, Laurence G, Smillie  A, Rzepczyk CM, Reed C, Taylor D, Anderson K, Stowers A, Kemp R, Allworth A,
Anders RF, Brown GV, Pye D, Schoofs P, Irving  DO, Dyer SL, Woodrow GC, Briggs WR, Reber R,
Sturchler  D. 1999. Human phase I vaccine trials of 3 recombinant  asexual stage malaria  antigens  with
Montanide ISA720 adjuvant. Vaccine 17:3145-59.
Smith T, Charlwood JD, Kihonda J,  Mwankusye S, Billingsley  P, Meuwissen J, Lyimo E, Takken W, Teuscher
T, Tanner  M. 1993. Absence of seasonal variation  in malaria  parasitaemia  in an area of intense seasonal
transmission. Acta Tropica 54:55-72.
Smith T, Beck HP, Kitua A, Mwankusye S, Felger I, Fraser-Hurt  N, Irion A, Alonso P, Teuscher T, Tanner  M.
1999a. The epidemiology of multiple  Plasmodium falciparum infections. 4. Age dependence of the
multiplicity of Plasmodium falciparum infections and of other malariological indices in  an area of high
endemicity. Transactions of the Royal Society of Tropical Medicine and Hygiene 93 (Suppl.1):S1/15-
S1/20.
Smith T, Felger I, Fraser-Hurt N, Beck HP. 1999b. The epidemiology of multiple  Plasmodium falciparum
infections. 10. Effect of insecticide-treated bed nets on the dynamics of multiple  Plasmodium falciparum
infections. Transactions of the Royal Society of Tropical Medicine and Hygiene  93 (Suppl.1):S1/53-S1/57.
Smith T, Felger I, Tanner  M, Beck HP. 1999c. Epidemiology of multiple  Plasmodium falciparum infections:  11.
Premunition  in Plasmodium falciparum: insigh ts from the epidemiology of multiple infections.
Transactions of the Royal Society of Tropical Medicine and Hygiene  93 (Suppl.1):S1/59-S1/64.
Smythe JA, Peterson MG, Coppel RL, Saul AJ, Kemp DJ, Anders RF.1990. Structural diversity in the 45-
kilodalton merozoite surface antigen of Plasmodium falciparum. Molecular and Biochemical Parasitology
39:227-234.
Snow R and Marsh K.1995. Will reducing Plasmodium falciparum transmission alter mortality  among African
children?. Parasitology Today 11:188-190. 
Molecular Diversity and Immunological Properties of MSP2II20
Snow RW, Nahlen B, Palmer A, Donnelly CA, Gupta S, Marsh K.  1998. Risk of severe malaria among African
infants:  direct evidence of clinical protection during early infancy. The Journal of Infectious Diseases
177:819-22. 
Stowers A, Taylor D, Prescott N, Cheng Q, Cooper J, Saul A. 1997. Assessment of the humoral  immune  response
against Plasmodium falciparum rhoptry-associated proteins 1 and 2. Infection and Immunity 65:2329-
2338.
Takacs BJ and Girard MF. 1991. Preparation of clinical grade proteins produced by recombinant DNA
technologies. Journal of Immunological Methods 143:231-240.
Taylor RR, Smith  DB, Robinson VJ, McBride JS, Riley EM. 1995. Human antibody response to Plasmodium
falciparum Merozoite Surface Protein-2 is serogroup specific and predominantly  of the immunoglobulin
G3 subclass. Infection and Immunity 63:4382-4388.
Taylor RR, Allen SJ, Greenwood BM, Riley EM. 1998. IgG3 antibodies to Plasmodium falciparum merozoite
surface protein 2 (MSP2): increasing  prevalence with age and association with clinical immunity to
malaria. American Journal of Tropical Medicine and Hygiene  58:406-413.
Thomas AW, Carr DA, Carter JM, Lyon JA. 1990. Sequence comparison of allelic forms of the Plasmodium
falciparum merozoite surface antigen MSA2.  Molecular and Biochemical Parasitology  43:211-220.
Trape JF and Rogier C. 1996. Combating malaria  morbidity and mortality  by reducing transmission.  Parasitology
Today 12:236-40.
Vounatsou P, Smith T, Smith  AFM. 1998. Bayesian analysis of two-component mixture distributions applied to
estimating malaria attributable fractions. Applied Statistics 47:575-587.
Weisman S, Wang L, Billman-Jacobe H, Hanh Nhan D, Richie TL, Coppel RL. 2001. Antibody response to
infections with strains of Plasmodium falciparum expressing diverse forms of merozoite surface protein
2. Infection and Immunity 69:959-967.
Dynamics of P. falciparum  infections and anti-MSP2 immune response III1
Dynamics of Plasmodium falciparum infections and anti-MSP2
immune response in young children
Andrea Irion, Ingrid Felger, Tom Smith, Hans-Peter Beck*
Swiss Tropical Institute, Socinstrasse 57, Postfach, CH-4002 Basel, Switzerland
Abstract
In order to investigate the correlation between Plasmodium falciparum infection dynamic and
serological stimulation,  we conducted a longitudinal  study with children aged initially  between 5-
15 months in a highly malarious endemic area of Tanzania. All infections were genotyped by
msp2-PCR-RFLP and sera of the identical children were tested in IgG-ELISA against various
recombinant  constructs of MSP2. It seems that msp2 alleles of the FC27 allelic family stimulate
the antibody response to distinct parts of both allelic families, including  the conserved regions and
the 3D7 family specific part. In contrast, P. falciparum infections expressing 3D7 alleles
stimulated only the antibody response to the antigen which represented the 3D7 repeats. The
dynamic of infections itself showed significant  differences in their duration between infections
expressing MSP2 alleles of the different allelic families.
Key words: duration of infection, recovery rate, dynamic of antibody response, merozoite surface
protein 2, Plasmodium falciparum, malaria.
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Introduction
In areas highly endemic for Plasmodium falciparum, age variation in the outcome of the malaria
disease and in parasitological profiles have been reported (Baired et al. 1993; Trape and Rogier
1996; Konaté et al. 1999; Smith  et al. 1999a). P. falciparum infected infants in highly endemic
areas have higher  parasite densities than older children (Molineaux & Gramiccia 1980; Kitua et
al. 1996; Smith et al. 1998), but they show lower multiplicity  of infection and microscopically sub-
patent infections are not present (Felger et al. 1999b). As children grow older, parasite densities
decrease and the prevalence of microscopically sub-patent parasitemia increases (Felger et al.
1995). The period of highest susceptibility to clinical malaria  among infants in highly endemic
areas occurs between the ages of four and 12 months, when the mean parasite density and the risk
of fever reach their maximum  (Kitua et al. 1996). During  this period the bulk of maternal
antibodies decreases but the specific immune response of the child is still weak. It was
hypothesized that clinical immunity  in highly endemic areas depends on cross protection by
concomitant infections (Al-Yaman et al. 1997a; Smith et al.  1999c; Färnert  et al. 1999). Hence,
the higher  susceptibility of infants to clinical malaria  in comparison with older children may be
largely a consequence of the short duration of infections which precludes the establishment of
concomitant immunity  and the lower multiplicity  of infection reported in children might  be rather
the consequence of the rapid clearance than the slow accumulation  of infections in infants (Smith
et al. 1999c).
Most data on the immune  response to Plasmodium falciparum antigens during  the first two years
of age are described indirectly by the prevalence of asymptomatic children,  infection multiplicity
or parasite densities. Actively acquired immunity  to malaria  in humans  are believed to be strain-
specific, partly mediated by recognizing  polymorphic epitopes in merozoite proteins (Berzins and
Anders 1999). The merozoite surface protein 2 (MSP2) is one of the well-characterized surface
proteins of P. falciparum. MSP2 contains a single, centrally located block of tandem repeats
(Smythe et al. 1988; Fenton et al. 1989). And despite of being highly  polymorphic the molecule
has essentially a dimorphic  structure (Thomas et al. 1990; Marshall et al. 1994), which defines the
two allelic families, FC27 and IC1/3D7 (Smythe et al. 1990; Fenton et al. 1991). msp2 genotypes
of the FC27 allelic family have been associated with higher  parasite densities and morbidity
(Engelbrecht  et al. 1995), which might  be prevented by simultaneous infections with P.
falciparum expressing MSP2 alleles of the 3D7 allelic family. 
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Involvement of MSP2 in protective immune responses was indicated by  the merozoite invasion
inhibitory  effect of monoclonal antibodies to the antigen (Clark et al. 1989; Epping et  al. 1988).
The antibody response to MSP2 in humans  is mainly directed against the central polymorphic
region (Al-Yaman et al. 1994; Taylor et al. 1995),  although,  in some populations, antibodies to
the conserved and semi-conserved regions develop at later ages after a life long exposure to
malaria  and were associated with fewer fever episodes and less anaemia (Al-Yaman et al. 1994).
Associations between antibody level to 3D7 alleles and resistance to clinical malaria were also
demonstrated indicating a protective role for these antibodies (Al-Yaman et al. 1994, 1997b). 
However, little is known about the dynamic of specific immune  responses in natural  settings with
frequent new infections and loss of existing infections. Similarly, it has never been studied in
detail, which domains of the molecule elicit an antibody response with subsequent analysis of the
specificity and cross-reactivity. We report here the detailed PCR analysis of longitudinal  blood
samples from young children with a detailed analysis of elicited antibody responses. With this
study we provide a first insight into the development of a specific immune response in early
childhood using recombinant  proteins in serological assays with children sera. The presented data
were part of a longitudinal  study of immune  response to distinct parts of the merozoite surface
protein 2 (MSP2) reported elsewhere (Irion et al. 2001a).
Study Design and Methods
Subjects: the samples for this study originated from a insecticide treated bed nets (ITN) trial
which was carried out in Kiberege Village in the Kilombero valley in southeastern Tanzania, an
area highly endemic for  P. falciparum malaria  (Tanner  et al. 1991). The design of the study has
been described in detail by Fraser-Hurt et al.(1999). Seven consecutive finger-prick  blood samples
collected at one month intervals were  selected from 60 children initially aged five to 24 months
who used insecticide-treated nets, and from 60 children of the same age group not using ITNs.
All blood samples were genotyped by PCR-RFLP on msp2 as described and reported elsewhere
(Felger et al. 1999a, Smith et al. 1999c). Twenty serum samples from semi-immune  adults from
PNG were used as positive controls. Sera from 36 healthy European adults and from 36 European
children aged 5-15 months, all never exposed to malaria, were used as negative controls. 
Estimation of the probability of recovery, M, and the sensitivity of detection, S
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M and S were estimated by maximum likelihood as described previously (Smith et al. 1999c)
Protein expression and ELISA: expression in the procaryotic pQE expression system (Qiagen)
in E. coli and purification  of seven different recombinant  msp2-clones were described previously
(Irion et al. 2001a). Briefly, PCR products corresponding to distinct parts of msp2 (table 1), were
cloned in the pQE30 expression vector as a fusion protein with six histidine  residues at the 5' end.
Protein expression and purification were done  according to the manufacturer’s protocol
(Qiagen). Pure protein fractions were pooled and renatured by dialysis as previously described for
other MSP2 recombinant  proteins (Takacs and Girard 1991). Protein preparations under native
conditions were dialysed against PBS pH 7.2 to remove imidazole. Protein content was estimated
by the method of Bradford at 595 nm (Bradford 1976).
All immunological  assays were carried out as described previously (Irion et al. 2001a). For ELISA
optimal dilutions of the immunogens  and reagents were determined by checker titration with
positive and negative control sera (Quakyi 1980). After coating with antigens and blocking with
5% milk powder in PBS, 50 :l of test sera in 1:500 dilutions (1:1500 dilutions for the
5'3'-construct  and the 6x12 aa repeats) in PBS, containing  0.5% Tween 20 and 0.5% milk
powder, were added in duplicates. IgG antibody binding was revealed by addition of 50 :l horse
radish peroxidase-conjugated second antibody (dilution1:2000  in PBS-0.5% Tween20/0.5% milk
powder). Subsequently, 50 :l peroxidase substrate (ABTS peroxidase substrate, KPL) were
added to each well, and the absorbance was measured at 405 nm in a spectrophotometer (Titertek
Multiskan MCC/340). Each sera was also tested against a similarly produced DHFR-6His
preparation.  Presentation of antibody units was carried out as described previously (Irion et al.
2001a). A latent class model based method was used to determine positivity of test samples
(Vounatsou et al. 1998, Irion et al. 2001b).
Statistical analysis: to determine if any relation between different variables and antibody unit
values was significant  Spearman’s correlation analyses were performed on the sets of continuous
data on antibody response to an antigen versus listed variables: number of new acquired infections
and number of lost infections separately for the allelic families.  Spearman’s correlation analyses
were used because the data distribution  was non-normal for antibody responses and the other
variables.
Subsequent sample pairs of an individual  were formed and divided in three groups: (A) sample
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pairs with an increasing number of infections with P. falciparum expressing msp2 alleles of the
FC27 allelic family or of the 3D7 allelic family, (B) sample pairs with a decreasing number of
infections expressing FC27 alleles or  3D7 alleles, and (C) sample pairs with a constant number
of infections. First, the antibody titres of group (A) or (B) were compared with the antibody titres
of the current samples of group (C) (table 3). Second, the changes of antibody titres from the
previous to the current sample of an individual  of the sample pairs with non-constant  number of
infections (group (A) or (B)) were compared with the changes of antibody titres in samples from
group (C) (table 4).
Results
Duration of infections: The distribution  of duration estimates was significantly  different between
age groups 6-18 months and 18-37 months (p<0.05) when P. falciparum infections were
separated according to the expressed MSP2 allelic family (table 2). Estimates of the duration of
infections expressing different allelic families reverses when the children getting older. Infections
expressing MSP2 alleles of the 3D7 allelic family show a decreased duration of 80 days in children
older than 18 months whereas infections expressing FC27 alleles persist longer in this age group
(120 days). In children under 18 months of age, the situation is different. 
Dynamics of immune response: The results of Spearman correlation analyses are summarized  in
table 3 and 4. Overall, both the number and acquisition of  infections with an msp2 allele of the
FC27 allelic family seem to be correlated with an increase of titres against all constructs. An
acquisition of an FC27 expressing infection however seems  to stimulate only antibodies against
the 5'3'construct, the 4x32 aa repeats and surprisingly  against the 3D7 family specific and 3D7
repeats domain. Hence, MSP2 of the FC27 allelic family seems to boost the IgG immune  response
to both allelic families. 
In contrast, the acquisition of 3D7 allele expressing infections stimulates only the antibody
response to the 3D7 repeats. This is also reflected by the correlation of the change  of antibody
response between the previous and the current  sample and the number of infections expressing
msp2 alleles of the 3D7 allelic family. The numbers of infections expressing a 3D7 allele is
positively correlated with the change of antibody level only against the 3D7 repeats representing
antigen (p=0.04). Whereas the number of infections expressing a FC27 allele is  correlated with
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the antibody level change against the antigens representing  4x32 aa repeats, 3D7 repeats and the
3D7 family specific part (p=0.012, p=0.029, p=0.030, respectively). 
During  the monthly intervals in which loss of infections were determined by PCR, no decrease of
antibodies was observed. There was a borderline positive correlation between loss of 3D7 allele
expressing infections and titres against the 5'3'construct and a negative correlation between loss
of FC27 allele expressing infections and antibodies against the 4x32 aa repeats. 
Discussion
The pronounced dichotomy between the two allelic families of MSP2 led us to analyse their
biological significance by estimating  the duration of infections with the different alleles. Since the
immune response of the host seems to be one of the limiting factors for the surviving of the
parasites, we analysed, additionally, the dynamics of the MSP2 specific antibody response in
respect to the present and recent P. falciparum infections with genotyped msp2 alleles.  
The duration of P. falciparum infections expressing MSP2 alleles of the two families seems to be
considerably different and reverses when  the children grow older. We showed that infections
expressing MSP2 alleles of the 3D7 allelic family present a decreased duration in children older
than 18 months in contrast to the situation in younger children whereas infections expressing
FC27 alleles persist longer in the older age group. If this is a continuing process, our finding
explains an earlier observation of Felger et al. (1994; 1999b), when the distribution of the two
allelic families of MSP2 differed significantly  between semi-immune adults and children. FC27
alleles were predominantly  found in adults, whereas 3D7 alleles  were found more frequently in
children.
In addition the sensitivity of detection increases for the 3D7 alleles and decreases for FC27 alleles
with age. This might  indicate that infections expressing a 3D7 allele do not persist as low density
infections, whereas the FC27 allele infections are able to persist with densities below the detection
limit. 
In infants members of both allelic families are affected in the same extent by innate immune
mechanisms,  hence the duration of infections are of equal length (Smith et al. 1999b). Then  the
duration of infections with both allelic families increases significantly when the innate immune
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mechanisms are losing their importance and the acquired immunity is only little  developed. The
immune  response of the host seems early to be able to limit P. falciparum infections expressing
3D7 alleles, beginning  gradually in the first and a half year of life, when the duration of infections
with 3D7 alleles decreases. At this time point the duration of infections with FC27 alleles
increases indicating  that these infections profit from the limitation  of 3D7 infections or FC27
infections evade the immune  response by mechanisms such as original  antigenic  sin (Good et al.
1993) or altered ligand peptides (Plebanski et al. 1997). The ability of limiting infections
expressing FC27 alleles needs probably another process in which other antigens might  also be
involved. The negative correlation of the change of antibody titres to 32 aa repeats from the
previous to the current sample of one individual with the loss of infections expressing MSP2 of
the FC27 allelic family might  indicate a short duration of this antibody response, which might  need
reinfection with P. falciparum expressing a FC27 allele for boosting. Additionally, the lowest
antibody level measured in the study was that against 32 aa repeats (Irion et al.2001a). 
It was suggested that current infections protect, enhanced by the multiplicity  of infection, against
superinfection and prevent clinical malaria  (Ntoumi et al. 1995; Al-Yaman et al. 1997a; Beck et
al. 1997; Färnert  et al. 1999). Observed differences in parasitologic profiles between single
children might  be rather qualitative differences in protective immunity than differences in the
genotypes of infecting parasites (Färnert et al. 1999). This might be related to continuous
presence of diverse parasite clones, which in turn may depend on immunogenetic properties. In
older children low density chronic infections resulting  in high multipl icity of infection have a
protective effect against clinical malaria, but in infants acute episodes of clinical malaria are
positively associated with multiplicity  of infection (Felger et al. 1999b) and the protective effect
of concomitant infections is not observed. The cross-protecting potential might  be developed at
later ages, since adults show considerable higher  antibody levels to all recombinant  antigens tested
than the children enrolled in the study (Irion et al. 2001a). 
Recently, the cross-protection to FC27 alleles mediated by 3D7 alleles (Engelbrecht  et al. 1995)
could not be induced by vaccination with a recombinant  3D7 protein (Genton et al. 2001).This
and the difference in duration of infections might indicate the lack of a protective role for
antibodies to the conserved regions of the molecule. It might be speculated that the observed
protective effect of 3D7 alleles bases only on the absorption of  FC27 specific antibodies by the
repeat structure of present P. falciparum infections expressing a 3D7 allele and not on the
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induction of protective antibodies.
Additionally,  we showed that msp2 alleles of the FC27 allelic family seemed to stimulate the
antibody response to parts of its own molecule and in addition a stimulation of the antibody
response to parts of the 3D7 alleles was observed in children under 21 months. Due to the
observed difference in the duration of infections, further  investigations  comparing  antibody
response of older children are needed. In contrast, P. falciparum infections expressing 3D7 alleles
stimulate only the antibody response to the antigen which represents the 3D7 repeats. This might
reflect the ability of FC27 alleles to confuse the immune  system of the host by broadening the
immune  response, which was thought  to be responsible for the lack of sterile immunity  to malaria
(Anders 1986). P. falciparum infections expressing FC27 alleles might  displace infections
expressing the 3D7 alleles by influencing  the immune  response to the 3D7 family specific part.
Hence, a protective mechanism of 3D7 alleles observed in children with less morbidity might  be
prevented (Engelbrecht  et al. 1995). There is an indirect evidence that the loss of infections with
3D7 alleles allows infections with FC27 alleles to reproduce. The induction  of  antibodies to the
antigen representing  the conserved regions by FC27 alleles, especially by a high number of 12 aa
repeats (Irion et al. 2001a), whereas a positive correlation of these antibodies to the loss of
infections expressing 3D7 alleles was shown. Shifting  the immune  response towards the 3D7
allelic family could be a strategy of the parasite to limit competing infections. Furthermore a
correlation between the number of 32 aa repeats of the infecting parasite and the  stimulation of
the specific antibody response to 3D7 repeats was shown (Irion et al. 2001a). Polyclonal
antibodies induced by vaccinating  mice with the recombinant  antigen representing  the 3D7 repeats
were interacting with  cloned lines of P. falciparum expressing FC27 alleles (Irion et al. 2001a).
These findings  indicate a shared epitope that might  be located at the 5'end of the 32 aa repeat
(Irion et al. 1997). 
Our study clearly shows that there are differences in the duration of infection and in the induction
of immune  response between the two allelic families of MSP2. This is of additional  evidence that
the two allelic families represent different evolutionary strategies (Felger et  al. 1997). The 3D7
alleles have very divers repeat regions but alleles are of low allelic frequencies.  In contrast, the
alleles of the FC27 allelic family are of high frequencies and of a relative conserved repeat
structure. Infections expressing 3D7 alleles might  respond to the immune  pressure of the host by
diversification of their repeat sequence, repeat length,  and number of repeats, whereas infections
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with FC27 alleles partly count on shifting the immune response  towards 3D7 alleles or evading
the FC27 specific antibody response. 
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Table 1: recombinant antigens corresponding to distinct parts of MSP2
antigen amino acid sequence (allele)
23xNAP repeats MRGS-HHHHHH-GSR-SVGA-(NAP)23-NADTIASG-YPGSTCSQA (Ifa23)
3D7 fsp MRGS-HHHHHH-GSR-(3D7allele FCR3 aa109-214)-GYPGSTCSQA (FCR3)
4x32 aa repeats MRGS-HHHHHH-GSR-APK-(32aa repeat)4-ADTP-GYPGSTCSQA  (Ifa45)
6x12 aa repeats MRGS-HHHHHH-GSR-TAT-(ESNSRSPPITTT)6-ESS-GYPGSTCSQA (K1+1)
FC27 fsp MRGS-HHHHHH-GSR-KSVGANAPK-GIP-(FC27fsp)-APQEPQTAENENPA-
GYPGSTCSQA (K1)
5'3'construct MRGS-DHFR-(5'-region K1 aa 1-50)-RNS-(3'-region K1 aa)-RRS-HHHHHH
3D7 repeats MRGS-HHHHHH-GSR-PPT-GAGASGRAGA-GA-GAGASGRAGA-GAGASGRAG
S-GSGDGAVASA-GSGADAEGGSSTPATT-GYPGSTCSQA (84aa)
Table 2: Duration of infections expressing MSP2 alleles of both allelic families
Sensitivity of
detection S
recovery
probability M
recovery rate : duration [days]
3D7 <18 months 0.49 0.23 0.01 100
3D7 >18 months 0.6 0.29 0.0126 79.4
FC27 <18 months 0.73 0.27 0.0117 85.5
FC27 >18 months 0.64 0.19 0.0083 120.5
3D7 no net 0.53 0.24 0.0104 96
3D7 net 0.55 0.28 0.0122 82
FC27 no net 0.6 0.2 0.0087 115
FC27 net 0.78 0.25 0.0109 92
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Table 3: Correlation of achieved antibody titres with acquisition and lost of P. falciparum
infections expressing MSP2 of different allelic families (Spearman correlation analysis)
group (A) group (B)
antigen FC27 aq 3D7 aq FC27 lost 3D7 lost
6x12 aa repeats r 0.08 -0.01 0.05 0
P 0.14 0.848 0.395 0.955
3D7 fsp r 0.32 0.41 0.22 0.39
P 0 0 0 0
3D7 repeats  r 0.32 0.3 0.2 0.25
P 0 0 0 0
5'3'construct r 0.22 0.02 0.18 0.01
P 0 0.781 0.002 0.926
4x32 aa repeats r 0.27 0.25 0.24 0.24
P 0 0 0 0
FC27 fsp r 0.16 0.18 0.09 0.16
P 0.003 0.001 0.098 0.003
23xNAP repeats r 0.25 0.26 0.25 0.24
P 0 0 0 0
n 335 335 335 335
Statistically significant  correlations are stressed by bold letters (p<0.05). *: borderline significance,  aa: amino acid,
aq: acquisition,  fsp: family specific part, n: number of analysed samples, NAP: single letter code for amino acids,
p: p value, r: correlation coefficient.
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Table 4: Correlation of the change of antibody titres between current and previous sample
with acquisition and loss of P. falciparum infections expressing MSP2 of different allelic
families (Spearman correlation analysis) sample1   ) antibody   sample 2.
group (A) group (B)
antigen FC27 aq 3D7 aq FC27 lost 3D7 lost
6x12 aa repeats r 0.04 -0.005 -0.018 0.044
P 0.4 0.9 0.8 0.4
3D7 fsp r 0.12 0.09 -0.04 -0.04
P 0.029 0.1 0.5 0.5
3D7 repeats r 0.14 0.12 0.02 -0.02
P 0.009 0.022 0.7 0.7
5'3'construct r 0.13 -0.04 0.1 0.11
P 0.031 0.5 0.09 0.053*
4x32 aa repeats r 0.17 0.09 -0.1 0.01
P 0.002 0.096 0.060* 0.8
FC27 fsp r 0.08 0.04 0.07 0.05
P 0.16 0.5 0.2 0.4
23xNAP repeats r 0 -0.04 0.01 -0.01
P 0.9 0.4 0.9 0.8
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Assessment of positivity in immuno-assays with variability in
background measurements: a new approach applied to the
antibody response to Plasmodium falciparum MSP2 
Irion, A., Beck HP., Smith T.*
Swiss Tropical Institute, Socinstrasse 57, Postfach CH-4002, Basel, Switzerland .
Abstract 
Measurements of immune  responses often show high levels of heterogeneity, making  it impossible
to clearly distinguish responders and non-responders to particular antigens. Typically, in, e.g.
ELISA assays, a non-exposed control group is used to assign a cutoff value of positivity,
calculated as the mean plus either 2 or 3 standard deviations. This can give rise to extremely
biased estimates of response rates when the background is variable, and especially when there is
overlap between the distribution of the control levels and that of responders. This problem is
compounded when results of assays with different background levels are compared. We illustrate
this with hypothetical data sets reflecting frequent patterns seen in laboratory and epidemiological
studies. 
We propose that such data should be analysed by statistical modelling  of the ratio of numbers of
test samples:control samples as a function of the readout from the assay. Rather than classifying
samples dichotomously as negative or positive, this provides estimates of the prevalence of
positivity 8, and the probability, for each sample, that the measured activity is above background.
Several statistical methods can provide such estimates. Analyses of simulated data sets using our
preferred estimation method (a latent class model), demonstrate that this gives more reliable
results than the traditional  assignment  using cutoff values. We have applied this approach to the
analysis of ELISA assessments of antibodies against distinct regions of the Plasmodium
falciparum merozoite surface protein 2 (MSP2) in human sera from Tanzania. 
Key words: ELISA, malaria,  latent class model, cutoff, prevalence of positivity, probability of
positivity.
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1. Introduction 
Many laboratory methods, for instance enzyme-linked immunosorbent assays (ELISA) can be used
as diagnostic tools to assess the prevalence of a disease and/or the extent of the immune  responses
in populations exposed to the infective agents. Measurements made on samples from an exposed
group are compared with those from a non-exposed control or standard group, in order to
determine which samples are positive. 
In ELISA antibody assays a common practice is to report  an individual  sample as positive when
its titre or optical density is higher than the mean of the corresponding measurements for a
negative control group plus either 2 or 3 standard deviations (the ‘classical’ approach). When
there is a good separation between negative and positive samples, and when the background levels
measured in the controls are not very variable, this gives clear and unbiased results.  However,
these conditions are not always met. Figure 1 illustrates several scenarios that can arise in
epidemiology and in the  application of diagnostic assays when an exposed group is compared to
a non-exposed control group. All the samples of the non-exposed control group are by definition
negative, whereas the individuals  of the exposed group comprise two subgroups: the negative and
the positive ones (in a ratio of (1-8) : 8).  
Immune  responses encountered in human populations are extremely heterogeneous, as is the
performance of immunoassays. This can lead to three kinds of problems with the ‘classical’
approach. (i) The average difference in measurement  between negative and positive samples may
be so small that there  is insufficient  separation between controls and positive samples (Figure 1
a,b,c). (ii) The difference in measurements may be variable so that not all positive samples can be
clearly distinguished  (Figure 1 d,e,f). (iii) The measures for control samples (background) may be
highly variable (i.e. with a high standard deviation) (Figure 1 b,e,h) so that even if the separation
is good, many positive samples have measurements below the cutoff (Figure 1h). Only if none of
these problems arise (Figure 1 g,i), does the classical approach correctly identify the group of
positive samples. In all other cases, a substantial proportion of the test samples cannot be assigned
with confidence.
If the assay is intended for diagnostic purposes and cannot be optimized, the appropriate response
to such problems may be to abandon the assay. However in epidemiological surveys the objective
is usually to estimate the number of positive samples, rather than to assign each individually.  Even
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if it is not obvious exactly which samples are positive, it may be possible to estimate the
probability, 8i, for each sample i, that the measured activity is above background. The average of
the values of 8i provides an estimate of the prevalence of positivity, 8.
As an example, we consider data from a study of antibody levels to distinct parts of the
Plasmodium falciparum merozoite surface protein 2 (MSP2) among children in Tanzania . The
data were described previously by Irion et al. (2001). Antibody levels in both the malaria  exposed
Tanzanian  and non-exposed European children of the same age were measured. The objective of
the analysis is to determine the proportion of the Tanzanian  children with higher  levels of specific
antibodies than those in the European controls. 
Optimally, an estimate of 8 should be consistent (converge on the correct value when the sample
size is large), and unbiased (should not show any systematic tendency to over- or under-estimate
when the sample size is small). There are several ways of making such estimates.  Our preferred
approach is a latent class model for non-parametric  decomposition of two-component mixture
distributions (Vounatsou et al. 1998). We demonstrate the use of this to estimate the proportion
of children with antibodies attributable to distinct regions of MSP2. The principles illustrated  with
this example can also be applied to a wide range of other assays.
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2. Theory 
Assume that an observed population  consists of a mixture  of samples from non-responders and
from responders to some stimulus,  in proportions 1-8 and 8 respectively, where 8 is the mixing
proportion or equivalently, the prevalence of positivity or the attributable fraction. The distribution
of immunological  measurements, F(.), thus comprises two components  (g1(.) and g2(.)), neither
of them necessarily normally  distributed. g1(.) corresponds to the distribution  of measurements in
control individuals  who have not been exposed to the stimulus,  and g2(.) to the levels in
responders, and hence:
F(x) = (1 - 8 ) g1(x) + 8 g2(x),
where x denotes the value of the chosen measure of immune response.
For the assay to be meaningful,  observations from g1(.) must be smaller on average than those
from g2(.) but there may be overlap between the two distributions.
The density ratio D(x)=F(x)/g1(x) is the ratio of the frequency of any given antibody unit value in
the population, to the frequency in the control group. If there are no additional antibodies
measured in the tested samples then we expect this ratio to be uniformly  1 and 8=0. On the other
hand, if 8 is greater than 0, we expect D to be an increasing  function of x. The limiting  case of no
overlapping, where g2(x)=0, provides D(x)=(1- 8) for all x. Figure 2a illustrates D(x) for the
example of Figure 1e.
A simple way to estimate 8 for real data is to group the measurement  (x) into distinct categories
and to plot D(x) for these categories. This is calculated by taking the proportion of the tested
population in that category and dividing  by the proportion of the control  group which falls into
the same range (Figure 2b). The average value that D( x) achieves over low values of x can than
be used to obtain a minimally biased estimate of (1- 8) and hence of 8. 
Besides its use in estimating  the overall prevalence of positivity, the density ratio curve can be used
to estimate the probability that samples with a given measurement  value have an immune  response
to the stimulus. If there were no effect of the stimulus then the probability of obtaining
measurement  value x would be g1(x). However, the actual probability is F( x). The difference is
attributable to the positive samples. The proportion of those samples with measurement  x that are
positive is therefore equal to: 
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It follows, that if D(x) and 8 can be estimated, that p(x) can also be obtained, and used as an
estimate of the probability that a test sample is positive. This probability depends not only on the
sample’s value, but also on both the distribution of measurements  made on control samples and
that of the other test samples.
Unfortunately, when there is only a limited amount of data then estimates of 8 made graphically,
as described above, will be very imprecise. In such situations it is necessary to use a statistical
model to fit a curve to D(x) or p(x). Several different statistical methods are available. If the
distributions g1(x) and g2(x) are known to belong to particular  families (e.g. Normal distributions)
then their parameters, together with 8, can be estimated by maximum  likelihood. However, more
usually there is no reason to suppose that either g 1(x) or g2(x) belong to any particular  type of
distribution,  and the strongest assumption which we would like to make is that as x increases, so
do D(x) and p(x). We have already investigated various statistical approaches to this problem,
which incorporate this assumption but do not assume particular  distributional  forms for g1(x) and
g2(x) (Smith  et al. 1994; Vounatsou et al. 1998; Smith and Vounatsou 1997). Our preferred
approach (Vounatsou et al. 1998) fits a latent class model (LCM) to the data, and can be
implemented in the freely available software package Winbugs (Spiegelhalter et al. 2000).
3. Examples
3.1. Simulated example  
To illustrate  the performance of our proposed method, we simulated a data set corresponding to
that of Figure 1e. We drew 500 samples from the distribution  F(x), and 100 samples from g 1(x).
The columns in Figure 2a illustrate  the resulting distributions, binned into intervals of length 2.
The distributions obtained differ a little from those shown in Figure 1e because of chance sampling
variations. 
In this example the density ratio in the 0<x<2 category is by chance exactly equal to 0.2,
corresponding to the correct value of (1- 8). The density then increases with x. Corresponding to
this density ratio curve, the model estimates the function p(x) (the probability that a sample is
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positive), as a smooth increasing function of x. The method of (Vounatsou et al. 1998) also
provides an overall estimate of 8, which for this example was 0.717. This estimate is much closer
to the true value of 8=0.8, than is the value  obtained from the classical cutoff approach (Figure
1e; estimate 0.395) but is not exactly equal to the correct proportion positive. In general, this
LCM approach will give estimates of 8 which are much closer to the true value than those
obtained using the cutoff approach, but the sampling  variation means that these will not be exactly
equal to the true value especially when the sample size is small.
3.2 Levels of antibodies against MSP2 
As part of a study of the antibody response to malaria  antigens in Tanzania,  levels of total IgG
were measured by ELISA against a series of seven recombinant  proteins comprising  parts of the
merozoite surface protein 2 (MSP2) of Plasmodium falciparum. The study involved more than
four hundred sera from children aged 5-21 months. The procedures for these ELISA assays have
been described in detail elsewhere (Irion et al. 2001). Briefly, microtitre  plates (Immulon  2; Dynex
Technologies, USA) were coated with 50 :l of one of the set of protein preparations. Immunogen
concentrations ranged from 0.1 :g/mL – 10 :g/mL in PBS at pH 7.2. Titrations of a positive
standard of 20 pooled sera from semi-immune  adults from Papua New Guinea were performed on
each ELISA plate to standardise for differences between plates. Sera of 36 healthy European
children aged 5-15 months, who had not been exposed to malaria  were used as negative controls.
Each test serum and control serum was tested against the single immunogen  and, as a background
control, against a protein solution consisting of DHFR-6His (5 mg/ml PBS), produced like the
other recombinant proteins.
Estimates of positivity of test sera against the antigens calculated by the proposed approach in
comparison to the classical approach are shown in table 1.
Using estimates of 8 it is also possible to assess the levels of response in the positive samples,
without being biased by the effects of non-responders. The mean antibody levels of test sera in our
study are shown in table 1. The positive test sera have particularly  high antibody units to the
antigens 6x12 aa repeats and 5'3'construct. Moderate antibody units were seen with the antigens
FC27fsp, 3D7repeats and 23xNAP repeats. Low unit levels were found with the antigens 3D7fsp
and the 4x32 aa repeats. 
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4. Discussion 
The performance of immunological  tests is commonly assessed by examining  the ability of the test
to correctly classify individuals  into two subgroups, for example, a subgroup of individuals
affected by some disease and a second subgroup of unaffected individuals. If there is no overlap
in test results from these two subgroups, then the test can identify all individuals correctly,  that
is, distinguish  the two subgroups perfectly, otherwise false positive and false negative results must
be considered. 
Some data sets exhibit a clear distinction  between responders and non-responders, and then there
is a strong argument for using  a threshold value to define positivity, on the grounds of clarity of
presentation, or where an unambiguous  diagnosis is needed for clinical purposes. However for
many others there is no evidence of dichotomy. Defining a cut-off value when there may be no
obvious division of individuals  into two groups, is potentially misleading  and a rather arbitrary
process, which can have profound effects on the results. 
Different attempts have been made to manage this problem. Where a gold standard exists,
predictive values can be calculated, describing the likely correctness of positive (or negative) test
results. The efficiency, i.e. the percentage of all test results which will be correct for a particular
population, can also be calculated. Receiver Operating Characteristic (ROC) curves can also be
used to assess the sensitivity and specificity of the assay in a particular population (Zweig and
Robertson 1987; Xu et al. 1997).  
Where there is no gold standard, the assessment of diagnostic accuracy represents a more
challenging  statistical problem. Latent class models have been applied in a number of such
situations, for instance assessment of true disease status (Boelaert et al. 1999), and comparison
of several diagnostic tests or of several readers (Yang and Becker 1997, Qu et al. 1996, Walter
et al. 1999). The objective here is to assess the extent of misclassification,  or to optimise the
assignment to classes, whilst accepting that there will be a certain level of misdiagnosis. 
Where the objective is to estimate the proportion of positive samples, however, it is not necessary
to assign each sample using a dichotomous grouping.  This is very often the case in epidemiological
studies. We propose the use of statistical models to assess the relationship  between positivity and
the measured response in the analysis of immunoepidemiological  data, and illustrated this with
ELISA data from a study of malaria. This approach assigns a probability of positivity and hence
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those samples that cannot be assigned with certainty need not be allocated to one or other
category. We believe such methods could be useful in the characterization  of antibody responses
measured by many different immunological methods with quantitative readouts. 
One advantage of this approach is that it automatically introduces consistency into the definition
of a positive responder, making it  easier to compare results between studies, and between tests,
and reduces the sensitivity of the results to outliers in the distributions of control values.
Moreover, when fixed cutoffs are used to analyze ELISA tests, rates of responders are often
seriously under-estimated,  depending on the absorbance cut-off method applied for negative
controls. This is especially a problem when the immune responses  are weak and the differences
between responders and non-responders small, as with our malaria data set. 
Statistically, it is more efficient to compare average levels of response rather than proportions of
“responders” when comparing groups where all individuals are at least partially immune or
“exposed” (Bennett and Riley 1992). However, such analyses presupposes that the level of
response is important  and that we are not interested in knowing whether this response is accounted
for by contributions from the whole population, or from only a few individuals.  Mechanisms such
as genetic restriction,  altered peptide ligands antagonism  (Kersh and Allen 1996; Plebanski et al.
1997) or original  antigenic  sin (Good et al. 1993; McMichael 1998) predict that responses (against
e.g. malaria  antigens)  should be limited to some individuals,  and it can therefore be relevant to
know the proportion of responders. Estimation  of 8 for different specific antibody responses in
different populations may thus represent a valuable step towards understanding immune
mechanisms.
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Figure 1: Comparisons of hypothetical data sets 
Each sub-figure illustrates the hypothetical distributions of measurements observed using an assay
where the test samples comprise a mixture  of 80% positive samples and 20% negative samples
(true value of 8=0.8). The unshaded peak is the distribution of the controls, the dark grey area
corresponds to the true negative samples, and the light  grey area to the true positives. The arrow
indicates the location of the mean + 2 s.d. cutoff, and P is the percentage of test samples with
measurements greater than the cutoff.
) : mean increase in )  above background for the test samples, :: mean of the control samples, F2:
variance of ) .
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Figure 2: A simple way to estimate 8 for real data is to group the measurement (x) into distinct
categories and to plot D(x) for these categories. This is calculated by taking the proportion of the
tested population in that category and dividing  by the proportion of the control group which falls
into the same range. The average value that  D(x) achieves over low values of x can than be used
to obtain a minimally biased estimate of (1- 8) and hence of 8. 
(a) illustrates the density ratio D( x) for the example of Figure 1e.
(b) illustrates the density ratio D(x) for the data set of antibody response to the antigen
representing the FC27 family specific part.
Dashed line: density ratio D(x)
Thick line: 8 as estimated from the latent class model 
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Table 1: Mean titres, estimates of positivity and cutoffs.
antigens
representing
defined regions
of the MSP2
molecule 
Mean titre in
negative
controls (s.d.)
Classical aproach used to
define positivity 
Estimations from latent class model Overall
mean titre in
test sera
(units)
Cutoffs
x+2s.d.
Proportion of
test sera
positive
Estimated
Proportion of
test sera
positive
Mean titre
in positive
test sera
(units) 
Mean titre
in negative
test sera
(units)
6x12 aa repeats 0.032 (0.022) 0.077 0.928 0.923 0.481 0.049 0.447
3D7 fsp 0.003 (0.003) 0.010 0.579 0.754 0.067 0.004 0.052
3D7 repeats 0.009 (0.005) 0.020 0.864 0.895 0.210 0.012 0.190
5'3' constant 0.281 (0.280) 0.840 0.540 0.856 1.866 0.344 1.647
4x32 aa repeats 0.004 (0.003) 0.010 0.396 0.526 0.071 0.004 0.039
FC27 fsp 0.090 (0.094) 0.278 0.441 0.786 0.356 0.106 0.302
23x NAP repeats 0.007 (0.005) 0.018 0.134 0.660 0.162 0.010 0.111
The antigens used in ELISA are described and defined in Irion et al. 2001. 
x+2s.d.: mean  of the negative controls  + 2 standard deviations; aa: amino acid; fsp: family specific part; NAP:
single letter code for amino acids.
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Immunogenicity of MSP2 and monoclonal antibodies to conserved regions V1
Immunogenicity of recombinant protein domains derived from 
merozoite surface protein 2 (MSP2) and production of
 monoclonal antibodies to the conserved protein regions
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Introduction 
Merozoite surface protein 2 (MSP2) of Plasmodium falciparum is a potential component of a
malaria vaccine (Genton et al. 2000, 2001). The MSP2 is a highly polymorphic 45-52 kDa integral
membrane protein located on the surface of merozoites. The molecule has highly conserved N-
and C-terminal regions with a central block composed of variable repeat domains flanked by
dimorphic, non-repetitive, family-specific sequences. Even though MSP2 is naturally antigenic in
man and antibody responses to conserved regions do occur during malaria infection, these
responses predominantly recognize the dimorphic and polymorphic regions of the molecule
(Taylor et al. 1995; Al-Yaman et al. 1995). Several studies were performed to assess the antibody
response to corresponding peptides (Ramasamy et al. 1998; Lougovskoi et al. 1999) or
recombinant MSP2 protein (Al-Yaman et al. 1994, 1995, 1997a, 1997b; Rzepczyk et al. 1997)
representing all parts of the molecule. Several B cell epitopes have been identified in different
parts of the molecule by peptide mapping. In order to improve our understanding of MSP2 as an
antigen and vaccine candidate, which elicit antibodies with different protecting qualities in natural
infections (Al-Yaman et al. 1994, 1995), the distinct domains of the molecule must be 
Key words: merozoite surface protein 2, immunogenicity, monoclonal antibodies, conserved
regions, malaria, Plasmodium falciparum. 
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investigated separately. Especially those  regions of the protein, which are conserved even in
different species of plasmodia, could be responsible for functions important for the survival of the
parasite and might be a promising base for a malaria vaccine. Therefore, we have expressed
several recombinant MSP2 proteins in Escherichia coli representing the entire sequence of the
mature protein and assessed the immunogenicity of seven of these proteins by immunisation of
mice. In addition the protein construct with the dimorphic and variable central parts deleted was
used to generate monoclonal antibodies.  To investigate the importance of the conserved regions,
these monoclonal antibodies could be further used in inhibition and competition assays. 
Methods
Production and purification of recombinant proteins
Several different MSP2 protein constructs with essential parts deleted (Fig. 1) were expressed in
a procaryotic expression system (Qiagen) in E.coli  M15 strain, initially transformed with pREP4
repressor plasmid. Corresponding primer pairs with specific restriction sites (5' Bam HI, 3' Kpn
I) were used to amplify distinct regions in the msp2 gene (Table 1) derived from different msp2
alleles. The PCR products were cloned in the pQE30 expression vector as fusion proteins with
six histidine residues at the 5'end. For better expression yield the 5'3'construct recombinant
protein was fused to the gene coding for mouse DHFR protein (pQE16 expression vector). For
cloning into this vector the Bgl II restriction site was used. The expression of the fusion proteins
was under control of the lac promoter and hence inducible by addition of IPTG. The constructs
are shown in Fig.1. Their positions relative to the msp2 gene are presented. It should be noted
that the restriction sites (Bam HI, Kpn I, Eco RI, Bgl II), by which the fragments were ligated into
the pQE vector, are not represented in the  msp2 gene itself, but come from the primer used for
amplification of the DNA fragments.
Sequences of rMSP2 proteins
All constructs were confirmed by DNA sequencing with ABI-Sequencer (Perkin Elmer) and the
deduced amino acid sequences of the recombinant proteins were compared to that of  MSP2  of
the origin allele (Table 1). Recombinant proteins 23xNAP  repeats, 3D7 family specific part, 4x32
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aa repeats, 6x12 aa repeats, and 3D7 repeats have amino acid sequences identical to the origin
protein regions plus the amino acids resulting from the restriction sites at the ends of the
sequences. Sequence encoding protein 5'3'construct contains a single non-synonymous nucleotide
change leading to an amino acid change in the protein, which is found in other msp2 alleles, also.
The antigen representing the family specific part of FC27 alleles showed an additional doubling
of the last 14 amino acids. 
Expression and purification of rMSP2
Expression and purification of the protein constructs were done according to the manufacturer’s
protocol (Qiagen) and were described in detail elsewhere (Irion et al. 2001). Briefly, E. coli cells,
transformed with one of the expression vectors, were grown in Super broth (25 g Trypton, 15 g
yeast extract, 5 g NaCl ad 1 L) using the appropriate antibiotics, 100 mg/L ampicilline
(Appligene) and 25 mg/L kanamycin (Sigma) at 37/C to OD600 nm = 0.5-0.8, when the protein
production was induced by addition of IPTG (Appligene) to a final concentration of 1 mM. The
harvested cells were resuspended in lysis buffer (50 mM Sodium dihydrogenphosphate  pH 8.0;
300 mM Sodium chloride; 10 mM imidazole). Bacterial cells were broken by lysozym digestion
and ultrasound on ice. The fusion proteins were purified by binding to Ni-2+ -agarose and elution
was performed with imidazole (250 mM imidazole). The 5'3'construct recombinant protein was
expressed at 25/C to prevent inclusion body formation and denatured with 6 M
Guadininehydrochloride (6 M GuHCl; 0.1 M sodium dihydrogenphosphate; 0.01 M TrisCl, pH
8.0). Purification was performed with 8 M Urea (decreasing pH 8.0-4.5). The recombinant protein
was eluted at pH 4.5. Pure protein fractions were pooled and renatured by dialysis as previously
described for other MSP2 recombinant proteins (Takacs and Girard 1991). Protein preparations
under native conditions were dialyzed against PBS pH 7.2 to remove imidazole. Immunoblots and
ELISAs showed a good recognition of the recombinant proteins by serum from semi-immune
adults from PNG and Tanzania. Sera from healthy Europeans (36 adults and 36 children aged 5-
15 months) non-exposed to malaria were used as negative controls. The proteins were stored at
–70/C until required.
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Immunogenicity in BALB/c mice
The immunogenicity of the recombinant proteins was investigated in female BALB/c mice (4-6
months old) by four injections (4x i.p.) of each immunogen (2.5-10 mg) without adjuvants except
polyacrylamide. Each immunogen was tested in two mice. The immunisation scale was: 0, 14, 28,
42 days. Pre-immune serum was collected from each mouse. Immune sera were collected 14 days
after the last injection. The murine sera were used in ELISA and immunoblotting to test for
recognition of the immunogens and parasites in IFAs. Sera were stored as aliquots at -20/C.
The immunisation time scale for mice used for monoclonal antibody production was different.
Four mice were immunized by three injections (i.p.) of the immunogen (10 :g each) at day 0, 14,
28. Sera were collected from the tail vein. The specificity of produced polyclonal antibodies was
tested by ELISA, IFA and immunoblotting. Three months later, the mice received the forth
injection i.v. in the tail vein of the immunogen (12 mg) suspended in PBS without any
polyacrylamide. After three days the mice were dissected.  The murine sera were also tested in
ELISA and immunoblotting to assess the recognition of  the immunogen and parasites in IFAs.
Some sera were tested against longer recombinant proteins, since no parasite derived antigen with
the corresponding msp2 gene was available. 
Enzyme-linked immunosorbant assays (ELISAs)
ELISAs were performed as described by Irion et al. (2001). Microtitre plates (Immulon 2; Dynex
Technologies, USA) were coated with 50 :l of antigen. Protein concentrations ranged from
0.1:g/ml to 10 :g/ml in PBS pH 7.2. Sera from mice were used in serial dilution starting from
1:50 in two-fold steps. The second antibody was alkaline phosphatase conjugated, and 1mg/ml
p-nitrophenyl in a carbonate buffer (Na2CO3, NaHCO3, MgCl2 pH 9.6) was used for colour
development. The absorbance was measured at 405 nm in a spectrophotometer (Titertek
Multiskan MCC/340). Each antiserum was tested against the single immunogen and, as a
background control on the same plate, against a protein solution consisting of DHFR-6His (5
:g/ml PBS) produced in the same way like the other recombinant proteins. Pre-immune control
sera were included in each ELISA assay. The antibody levels were reported as the reciprocal
antibody titre which gave an OD405 of 0.1 over background. 
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Immunoblot analysis of recombinant immunogens and of parasite derived MSP2
Recombinant protein constructs were tested by immunoblotting for reactivity with specific anti-
6His-antibody (Qiagen, R&D) and with anitsera of immunized mice. Purified protein was
subjected to SDS-PAGE under reducing and non-reducing conditions. Proteins were transferred
to a nitrocellulose membrane, which was then blocked overnight in blocking buffer (3% BSA in
PBS pH 7.2). Diluted anti-6His-mouse-antibody (1:1000) was incubated with the membrane for
one hour, washed, and subsequently incubated with alkaline phosphatase-conjugated secondary
antibody for an additional hour and washed. Alkaline phosphatase substrate (NBT, BCIP, Biorad)
was added in development buffer (100mM TrisCl, pH 9.5; 100 mM NaCl; 5 mM MgCl2) and
incubated until bands became visible.
In vitro cultured parasites of the cloned lines K1 and NF54 were isolated by saponin lysis (Goman
et al. 1982). Preparation of parasite derived proteins was done as described previously (Lanzer
et al. 1992). About 5x109 parasites were suspended in 1ml of lysis buffer (10 mM HEPES pH 7.9,
10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM DTT, 0.5 mM PMSF and 0.65% NP-40) and
centrifuged to pellet the nuclear debris. Parasite proteins were resolved in an SDS-PAGE gel and
electroblotted onto a nitrocellulose membrane. The membrane was probed  with immune sera of
the immunized mice as above.
Immunofluorescence assay (IFA)
Each murine serum sample was incubated at the appropriate dilution (according ELISA titres)
with acetone-fixed cultured parasites expressing different msp2 alleles (K1= K1-allele, HB3 =
wos3-allele, NF54 = 3D7-allele, ITG2F6= 3D7-allele) for one hour at 37/C. IFA slides were
washed and then incubated with fluorescein isothiocyanate-labelled secondary antibody (goat anti-
mouse IgG(g), KPL) for one hour at 37/C in a humid chamber, washed, and examined with a
fluorescence microscope. As negative controls non-infected erythrocytes and pre-immunization
serum were used.
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Monoclonal antibodies
To generate monoclonal antibodies directed against the 5'3'construct protein spleen cells of the
immunized BALB/c mouse were fused with PAI myeloma cells (mouse myeloma HGPRT-
deficient cells). The fusion was performed according to standard procedures (Coligan et al. 1995).
Instead of feeder layers, HAT medium was supplemented with 5% conditioned medium from
supernatant of an LPS activated monocytic cell line (P388/D1; Koren et al. 1975; Melchers and
Corbel 1983; Perstidge et al. 1984). Three days after the last antigen booster injection (i.v.) the
mouse was dissected under sterile conditions and the spleen tissue was pressed through a mesh
net by using a plunger of a syringe to obtain a single cell suspension. Both spleen and prepared
PAI myeloma cells were washed twice in wash medium by repeated centrifugation for 5 min at
180g. Prior to a third centrifugation step cells were pooled in equal proportions (cells per spleen
1x 108). After complete removal of wash medium, 1 ml PEG 1500 solution (Boehringer
Mannheim) was added in steps of 100 :l within one minute. The resulting two phases were mixed
by slow rotation during 10 min. After addition of 35 ml wash medium the cells were centrifuged
for 5 min at 180g and resuspended in 160 ml HAT medium (IMDM, 36 mM NaHCO3, 5x10-2 mM
$-mercaptoethanol, 100 U/ml Penicillin/100 :g/ml Streptomycin, 0.1 mM Hypoxanthine, 0.4x10-3
mM Aminopterin, 0.016 mM Thymidine, 20% FCSi, 5% P388/D1 conditioned medium). This cell
suspension was distributed in 200 :l portions in a 96-well culture plate and incubated at 37/C in
an atmosphere containing 5% CO2 (Carbagas, Basel, CH). Growing colonies were examined for
production of anti-5'3'construct antigen antibodies by ELISA. Mother clones producing the
highest IgG titer were transferred into 48-well culture plates. The specificity of the produced
antibodies was tested by IFA and immunoblotting. The IFA positive hybridoma cells were cloned
by limiting dilution in HAT medium to two different final concentrations: 0.3 and 3 cells / well.
Growing single colonies were screened by ELISA. Cell lines with the highest titres were
transferred into 24-well culture plates. At this point, culture medium was changed from HAT
medium to hybridoma medium. A final transfer in 25 cm2 tissue culture flasks followed. The
antibody containing supernatant was removed after overgrowth of  cells, centrifuged for 10 min
at 180g, and aliquots were stored at –70/C until use. 
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Results
Immunogenicity of recombinant MSP2 constructs
Mice were immunised with the purified recombinant MSP2 antigens with essential parts deleted
(except  recombinant 3'end protein) to show that all seven protein constructs were immunogenic.
This also established the protein similarity to parasite derived MSP2 (PfMSP2) as seen on
immunoblotting using parasite derived proteins and to the native MSP2 on the parasite itself by
IFA. Antibody titres against the seven recombinant MSP2 protein constructs were measured by
ELISA, immunoblot, and IFA after four injections in BALB/c mice. High antibody titres were
observed in ELISA and immunoblot with rMSP2 constructs against the immunogens
5'3'construct, 6x12 aa repeats, 4x32 aa repeats, FC27 family specific part (table 2), medium
antibody titres were reached against 3D7 repeats and only low antibody titres were achieved
against the immunogens 23xNAP repeats and 3D7 family specific part even after the fourth
injection. IFA was used to assess stage specificity and subcellular distribution of positive
reactions. All IFA positive sera resulted in reactions typical of PfMSP2 (Smythe et al 1988), a
grape-like pattern on segmented schizonts and extracellular merozoites. Antibodies against the
5'3'construct showed a distinct pattern with stained schizonts, extracellular merozoites, but also
all other parasite stages. The strength of response induced by different rMSP2 constructs varied.
Both mice immunized with 5'3'construct, 6x12 aa repeats, 4x32 aa repeats, FC27 family specific,
3D7 repeats showed positive reaction with parasites. Antibodies to the 4x32 aa repeats recognised
also parasite derived protein containing 4x32 aa repeats (Wos6). All sera from mice immunized
with 23xNAP repeats and  3D7 family specific failed to react with parasites. Antisera against
23xNAP repeats were tested to a longer recombinant MSP2 antigen with 23xNAP repeats (nested
Ifa23) and showed recognition in ELISA and immunoblot. The specificity of all antisera was good
since polyclonal antisera recognised only parasites with corresponding MSP2 alleles except
antisera against 3D7 repeats where a cross-reaction with FC27 alleles was observed. In addition,
for the assessment of natural immune recognition eighty sera from patients attending the Policlinic
of the Swiss Tropical Institute (traveller and migrants from endemic areas) with a diagnosed P.
falciparum malaria, were used in immunoblot analysis against the 5'3'construct and a recombinant
protein representing the entire conserved 3'-end. Eight individuals (10%) showed an antibody
response to the 5'3'construct antigen, and two individuals (2.5%) recognized the 3'end. 
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Monoclonal antibodies
Polyclonal antisera raised in 4/4 BALB/c mice recognized the 5'3'construct in immunoblot and
ELISA. Additionally, these antisera recognized several proteins with the maximum apparent mass
(Mr) of ca. 45 kDa by immunoblotting of P. falciparum K1 antigen extracts. The levels of
antibody response raised against the immunogen were estimated by ELISA, and the results are
presented as reciprocal titre in table 3. For the antisera, a grape like pattern of fluorescence was
observed in IFA with P. falciparum cloned lines K1 (FC27 allele) and NF54 (3D7 allele),
suggesting recognition of protein(s) on the surface of merozoites within schizont stage parasites.
Parasites in other stages were also recognized by staining the cytoplasma of the cells.
Five hybridoma cell lines produced antibodies which specifically recognized the immunogen in
ELISA (mab A1.108, A1.3, A1.27, A1.36, A1.81, see table 3). Three antibodies were also tested
as positive against the 3'protein in ELISA (mab A1.108, A1.3, A1.36). There are two groups of
monoclonal antibodies. One group of antibodies recognized the recombinant immunogen and the
recombinant 3'end protein in immunoblots, but did not  recognize parasites in IFA. The other
group of monoclonal antibodies recognized all stage parasites in IFA, but did not recognize
neither the recombinant immunogen nor the recombinant 3'end protein in immunoblots. In
immunoblots with parasite derived proteins these antibodies recognized several bands including
the MSP2 corresponding band (Figure 2).  
Discussion
The aim of this study was to characterize the antibody response to distinct parts of the merozoite
surface protein 2 in mice to assess the immunogenicity of the recombinant proteins. In addition
the production of monoclonal antibodies to the chimeric protein representing the conserved
regions of the molecule was performed to estimate the significance of the conserved regions for
the function of the MSP2 molecule by in vitro inhibition assays. The antibody responses obtained
in mice immunized with recombinant proteins were analysed by IFA, immunoblot and ELISA. 
Sequencing studies have shown that many malarial antigens contain extensive arrays of tandemly
repeated short amino acid sequences, and much of the antibody response induced by malaria
infections is directed against epitopes encoded by these repeats (Cowman et al. 1984; Anders et
al. 1985). It is known that short amino acid repeats elicit a rather ineffective T-cell-independent
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antibody response, whereas a T-cell-dependent response against non-repeat regions would be
more effective (Vergara et al. 1985; Bachmann et al. 1995). Thus, it had been argued that the
primary function of the repeats is the induction of a strong T-cell-independent response to the
repeat region in order to prevent development of a T-cell-dependent response (Enea & Arnot
1988), thereby favouring the parasite’s evasion. It is reported that the fine specificities of the
humoral immune response in P. falciparum infected individuals are dominated by the repeat
peptide structures and the conserved regions seem to be cryptic B epitopes, at least during the
course of natural infections (Ballou et al. 1985; Bharadwaj et al. 1998). 
In our hands, the repetitive sequences of MSP2 showed high immunogenicity in mice and elicited
high level of antibody titres. In addition the protein which represents the family specific region of
FC27 alleles was highly immunogenic in mice, with high antibody level and high specificity. The
only exceptions were 23xNAP repeats and the family specific part of 3D7 alleles, where only
marginal antibody titres were reached and no recognition of parasites could be demonstrated. The
negative IFA with polyclonal antisera against the 3D7-family specific part could be due to the low
antibody titres. Since the serum samples of semi-immune adults showed a very good reaction with
the recombinant antigen representing the 3D7 family specific part in contrary to the sera of non-
exposed children and adults (together  with a very low background), we rated this antigen as at
least partly similar to the PfMSP2 and therefore useable for ELISA (Irion et al. 2001). But this
could indicate, that the 3D7 family specific part is little immunogenic and requires frequent natural
infection or boosting to reach high antibody titres. Unfortunately a parasite culture expressing
MSP2 with more than one NAP-repeat was not available. However, a longer recombinant protein
with 23xNAP repeats was recognised in immunoblot. In summary, immunisation of mice showed
that all seven recombinant proteins were immunogenic, and antibodies to five proteins recognised
PfMSP2, indicating that at least these proteins had epitopes of the native protein. Once the
antigenic similarity of the rMSP2 proteins to PfMSP2 was estimated, we were confident in using
these proteins for serological assays. Hence, the proteins could be used in an ELISA assay to
detect MSP2 specific antibodies in consecutive sera of children initially aged 5-15 months from
Tanzania. This study is described elsewhere (Irion et al. 2001). 
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IFA positive polyclonal antisera (32 aa repeats, 12 aa repeats, FC27 fsp, 3D7 repeats) showed a
typical MSP2 staining pattern with grape like schizonts and merozoite surface staining. However,
antisera to 5'3'construct reacted with all parasite stages indicating the recognition of a shared
epitope of several proteins. Further investigations with monoclonal antibodies originated from
mice immunized with 5'3'construct elucidated these findings.
Antibodies that recognized P. falciparum parasites by IFA were produced by all of the four
BALB/c mice immunized with the 5'3'construct. Produced monoclonal antibodies could be
divided in two groups. On the one hand monoclonal antibodies recognizing the recombinant
immunogen in immunoblots and ELISA did not show any recognition of parasites in IFA. The
recognition of the recombinant 3'end protein showed that the C-terminal region and not the N-
terminal region is the immune target for these antibodies. Previously it was reported that antisera
from mice immunized with an antigen similar to the 5'3'construct responded to an amino acid
sequence at the C-teminus which is cleaved from the mature MSP2 protein (Lawrence et al.
2000). This might explain the lack of recognition of the parasites in IFA and of the parasite
derived protein in immunoblot although the monoclonal antibodies recognized the recombinant
immunogen in ELISA and immunoblotting. Another explanation could be neoantigens created by
fusing the different parts of the molecule to DHFR, but the 3'-end recombinant protein was
expressed without fusion to the DHFR-protein. Hence,  we favour the first explanation, and this
has to be proven using short peptides representing the whole 3'end of the MSP2 molecule. 
On the other hand, those monoclonal antibodies recognizing all stage parasites in IFA did not
recognize the immunogen in immunoblots, but in ELISA. In addition, the 3'protein was also
recognized in ELISA, indicating the recognition of a conformational epitope, which is located
within the 3'region of the protein. In addition, this second group of antibodies showed a reaction
with several bands of the parasite derived protein preparation, including the MSP2 band. This
indicates the recognition of an epitope which is shared by several plasmodial proteins of all
parasite stages. Therefore these antibodies are not expected to be protective or the target epitope
is not immunogenic like a cryptic epitope in natural infections. Hence, these antibodies might not
be present in malaria patients. The nature of this shared epitope has to be investigated. Whether
these antibodies show an inhibitory effect on P. falciparum culture, has to be further examined
in inhibition and competition assays.
Immunogenicity of MSP2 and monoclonal antibodies to conserved regions V11
Only, ten percent and two and a half percent of sera from travellers and migrants with a diagnosed
P. falciparum malaria reacted with recombinant 5'3'construct and 3'protein in immunoblots,
respectively. These results are in agreement with previous findings from Lawrence et al. (2000).
Whereas sera from children, non-exposed and exposed to malaria, showed a moderate antibody
level against the 5'3'construct in ELISA, even the non-exposed children (Irion et al. 2001)
indicating a conformational epitope as immune target. Whether this target is equivalent to the
conformational epitope of the monoclonal antibodies has to be investigated. Affinity purification
of these human antibodies and subsequent IFAs with parasitized erythrocytes will elucidate this
finding.
Figure 1: Schematic structure of the merozoite surface protein 2 
The two allelic families and the recombinant proteins with essential parts deleted are shown.
aa: amino acid, cons: conserved, fsp: family specific part, NAP: single letter code for amino acids,
Thr: Threonine
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Figure 2: Immunoblot of parasite derived protein preparation MSP2 of the cloned line K1
(A) monoclonal antibody A1.3 on protein preparation of a non-synchronized cloned line K1; 
(B) anti-6x12 aa repeats antiserum:  
Lane 1: Ring stages and trophozoites
Lane 2: Trophozoites with segmented nuclei
Lane 3: Schizonts and merozoites
Lane 4: Schizonts and merozoites
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Table 1: Deduced amino acid sequences of tested antigens 
antigen deduced amino acid sequence (allele)
23xNAP repeats MRGS-HHHHHH-GSR-SVGA-(NAP) 23-NADTIASG-YPGSTCSQA (Ifa23)
3D7 fsp MRGS-HHHHHH-GSR-(3D7allele FCR3 aa109-214)-GYPGSTCSQA (FCR3)
4x32 aa repeats MRGS-HHHHHH-GSR-APK-(32aa repeat) 4-ADTP-GYPGSTCSQA  (Ifa45)
6x12 aa repeats MRGS-HHHHHH-GSR-TAT-(ESNSRSPPITTT) 6-ESS-GYPGSTCSQA        
(K1+1x12 aa repeat)
FC27 fsp MRGS-HHHHHH-GSR-KSVGANAPK-GIP-(FC27fsp)-APQEPQTAENENPA-
GYPGSTCSQA (K1)
5'3'construct MRGS-HHHHHH-GSR-(5'-region K1 aa 1-50)-RNS-(3'-region K1 aa 207-280)-
GYPGSTCSQA                 aa 23 E (like FC27-genotype)
DHFR-
5'3'construct
MRGS-(mouseDHFR)-GSRSS-(5'-region K1 aa 1-50)-RNS-(3'-region K1 aa 207-
280)-RRS-HHHHHH aa 23 E (like FC27-genotype)
5'3'const w/oSP MRGS-HHHHHH-GSR-(5'-region K1 aa 18-50)-RNS-(3'-region K1 aa 207-280)-
GYPGSTCSQA                 aa 23 E (like FC27-genotype)
3'end MRGS-HHHHHH-GSR-(3'-region K1 aa 207-280)-GYPGSTCSQA
3D7 repeats MRGS-HHHHHH-GSR-PPT-GAGASGRAGA-GA-GAGASGRAGA-GAGASGRAGS-
GSGDGAVASA-GSGADAEGGSSTPATT-GYPGSTCSQA (84aa)
nested rMSP2 MRGS-HHHHHH-GSR- (SIR-- //--MHGS) -RGYPGSTCSQA
DHFR control MRGS-(mouseDHFR)-RRS-HHHHHH
aa: amino acid, const.: construct,  fsp: family specific part, IFA: immuno fluorescence assay, NAP: single letter
code for amino acids, nd: not done, PfMSP2: parasite derived protein MSP2, w/oSP: without signal peptide
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Table 2: Reciprocal antibody titres and reaction of polyclonal antisera from immunized mice in
ELISA, immunoblot and IFA.
immunogen ELISA immunoblot IFA
immunogen PfMSP2 nested
rMSP2
K1/
HB3
3D7/
NF54K1 NF54
5'3'construct 12 800 pos (500) several
bands
several
bands
K1 pos. ++/++ ++/++
FC27 fsp 12 800 pos (500) pos neg K1 pos ++/++ neg
3D7 fsp    100 neg (50) nd nd nd neg neg
23xNAP repeats    100 pos (50) nd nd Ifa23 pos nd nd
4x32 aa repeats 12 800 pos (500) nd nd Wos6 pos (+) neg
6x12 aa repeats 25 600 pos (500) pos neg K1 pos ++/+ neg
3D7 repeats   1 600 pos (500) pos pos nd +/+ ++/++
Table 3: Monoclonal antibodies produced against the 5'3'construct  
clone ELISA immunoblot IFA
DHFR
5'3'
const
5'3'
const
5'3'
const
w/oSP
3'end DHFR DHFR
5'3'
const
3'end DHFR Pf
MSP
2
K1 NF54
A1.108 pos pos pos pos neg pos pos neg neg neg neg
A1.3 pos pos pos pos neg neg neg neg pos pos pos
A1.27 pos pos pos nd neg neg nd neg neg neg neg
A1.36 pos pos pos pos neg neg neg neg pos pos pos
A1.81 pos pos pos nd neg pos nd neg neg neg neg
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7. General Discussion
The key feature of science is not measurement (this is just a tool), but understanding. To
understand the occurrence of disease in human populations we need to know something about
biology, but we also often need to know something about populations, including the population
of the host organism and the population of the infecting parasite. During the last two decades
large research efforts have been made to identify malaria antigens involved in protection and to
define mechanisms by which the immune system may neutralize the parasite, however the success
was only small. The extreme antigenic diversity within P. falciparum imposes major challenges
to identify which of its numerous proteins are important antigens eliciting protective antibodies.
This diversity (and variation) of antigens might be one of the cornerstones for understanding of
how semi-immunity against malaria develops. Polymorphic antigens have been described in several
parasite life cycle stages but are particularly a feature of the antigens associated with the surface
of the asexual blood-stage merozoites.
In this thesis, the merozoite surface protein 2 (MSP2), one of the well-characterized surface
proteins and a vaccine candidate of P. falciparum, is illustrated from two viewpoints: 
(i) the epidemiological viewpoint, which uses msp2 as a marker gene for PCR-RFLP genotyping
as an outcome measurement of interventions or of the status quo concerning malariometric indices
and (ii) additionally, the immunological viewpoint, which provides further information on the
biological role and significance of MSP2 as an immunological target. Both can contribute to the
understanding of evolution and ecology of P. falciparum, especially of survival strategies of the
parasite in the host organism and hence of the development of semi-immunity of the host. 
7.1 Methodological Aspects 
7.1.1 The appropriate analytic tool
Using objective methods for analysing biomedical research data would increase the power of
research studies and by that improve the outcome measurements of interventions. Therefore we
used a latent class model based methodology which promises almost unbiased analysis of
biomedical research data. This methodology can be applied to outputs of biomedical assays, like
the ELISA method, which are expected to classify samples into two groups which overlap each
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other to some extent (Vounatsou et al. 1998). Using real data sets we have considered the
application of a latent class model as a better method to calculate the probability of a sample to
be positive in an immunological assay. Although some data sets might give a clear distribution in
responder and non-responder, for many others no evidence of dichotomy occurs. Hence, defining
a cut-off value when there may be no obvious division of individuals into two groups, is
potentially unjustified and a rather arbitrary process. Since the latent class model does not classify
the sample dichotomously, it may be applied to any data set, regardless of the level of dichotomy.
We showed the usefulness of this methodology particularly for the analysis of  variable
background measurements (Paper IV), which arise frequently in immunology, since immune
responses encountered in human populations display a high level of heterogeneity. 
This does not mean that the cut-off method should not be used as a measure of the rate of
positivity in immunological methods. There may still be some argument for using a threshold
value, for reasons of clarity of presentation, or in a situation where some real evidence of a
dichotomy exists. This approach may be appropriate when the assay is used for diagnostic
purposes, but its suitability for epidemiological studies is less well-founded.
Since there is no agreement on how to define a “positive responder”, results from different studies
may be not comparable. Besides being valuable in evaluating a single test, a latent class model is
extremely useful in comparing tests with another one without having to choose any specific
decision level. Especially in small sample sets of the control group, calculating the cut-off value
as mean + 2sd is difficult, since out layers increase the cutoff value. 
We demonstrated that the rates of responders could be seriously underestimated from ELISA
tests, depending on the absorbance cut-off method applied for negative controls. Especially in
children where the immune response (to malaria antigens) is expected to be weak and the
differences between “responders” and “non-responders” may be small, it is important to choose
the appropriate analysis method. In a study such as ours where the development of an immune
response is the main issue, one cannot select a cutoff value simply on the basis of examining the
data.
The observed differences between the data sets are mainly based on the nature of the antigens
themselves and not on the performance of the assay. Comparing the latent class model to the cut-
off value method, the estimated proportions of test sera positive to the antigens 6x12 aa repeats
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and 3D7 repeats are very similar (Paper IV). In contrast there is a big difference in the proportion
of test sera positive to the other five antigens. The proportion of test sera positive was about 0.13
(4x32 aa repeats) to 0.53 (23xNAP repeats) higher when the latent class model was used.
Misclassifying 53% of samples by the cutoff method is considerably high. 
Especially in surveys evaluating intervention strategies, determining probability of positivity 8 in
the considered population is important. Interventions that reduce the force of infection may affect
the disease rate adversely by reducing boosting that may be required for the development and
maintenance of immunity to severe malaria. We found a highly significant decrease in antibody
response to the antigens 3D7 fsp, 3D7 repeats, 4x32 aa repeats, and 23xNAP repeats in the bed
net user group (Paper II). This difference might not be so clear when the cut-off value method is
used for estimating the rate of positivity. 
In addition when two groups of individuals were investigated, which are both at least partially
immune or “exposed”, it would be much more efficient to compare the mean level of response
rather than the proportion of “responders” (Bennett and Riley 1992). The mean antibody levels
of test sera positive and negative are easily calculated by the latent class model (Paper II and IV).
Overall, estimation of probability of positivity 8 or the mean level of response for different specific
antibody responses in different populations would represent a valuable step towards understanding
immune mechanisms acting against Plasmodium falciparum.  
7.1.2 The polymorphic gene - The appropriate marker gene
The development, accuracy and effective use of PCR-based diagnostic markers in the study of
malaria epidemiology are dependent upon an understanding of the assumptions and limitations of
the techniques used to generate the markers and the use of appropriate controls to test them. 
One of the major advantages of a PCR-based approach is the possibility of investigating from
circulating blood stages a large number of genetic characters, whatever the stage of the life cycle
at which these loci are expressed. In addition, PCR generates the material to be further analysed
during the analysis procedure instead of consuming it, as in all other methodologies (e.g.,
isoenzyme typing or  monoclonal typing). Single PCR reactions amplifying regions from single
copy genes routinely detect below the microscopic threshold and allow a semi-quantitative
amplification as in such reactions the intensity of the ethidium bromide staining roughly reflects
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the quantity of genomic template DNA added (Contamin et al. 1995). 
In practice, one of the major limitations of PCR is that the detection of a band surely denotes the
presence of parasites carrying this allele, but the failure to detect any specific band is more difficult
to interpret. This may be due to either the absence of this parasite type, to the presence of other
more abundant alleles or to an impossibility to amplify this allele because of a mutation in the
sequence where the primer should hybridize. This might be circumvented by using more than one
typing reaction. In addition, one should keep in mind, that due to very low density or
sequestration of parasites at the time of sampling one sample may only partly reflect the whole
parasite population in an infected individual (Färnert et al. 1997).
Genotyping P. falciparum infections in field isolates is suitable for various applications (Paper I).
Assessing the multiplicity of infections and, hence in longitudinal surveys, the infection dynamics
is only one example (Smth et al. 1999b; Paper III). For typing purposes, loci presenting a large
number of alleles with  distinct size and sequence polymorphism, such as msp1 and msp2 are
valuable markers. Hence, the high number of different alleles of msp2 detected so far in Tanzania
offers the genetic diversity necessary for single locus genotyping and the problem of
superinfection with the same genotype as the previous is prevented since the polymorphism is
prominent and distinct (Smith et al. 1999b). Epidemiological studies which involve msp2
genotyping give additional insights about the biological role of the expressed protein, e.g.,
morbidity association or protective potential of an allelic family, since the parasite's genotype
affects its phenotype, growth, population size and toxin production. But, host and parasite genetic
factors are both of importance, since the virulence of a particular parasite strain will depend in
part on the genetic makeup of the host.
Finally, there is the immediate issue of how candidate vaccines are to be evaluated in the field and
genotyping the msp2 locus provides one big advantage: the marker gene is a vaccine candidate
itself (Genton et al. 2000).
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7.2 The Polymorphic Gene - The Target of the Immune System
Besides using msp2 for genotyping as an epidemiologic tool, this method offers additional
information of the biological role and significance of MSP2 as an immunological target. Since
MSP2 is a prominent antigen on the surface of the merozoites, it is exposed to the selective
pressure of the immune system, resulting in a polymorphic structure of the antigen (Hughes and
Hughes 1995). In addition, the observed dimorphism of the msp2 locus might be the effect of the
competition between parasite genotypes mediated by the immune system of the semi-immune
host. Hence, understanding of immune response to MSP2 will provide valuable insights in the
surviving strategies of Plasmodium falciparum, e.g. evasion from the immune system of the host
and in the evolution of the polymorphic sequence.
Immunisation of mice showed that all recombinant proteins representing various parts of the
MSP2 sequence are immunogenic (paper V). Elicited antibodies recognized parasite derived
MSP2 and IFA positive polyclonal antisera showed a typical MSP2 staining pattern. Antisera and
monoclonal antibodies to the 5'3'construct showed a recognition of all parasite stages indicating
the recognition of a shared epitope. Cross reactions between malaria antigens have been seen with
a variety of monoclonal antibodies (Hope et al. 1984; Epping et al. 1988). Further investigations
with monoclonal antibodies from mice immunised with 5'3'construct would elucidate the nature
of this shared epitope(s). Whether these antibodies show an inhibitory effect on P. falciparum
culture, has to be examined. In addition the protein which represents the family specific region of
FC27 alleles was highly immunogenic in mice, with high antibody level and high specificity. The
only exceptions were the recombinant antigens representing 23xNAP repeats and the family
specific region of 3D7 alleles, where only marginal antibody titres were reached and no
recognition of parasites could be demonstrated. This observed lack of antibody response might
be due to restriction in Balb/c mice, which was also reported by others (Lawrence et al. 2000) or
a repeated exposure to these antigens might be necessary to reach higher antibody levels. Since
the serum samples of semi-immune adults showed a very good reaction with these recombinant
antigens in contrary to the sera of non-exposed children and adults, we rated these antigens as
partly similar to the PfMSP2 and therefore useable for ELISA. 
The high values of probability of positivity 8 obtained for the antibody response in children aged
5-21 months to each of the antigens encourages the direct evidence for the early acquisition of
an antibody response to the tested malaria antigens (paper II) in contrast to the antibody response
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to RESA (Al-Yaman et al. 1995b). It was hypothesized that clinical protection during the first few
months of life in high transmission settings allows active immunization to occur and contributes
to a reduction in the overall risks of severe complicated malaria throughout  childhood (Roberts
et al. 1994; Snow et al. 1998; Gupta et al. 1999). The fact that protection from life-threatening
disease is apparently acquired rapidly and early in life indicates that the reduction of severe malaria
through vaccination may be an achievable goal. Most of the tested children, initially aged 5-15
months, have antibodies to distinct parts of the merozoite surface protein 2, but the extent of the
antibody response was quite different compared to the antibody response of semi-immune adults.
In other words, the frequency of responders was high, although the magnitude of the responses
was generally low, but increases with age. The high proportion sera positive to 6x12aa repeats
provides some evidence for an age-independent marker of those antibodies for exposure, which
is in agreement with previous findings (Ranford-Cartwright et al. 1996). These antibody levels
may reflect an early history of exposure in combination with high immunogenicity of the antigen
plus the predominance of FC27 alleles with more than three 12 aa repeats. A different situation
was seen with the 4x32 aa repeats antigen. Although, this antigen is highly immunogenic the
antibody levels in sera of Tanzanian children were weak. This finding may be due to the
predominance of FC27 alleles with only a single 32 aa repeat unit and specific antibodies might
have a short half life or might be elicited only after several infections. In contrast, high antibody
levels to the recombinant construct representing the conserved parts of MSP2 might be due to
cross-reactive antibodies elicited by a ubiquitous antigen, since the background measurements
with the European control group were quite high. Cross-reactivity might be part of an explanation
for the age dependence of semi-immunity to malaria. People lacking exposure to malaria may
recognise malaria antigens, perhaps because of antigenic cross-reactivity between epitopes in
malarial parasites and other microorganism (Good et al. 1987; Jones et al. 1990; Good 1991,
1995; Beverley 1994; Elm et al. 1998; Good and Doolan 1999). Exposure to a myriad of
immunogenic microorganisms throughout  life is unavoidable. Accordingly, the accumulation of
memory to these antigens and the likelihood of ”incidental” cross-reactivity with antigens from
malarial parasites probably increases with age (Baired et al. 1993; Baired  1998).
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In several studies, both the prevalence and concentration of antibodies to the non-repetitive part
of the 3D7 antigen appeared to correlate with reduced morbidity due to malaria (Al-Yaman et al.
1994; Al-Yaman et al. 1995a; Al-Yaman et al. 1997; Taylor et al. 1998). In our study the antibody
response to the recombinant 3D7 family specific part was marginal in children aged 5-15 months
initially in comparison to the strong IgG antibody response in adults. The mean antibody level to
3D7 family specific part was much lower than those to FC27 family specific part and antibody
levels correlated with the presence and acquisition of infections expressing FC27 alleles. The
antibody responses to both family specific parts differ in background level, probability of
positivity, and ability to be induced by P. falciparum infections. These differences might reflect
those observed in the morbidity association of the different genotypes. Since morbidity data from
the tested children in our study are missing an association of a specific antibody response and
protection cannot be drawn. Therefore, a longitudinal prospective study  with children aged 0.5-5
years is needed to assess the impact of the humoral immune response on protection against
malaria disease. 
It might be postulated that Plasmodium falciparum infections expressing msp2 of the FC27 allelic
family distract the antibody response to the MSP2 molecule towards antibodies against parts of
the 3D7 allelic family, which might support protection to infections  expressing 3D7 alleles. The
part of the MSP2 molecule responsible for the induction of 3D7 specific antibodies might be the
32 aa repeat, where some similarities to the 3D7 repeat sequence are observed. 3D7 alleles with
this homologous sequence are more frequently observed in PNG than 3D7 alleles with other
repeat sequences (Felger pers. com.). It has to be investigated whether 3D7 alleles with repeats
containing the homologous sequence also predominate in Tanzania and whether these genotypes
have any advantages related to this homology.
Cross reactivity of affinity purified human antibodies to the 3D7 repeat Gly Gly Ser Ala and other
3D7 repeat sequences and to FC27 alleles was shown previously (Smythe et al. 1990). In addition
we showed that mice immunized with the recombinant 3D7 repeats antigen elicited antibodies
which reacted with FC27 alleles in IFA indicating a shared epitope in these repeats. One of the
protective monoclonal antibodies recognized an epitope located in the 32 aa repeats right behind
the short homologous sequence to the 3D7 repeats (Epping et al. 1988; Irion et al. 1997). It might
be speculated that antibodies recognizing the 3D7 epitope hinder sterically the induction or
binding of protective antibodies to the 32 aa repeat as it was shown with an epitope in MSP1
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(Guevara Patino et al. 1997). Previously, it was shown in PNG that MSP2 alleles of the FC27
family were strongly associated with malaria morbidity (Engelbrecht et al. 1995). But, individuals
with mixed infections of parasites expressing the different allelic families were only as likely to be
symptomatic as individuals with parasites of the 3D7 MSP2 genotype. It was concluded that
parasites belonging to the 3D7 allelic genotype must have a protective effect observed in adults
living in highly endemic areas (Engelbrecht et al. 1995). The finding that the loss of P. falciparum
infections expressing 3D7 alleles simplifies the establishment of a FC27 expressing infection,
supports the hypothesis of protective concomitant infections and the premunition hypothesis
(Smith et al 1999). Recently, the cross-protection to infections expressing FC27 alleles mediated
by infections expressing 3D7 alleles could not be induced by vaccination with a recombinant 3D7
protein (Genton et al. 2001, Combination B). It might be conjectured that the  protective effect
of 3D7 alleles bases only on the absorption of these “blocking” antibodies by the repeat structure
of present P. falciparum infections and not on the induction of protective antibodies. In the
vaccine trial in PNG the number of infections expressing FC27 alleles did not increase, but the
observed ratio FC27 alleles:3D7 alleles, would support this hypothesis (Genton et al. 2001).
7.3 Dynamics of P. falciparum infections
In this thesis it was shown that the dynamics of P. falciparum infections expressing different msp2
allelic families are different in an age-dependent way (paper III). The duration of infections
expressing different allelic families reverses when the children getting older. This finding explains
an earlier observation of Felger et al. (1994; 1999b), when the distribution of the two allelic
families of MSP2 differed significantly between semi-immune adults and children. FC27 alleles
were predominantly found in adults, whereas 3D7 alleles were found more frequently in children.
This difference in parasitological profiles might be the effect of qualitative differences in the grade
of immunity of individuals. And this again is probably influenced by the genotype of the infecting
parasite. Infections expressing MSP2 alleles of the 3D7 allelic family show a decreased duration
in children older than 18 months whereas infections expressing FC27 alleles persist longer in this
age group. The immune response of the host is able to limit P. falciparum infections expressing
3D7 alleles, beginning gradually in the first and a half year of life. This difference in duration might
indicate the lack of a protective role for antibodies to the conserved regions at the ends of the
molecule. The ability of limiting infections expressing FC27 alleles needs probably another process
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in which other antigens might also be involved. The negative correlation of the change of antibody
titres to 32 aa repeats from the previous  to the current sample of one individual with the loss of
infections expressing MSP2 of the FC27 allelic family might indicate a short duration of this
antibody response, which might need reinfection with P. falciparum expressing a FC27 allele for
boosting. Additionally, the lowest antibody level measured in the study was that against 32 aa
repeats. In addition, in early childhood the chronological sequence of P. falciparum infections
expressing the different msp2 allelic families might be important for the development of the
immune response, as it was shown in influenza virus infections (Virelizier et al. 1974, Good et al.
1993 `original antigenic sin`). 
It was speculated that the two allelic families represent different evolutionary strategies with
respect to their repeat regions (Felger et al.1997), which might be supported by the observed
difference of the duration of infections. 
Hence, further investigations comparing antibody responses of children older than 18 months are
needed, since the reported protective effect of infections expressing 3D7 alleles or of concomitant
infections are not seen in the younger age-group. Together with the finding of an antibody
response with a distracting effect on subsequent infections expressing FC27 alleles it might be
allowed to draw a simplified picture of interaction (Figure 2).
Molecular Diversity and Immunological Properties of MSP260
Figure 2: Model of interaction between Plasmodium falciparum infections 
The competition of different P. falciparum infections might be mediated by the immune system
of the host. Since the immune response evolves during the life of the host the interaction changes
over time and might have different effects on different genotypes of P. falciparum.
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7.4 The intervention strategies
The question whether ITNs may have a long term benefit to a host is still open. Instead of
reducing the toll taken by malaria, their use may merely lead to an increase in mortality and
morbidity in the older age groups (Snow et al. 1994; Snow and Marsh 1995; Trape and Rogier
1996). The reason for expecting rebound effects is that partial immunity against malaria develops
gradually and is dependent on exposure and the presence and frequency of blood-stage infections.
Data from PCR indicated that ITNs had only a small effect on prevalence, but mean parasite
densities were significantly reduced in ITNs users (Fraser-Hurt  et al. 1999). It was assumed that,
in children above one year of age, P. falciparum infections, once established, may become chronic
and last for a long time at low densities (Smith et al. 1999b). If this is the case, limited reduction
in exposure will not have much impact on multiplicity and may not hinder the establishment of
premunition (Smith et al. 1999c). However, in this study the use of insecticide-treated bed nets
showed a significant decrease in antibody levels to several parts of the MSP2 molecule, which
might result in a long-term disadvantage (paper II). In contrast, the antibody response to antigens
5'3'construct, FC27 family specific part, and 6x12 aa repeats are not affected significantly. But
as yet we are not able to identify which parts of the molecule are important as protective immune
targets (if any). Clearly that proves that it is not possible to conclude from a study with one or
two antigens tested that the transmission-reducing interventions may have little effect on antibody
levels in such children (Kitua et al 1999), since the nature of the immune responses varies between
different antigens even between different parts within one antigen. The findings have to be
examined by long-term monitoring of immunological, parasitological and clinical profiles of
subjects in areas with different malaria endemicity.
An intervention strategy that prevents either the  establishment of P. falciparum infection or the
onset of malaria morbidity/mortality is needed. The ideal tool is a vaccine that mimics natural
immunity without adverse effects of infection. But there is a need to understand the three-way
connection between infection, immunity and morbidity. The most successful vaccines of the past
were directed at organisms with little antigenic diversity, whereas the antigenic diversity of
parasites like Plasmodium falciparum raises a number of new questions, that have to be
addressed. How will populations of antigenically diverse parasites evolve in response to mass
vaccination, which may only target a subset of the antigenic variants, and how will this evolution
affect the benefit of the vaccine in reducing total disease? With molecular methods we can
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monitor in much more detail and many informations will be added to find answers. Most
importantly, these vaccines elicit sterile immunity, which does not represent the nature of anti-
malaria immunity in man, where chronicity of P. falciparum infections is an important factor of
protection. 
The reported significant differences in immune responses and dynamics of infections between age
groups have to be considered, since, the practice of taking vaccines from phase-IIa trials in non-
immune adults to phase-IIb trials in chronically exposed children may impede vaccine
development. A vaccine that establishes protection in non-immune adults may not do so in
chronically exposed children and vice versa. It is an even more difficult step to take a vaccine
from older children to very young children or infants. No new vaccine can yet be tested in phase
IIb trials in very young children first. 
Overall, this thesis gives valuable new insights into antibody responses and infection dynamics
which now have to be examined in other age groups in relation to morbidity data. With the
increase of the knowledge, the understanding of immune mechanisms of the host and the
mechanisms providing evasion of the parasite will improve and a vaccination against malaria
becomes viable. But despite all the new and surprising findings, we are still far away from
understanding malaria and its interaction with the immune system of the host. With pieces of
information gleaned from parts of a multidimensional puzzle it is tempting to try to put the pieces
of the puzzle together. It is important to identify those factors which manipulate the disease from
both sides, host and parasite, but often it is difficult to distinguish the cause from the effect.
Finally, molecular epidemiology might provide us with new insights for developing blood-stage
vaccines to reduce the burden of this disease.
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8. Conclusions and Outlook
1. It was shown that the methodology of the latent class model can be applied to outputs ofbiomedical assays, like the ELISA method, which are expected to classify samples into two
groups with some extent of overlapping between each other. Using real data sets this application
was compared to the commonly used cut-off method and gives more reliable results, especially
with variable background levels. Estimation of prevalence of positivity 8 for different populations
can be useful in, e.g. understanding of immune mechanisms providing immunity and,
consequently, in planning intervention strategies.
2. Genotyping P. falciparum infections in field isolates is suitable for various applications.Assessing the multiplicity of infections and, hence in longitudinal surveys, the infection
dynamics is only one example. The merozoite surface protein 2 (MSP2) is a useful marker gene,
since many different alleles are detected so far, that can be easily differentiated by PCR-RFLP.
msp2 offers the genetic diversity necessary to allow single locus genotyping and the polymorphism
is so prominent that a superinfection expressing the same msp2 allele as the previous one is highly
unlikely. Epidemiological studies which involve msp2 genotyping give additional insights about
the biological role of MSP2, e.g., morbidity association or protective potential of an allelic family.
3. Immunisation of mice shows that all recombinant proteins representing various parts of theMSP2 sequence are immunogenic. Elicited antibodies recognize parasite derived MSP2 and
IFA positive polyclonal antisera showed a typical MSP2 staining pattern. Antisera and monoclonal
antibodies to the 5'3'construct show a recognition of all parasite stages indicating the recognition
of a shared epitope. Further investigations with monoclonal antibodies from mice immunised with
5'3'construct will elucidate the nature of this shared epitope(s). Whether these antibodies show
an inhibitory effect on P. falciparum culture, has to be examined.
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4. The present study demonstrates that children aged 5-15 months produce antibodies todifferent parts of the MSP2 molecule. The frequency of responders is high, although the
magnitude of the responses is generally low, but increases with age. 
A. High antibody levels to the recombinant construct representing the conserved parts of
MSP2 might be due to cross-reactive antibodies elicited due to a ubiquitous antigen.
Cross-reactivity might be part of an explanation for the age dependence of semi-immunity
to malaria.
B. The antibody response to the recombinant antigen representing 6x12 aa repeats shows
no age dependence and might reflect infection history of the child.
C. The antibody response to different repeat structures shows distinct patterns, although
their immunogenicity in mice resembles each other. The differences in the MSP2 sequence
responsible for the different antibody response in natural settings have to be investigated
to assess their relevance for the protective immune response.
D. The antibody responses to both family specific parts differ in background level,
probability of positivity, and ability to be induced by P. falciparum infections. These
differences might reflect those observed in the morbidity association of the different
genotypes.   
5. Plasmodium falciparum infections expressing msp2 of the FC27 allelic family distract theantibody response to the MSP2 molecule towards antibodies against parts of the 3D7 allelic
family. The part of the MSP2 molecule responsible for the induction of 3D7 specific antibodies
might be the 32 aa repeat, where some similarities to the 3D7 repeat sequence are observed.
The loss of P. falciparum infections expressing 3D7 alleles simplifies the establishment of a FC27
expressing infection, which might be seen indirectly by the boosting of the antibody response to
the 5'3'construct. 
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6.  Dynamics of P. falciparum infections expressing different msp2 allelic families are differentin an age-dependent way. The duration of infections expressing different allelic families
reverses when the children grow older.  This difference in parasitological profiles might be the
effect of qualitative differences in the grade of immunity of individuals. And this again might be
influenced by the genotype of the infecting parasite. Hence, further investigations comparing
antibody responses of children older than 18 months are needed, since the protective effect of
infections expressing 3D7 alleles or of concomitant infections are not seen in the younger age-
group.  
7. Since morbidity data from the tested children in our study are missing an association of aspecific antibody response and protection cannot be drawn. Therefore, a longitudinal
prospective study  with children aged 0.5-5 years is needed to assess the impact of the humoral
immune response on protection against malaria disease. 
8.The use of insecticide-treated bed nets shows a decrease in antibody levels to several partsof the MSP2 molecule. Whether this influence results in a long-term disadvantage, has to be
examined by long-term monitoring of immunological, parasitological and clinical profiles of
subjects in areas with different malaria endemicity. 
A control strategy that prevents either the  establishment of P. falciparum infection or the onset
of malaria morbidity/mortality is needed. The ideal tool is a vaccine that mimics natural immunity
without adverse effects of infection. But there is a need to understand the three-way connection
between infection, immunity and morbidity. Overall, this thesis gives valuable new insights into
antibody responses and infection dynamics which now have to be examined in other age groups
in relation to morbidity data. With the increase of the knowledge, the understanding of immune
mechanisms of the host and the mechanisms providing evasion of the parasite will improve and
a vaccination against malaria becomes viable. 
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Appendices
Appendix I: Recombinant msp2 clones and protein amounts
a. Clones with parts of the sequence deleted:
Clone msp2 region protein amount ELISA conc.
D40/6 5'3'conserved regions with
signal peptide and GPI
anchor signal
0.2 mg/litre
D43/2 16xNAP repeats 5 mg/litre
D43/5 16xNAP repeats expression not done
D44/11 23xNAP repeats 10 mg/litre 10 :g/ml
D46/1 3D7 family specific part 10 mg/litre 0.1 :g/ml
D47/2 4x32 aa repeats 5 mg/litre 1.6 :g/ml
D70/2 4x32 aa repeats expression not done 
D56/2 6x12 aa repeats 0.1 mg/litre 15 :g/ml
D57/1 5x12 aa repeats 0.1 mg/litre
D61/9 FC27 family specific part 10 mg/litre 10 :g/ml
D86/2 5'3'conserved regions
DHFR fusion protein
0.4 mg/litre 10 :g/ml
D90/2 5'3'conserved regions, 23aa
are missing at the 3'end
expression not done
D99/1 3D7 repeats 25aa expression not done
D100/1 3D7 repeats 49aa 10 mg/litre
D101/1 3D7 repeats 48aa 10 mg/litre 2 :g/ml
D102/4 3D7 repeats 42aa expression not done
D109/12 3'conserved region 10 mg/litre
D110/2 5' conserved region 0.1 mg/litre
D111/1 5'3'conserved regions
without signal peptide
3 mg/litre
D112/2 5'3'conserved regions
without signal peptide
DHFR fusion protein
expression not done
D113/3 5'conserved region without
signal peptide 
1 mg/litre
D114/1 K1 full sequence without
signal peptide
expression not done
b. Clones with nested msp2 sequences:
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Clone msp2 nested repeat organisation expression
D1/9 wos3 1xNAP, 1x32, 3x12 x
D2/1 ifa46 1xNAP, 1x32, 1x12 x
D5/14 K1 1xNAP, 1x32, 5x12 x
D12/6 wos6 1xNAP, 4x32, 0x12 x
D22/15 wos12 1xNAP, 1x32, 4x12 x
D41/10 ifa41 16xNAP, 1x32, 2x12 (x)
D62/10,12
R73 culture
FC27 allele  full seq nd ?
D63/4,5
IFA18 culture
? seq nd ?
D64/2 
MAD20 culture
FC27 allele full 1xNAP, 2x32, 
at least 1x12
(x)
D65/4,5,6
NF54 culture
3D7 full seq nd ?
D66/1,2,3
Rfmef culture
3D7 allele seq nd ?
D67/1,2
7G8 culture
K1 allele seq nd ?
D68/2,7,8,9,12
W2mef culture
FC27 allele full seq nd ?
D72/6 NF54 culture 3D7 allele 6xGGSA, 14x Thr x
D77/7 ifa13 6xNAP, 1x32, 1x12 nd
D78/4 part of the 3D7
family specific region
nd
D79/6,7,8 ifa31 7xNAP, 1x32, 2x12 nd
D80/3,7,8 ifa41 16xNAP, 1x32, 2x12 nd
D81/4 ifa42 recombination nd
D82/2 ifa45 1xNAP, 4x32, 1x12 nd
D83/1 ifa14 recombination ?
D84/1 3D7 allele 1xGASGSG
1xGASGSA 5x Thr
?
D84/2 3D7 allele 1xGASGSG
2xGASGSA 5x Thr
nd
D84/3 3D7 allele 1xGASGSA 5x Thr nd
D84/5 3D7 allele 1xGASGSG
2xGASGSA 5x Thr
nd
D85/1 AW755 
very short
3D7 allele 1xGASGSA 5x Thr x
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AW755 short 3D7 allele 2xGASGSA 5x Thr nd
AW755 long 3D7 allele 6xGASGSG
2xGASGSA 5xThr
nd
D93/3 ifa56 2xNAP, 1x32, 1x12 x
D94/3 ifa27 recombination 3x32,
0x12
x
D98/17 K1 w/o GPI anchor
signal
x
D104/1 3D7 allele 1xGASGSA 5x Thr nd
D104/3 3D7 allele at least 4xGASGSG
2xGASGSA 5x Thr
nd
D104/8 3D7 allele 2xGASGSG
2xGASGSA 5x Thr
nd
mari ifa17/21 2xNAP, 3x32, 0x12 x
mari ifa52 15xNAP, 1x32, 1x12 x
D105/1 3D7 allele 8xAGAGGSGS nd
D105/11 3D7 allele at least
12xAGAGGTGT
nd
D105/12 3D7 allele 7xAGAGGSGS 
8x Thr
nd
D106/3 3D7 allele 2xAGAGGSGS
8x Thr
nd
D106/4 3D7 allele 6xAGAGGSGS nd
D106/10 3D7 allele 6xAGAGGSGS nd
nd = expression not done
? = the amount of expressed protein was very small and sometimes doubtful
x = the amount of expressed protein was between 1-10 mg/litre
(x) = the amount of expressed protein was between 0.1-0.5 mg/litre
seq nd = sequencing not done
Appendix II: Recovery rate
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msp2 genotype of
the P. falciparum
infection
Sensitivity
of detection 
S
recovery
probability
M
recovery
rate
:
duration
[days]
all all 0.61 0.25 0.0109 92
3D7 all 0.54 0.26 0.0113 88.5
FC27 all 0.68 0.23 0.01 100
all no net 0.57 0.23 0.01 100
all net 0.66 0.28 0.0122 82
all <18 months 0.6 0.26 0.0113 88.5
all >18 months 0.62 0.25 0.0109 92
3D7 <18 months 0.49 0.23 0.01 100
3D7 >18 months 0.6 0.29 0.0126 79.4
FC27 <18 months 0.73 0.27 0.0117 85.5
FC27 >18 months 0.64 0.19 0.0083 120.5
3D7 no net 0.53 0.24 0.0104 96
3D7 net 0.55 0.28 0.0122 82
FC27 no net 0.6 0.2 0.0087 115
FC27 net 0.78 0.25 0.0109 92
Appendix III: Positivity and net use
Presented for the investigating period of 7 months and for children divided in four age groups
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Appendix V: Median antibody levels and net use 
Presented for the investigating period of 7 months and for children divided in four age groups
Legend:
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Appendix VI: Cumulative frequency of antibody titres
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Appendix VII: Distribution of antibody units in negative control sera and test sera
Positive control serum pool is defined as one antibody unit.
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